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CHAPTER 1. AMINOGLYCOSIDE ANTIBIOTICS 
1.1. General introduction 
 The discovery and broad spectrum use of antibiotics may be considered as one of the 
most important healthcare achievements of the 20th century. The antibiotic era began with the 
discovery of penicillin by Alexander Fleming in 1928.1 Since then, a vast number of antibiotics 
including aminoglycosides, β-lactams, fluoroquinolones and others have been discovered and 
clinically implemented for treating multiple bacterial infections. Antibiotics can be sorted out 
into four types based on their mechanism of action: inhibition of cell wall synthesis (most 
common); inhibition of protein synthesis (second most common class); inhibition of DNA or 
RNA synthesis; and inhibition of folate coenzyme biosynthesis. The aminoglycosides antibiotics  
are an essential class of therapeutic agents, which target protein synthesis.2  
 
Figure 1: Number of antibacterial approvals by five year periods (from 1980-2009; 2010-
2012 is a 3-year interval)3 
 AGAs are broad spectrum clinically important antibacterials for human therapy, and have 
long been used as highly potent antibiotics for treating several bacterial infections. Their efficacy 
is demonstrated against many Gram-negative and Gram-positive pathogens, as well as against 
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multi-drug-resistant tuberculosis, strains of MRSA, and against complex infectious diseases such 
as exacerbated cystic fibrosis. Part of the reason why AGAs suffer from severe resistance 
problems is because of their extreme use in the healthcare system. Many bacterial strains have 
become resistant to regular doses of aminoglycosides through the evolution and action of 
AMEs.4 The consequence of antimicrobial resistance to AGAs on the human curative process, 
has been recognized by the WHO, which released a global action plan to address this menace.5 
The morbidity rate due to antibiotic resistant-infections in the USA is two million people/year, 
with at least 23,000 dying as a result, with estimates of $20 billion in excess direct healthcare 
costs.3 If drug-resistant infections are not tackled well, they could result in 50 million deaths and 
$100 trillion of treatment costs by 2050, according to an estimate by an official commission in 
UK.6 Further, the clinical utilization of AGAs and their development into therapeutics is limited 
because of their toxicity, in particular, the irreversible hearing damage called ototoxicity, and 
reversible kidney damage called nephrotoxicity. In addition, the number of new antibiotics 
approved by the FDA, has gradually decreased in the last three decades, which minimizes the 
options to treat bacterial resistant infections (Figure 1). Attempts aiming to generate better 
aminoglycosides have employed several approaches including chemoenzymatic modification and 
coupling of antibiotics. Toward this end aminoglycosides, like most other classes of drugs, have 
been extensively modified by synthetic or semisynthetic routes.4 
 The first of this thesis is directed towards developing new aminoglycoside antibiotics 
with emphasis on their chemical synthesis, and the biological evaluation of newly synthesized 
analogues, as well as the exploration of structure-activity relationships to obtain knowledge 
about antimicrobial activity. The goal of the research was the design and development of more 
active and less toxic aminoglycoside antibiotics. In particular, studies have focused on the 
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modification of the aminoglycosides, apramycin and paromomycin so as to develop the next 
generation of potent AGAs.  
1.2. History and structural features of AGAs  
 Streptomycin, the first aminoglycoside antibiotic drug discovered in the 1940s, was 
isolated from Streptomyces griseus, used successfully to treat tuberculosis, and has been in use as 
an antibiotics for over 60 years. After successful entry of streptomycin into clinical treatment 
against microbial infections, several other novel AGAs have followed to fight against bacterial 
infections. Some notable active AGAs are shown in Table 1. Most of the AGAs are available as 
natural compounds, which are obtained from actinomycetes of either genus Micromonospora 
(indicated as-“micin”) or genus Streptomyces (indicated as -“mycin”). 
Table 1: Sources and year of discovery of some notable AGAs 
S.No Aminoglycoside 
antibiotic 
Source Year 
1 Streptomycin Streptomyces griseus 1944 
2 Neomycin Streptomyces fradiae 1949 
3 Kanamycin Streptomyces kanamyceticus 1957 
4 Paromomycin Streptomyces rimosus forma 
paromomycinus 
1956 
5 Gentamicin Micromonospora purpurea 1963 
6 Tobramycin Streptomyces tenebrarius 1967 
7 Apramycin Streptomyces tenebraius  1968 
8 Sisomicin Genus Micromonospora 1970 
9 Butirosin Bacillus circulans 1971 
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10 Dibekacin Semisynthetic derivative of 
Kanamycin B 
1971 
11 Amikacin Semisynthetic derivative of 
Kanamycin B 
1972 
12 Arbekacin Semisynthetic derivative of 
dibekacin 
1973 
13 Isepamicin Semisynthetic derivative of 
Gentamicin B 
 
14 Netilmicin 1-N-ethyl sisomicin 1976 
 
As with other classes of antibiotics, resistance and toxicological issues observed in clinical usage 
of AGAs have become widespread. This has led to efforts to develop the pharmacological profile 
of AGA's and the consequent introduction of a second generation of AGAs, also known as semi-
synthetic derivatives, as shown in the Table 1. However, toward the end of 1970s, the 
introduction of a broad range of other antibiotics with lower side effects diminished the interest 
in the search for new AGAs. Isepamicin (1988) and arbekacin (1990) were the latest approved 
AGAs to be approved.7 However, this situation may change as plazomicin, a semi-synthetic 
AGA derived from sisomicin developed by Achaogen, recently completed phase II clinical trials 
for urinary tract infections.8  
 Despite the reduced interest the use of AGAs in the clinic continues, in part because of 
the growing resistance to all other general antibiotics. AGAs are currently predominantly used in 
nosocomial infections and in particular for severe Gram-negative infections. AGAs are water-
soluble, polycationic pseudo oligosaccharides with several hydroxyl and amino groups. Their 
structure consists of several aminated sugars connected by glycosidic linkages to a dibasic 
cyclitol. The AGAs are heavily protonated under physiological conditions, and have strong 
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affinity toward negatively charged nucleotides. The pKa values of individual amino groups of 
AGAs range from 5.7 to 10.1.9,10 AGAs have a relative low molecular weight (500 to 800) and 
are most frequently isolated as sulfate and acetate salts. Most are odorless, and white to off-white 
amorphous powders.  
1.3. Structural classification 
 AGAs, also known as aminoglycoside-aminocyclitol antibiotics, act as therapeutic agents 
by inhibiting protein synthesis. The term ʽaminoglycosideʼ generally refers to any carbohydrate 
that carries an amino functionality. The common aminoglycoside structural motif consists of a 
cyclitol derivative linked to minimum of one aminosugar, with the complete structure containing 
at least two amino functionalities and a number of free hydroxyl groups, which may also have 
further substituents.  
 
Figure 2: Structure of streptamine (1), 2-deoxystreptamine (2), Plazomicin (3), and 
examples of AGAs, that are not derived from 2-deoxystreptamine (4, 5) 
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 Most aminoglycoside molecules contain a central aminocyclitol ring, 2-deoxystreptamine 
linked to one or more amino sugars by pseudo glycosidic bonds. 2-Deoxystreptamine plays a 
vital role in aminoglycoside biological activity. The first AGA, streptomycin (5, Figure 2), 
belongs to a relatively rare class of AGAs that is made up of a scaffold of the disaccharide unit 
linked to the 4-position of a guanidinylated streptamine. 
 
Figure 3: Classification of monosubstituted 2-deoxystreptamine derivatives 
 Most AGAs can be sorted into two major classes: a large number of compounds 
containing 2-deoxystreptamine derivatives, and compounds without the 2-deoxystreptamine 
motif (e.g., streptomycin (4) and spectinomycin (5)) (Figure 2). The group containing the core 
scaffold 2-deoxystreptamine is the most essential and is usually further classified into mono and 
disubstituted 2-deoxystreptamine derivatives as shown in (Figures 3 & 4). 
 A large number of AGAs contain 2-deoxystreptamine as a center scaffold, and are 
biosynthetically derived from paromamine. These are classified into 3 major classes based on 
substituents of the core paromamine moiety, namely kanamycins, neomycins, and gentamicins.  
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Figure 4: Classification of disubstituted 2-deoxystreptamine derivatives 
 
 
Figure 5: Structures of the AGA classes based on paromanine: kanamycins, neomycins, 
and gentamicins 
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 The majority of clinically applied AGAs belong to the paromamine-derived AGAs. Of 
these the kanamycin family consists of 4,6-disubstituted-2-dexoystreptamine analogues with 
both a 2-amino or 2,6-diamino-glucose ring at the 4-position and a 3-amino substituted glucose 
ring at the 6-position. The neomycin category are of 4,5-disubstitued 2-dexoystreptamines with 
one furanoside and one or two pyranosides. Finally, the gentamicin class are 4,6-disubstituted 2-
dexoystreptamines, usually with two hexose rings and an additional carbon side chain (Figure 
5).7  
1.4. Mode of action of AGAs 
1.4.1. Functional and structural features of the ribosome 
 Since the discovery of streptomycin in 1943, aminoglycosides have served as 
chemotherapeutic agents in the treatment of a variety of bacterial infections, whose efficacy has 
been proven against a number of clinical pathogens, including both Gram-positive and Gram-
negative pathogens.11 Although the detailed mechanism of action of AGAs is still under 
investigation, AGAs mainly target the bacterial ribosome 16S decoding A site by direct 
interaction with ribosomal RNA thereby affecting bacterial protein synthesis by inducing codon 
misreading or by inhibiting translocation of the tRNA-mRNA complex.12  
 DNA and RNA are central players in gene expression, transmission and conservation of 
the genetic information. DNA directs its own replication (conservation) and through transcription 
(transmission) yields RNA, which in turn through translation (gene expression), leads to protein 
synthesis. This information flow is known as the central dogma of molecular biology.13 RNAs 
are constructed with four main nucleotides, each one of which has three constituents: a 
nucleobase, a ribofuranose, and a phosphodiester group. Among the four nucleobases, two are 
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purines; adenine (A) and guanine (G), and the remaining two are pyrimidines; uracil (U) and 
cytosine (C) (Figure 6).  
 
Figure 6: The four fundamental RNA nucleotides and the Watson-Crick base pairs 
 A codon is a part of mRNA, consisting of three consecutive nucleotides, whose sequence 
indicates one of the 20 amino acids. Each tRNA has an anticodon that matches with a specific 
mRNA codon. In the ribosome, codons on the mRNA travels through two channels on the small 
subunit to attain the decoding site where the codon contacts with the tRNA anticodon. Peptide 
bond formation is initiated when the first codon on the mRNA interacts with the initiator tRNA 
containing the amino acid methionine at the peptidyl site (P-site). Such peptide bond formation is 
illustrated in Figure 7. Protein synthesis by mRNA translation in the ribosome must be rapid and 
accurate. This accuracy, is achieved by the perfect pairing of three bases between the mRNA 
codon and the tRNA anticodon. The anticodon should have a perfect match with the first two 
codon positions based on the Watson-Crick base-pairing rules (Figure 6).14-18 
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Figure 7: Schematic representation of peptide bond formation 
1.4.2. Uptake and mode of action 
 Because the AGAs are water-soluble, polycationic oligosaccharides with several 
hydroxyl and ammonium groups they are heavily protonated under physiological conditions, and 
have strong affinity toward negatively charged nucleotides. There are two types of interactions 
that support the recognition and binding of AGAs to their bacterial rRNA targets. The most 
significant contribution is from electrostatic interactions and these are supplemented by 
hydrogen bonding between multiple amino and hydroxyl functionalities of the AGAs and the 
RNA bases. The antimicrobial activity of AGAs is an outcome of a multi-step process. The first 
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step requires the AGAs to reach their molecular target, for which they must penetrate into the 
cytoplasm of the bacterial cell. The mechanism by which AGAs penetrate into Gram-negative 
bacteria remains ambiguous. Nevertheless, according to the currently accepted mechanism, it 
consists of three consecutive steps. AGA uptake is the first stage, and is simply an electrostatic 
interaction between the positively charged aminoglycosides and the negatively charged 
lipopolysaccharides of the surface bacterial membrane.19,20 This interaction is mostly nonspecific 
and is solely due to the cationic environment of the AGAs resulting from the basic, ionizable 
amino groups. The subsequent stages are energy dependent steps known as EDP-I and EDP-II. 
After entering into the periplasmic space, the AGAs are transported through the cytoplasmic 
(inner) membrane. This step, which depends on electron transport and is the rate-determining 
step (slow rate), is termed as EDP-I and is associated with AGA concentration. Subsequently, the 
AGAs bind to the 30S ribosomal subunit, which is the EDP-II.21 AGAs interfere with protein 
synthesis (translation process) upon binding to rRNA, leading to membrane damage, which leads 
to the accumulation of the antibiotic in the cell, and eventually to cell mortality.22 
 The influence of AGAs on bacterial protein synthesis was first revealed in 1965.23 AGAs 
mainly target the bacterial ribosome by direct interaction with ribosomal RNA thereby affecting 
protein synthesis by inducing codon misreading or by inhibiting translocation of the tRNA-
mRNA complex. 
 
12 
 
 
 
 
Figure 8: (a) Secondary structure of the AGA-binding pocket in helix 44 of 16S rRNA in 
complex with paromomycin. Key residues for selectivity of AGAs are 1408 and 1491 (blue). 
(b) Detail of the paromomycin ring 1 bound to the bacterial A site24 
 
 The AGA molecular target is on helix 44 in the 16S rRNA subunit; the precise binding 
location is part of the aminoacyl-tRNA acceptor site, which is known as the decoding A site.25 
Although different modes of binding have been observed with a variety of aminoglycoside 
derivatives, the general interaction of AGAs with three unpaired adenine residues in the 
decoding loop displace the non-complementary adenines (A1492 and A1493) and locks them 
into a so-called “flipped-out” orientation (Figure 8).4 While majority of AGAs efficiently inhibit 
the propagation level in protein translation, their approaches are mechanistically varied. Thus, 
AGAs influence bacterial protein synthesis either by hindering translocation of the tRNA-mRNA 
complex or by provoke misreading.25  
 The two rings of the neamine core (rings I and II) are common for the 4,5- and 4,6- 
classes of AGAs, and are the main contributor to binding to the rRNA. They interact through 
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hydrogen bonding of the 6’- substituent (OH in paromomycin, NH2 in neomycin) and the ring 
oxygen with N1 and N6 of the highly conserved A1408 of helix-44 in the narrow drug binding 
pocket. The 2-deoxystreptamine (ring II) of the neamine core forms hydrogen bonds to U1406, 
U1495 and G1494 of the binding site. Based on the substitution pattern of the AGA, ring I binds 
to a number of ribosomal bases including A1408, A1493, A1492, and G1491.24 There are no 
significant binding interactions of ring III and ribosomal RNA. The additional rings attached to 
the deoxy streptamine ring at the 5- or 6- positions, might have impact have an AGA's 
specificity. Additional hydrogen bonding interactions form between various hydroxyl groups of 
the neamine core and the phosphate groups linked to the ribonucleosides in the binding pocket 
through water mediation. Paromomycin and apramycin represent two diverse mechanisms of 
action.  
 Paromomycin binds to the 16S bacterial RNA binding site in the major groove of helix 
44. The glucopyranosyl (ring I) of paromomycin, forms hydrogen bonds with A1408, A1492, 
A1493, and the base pair C1409–G1491 (Figure 8). Ring II forms strong hydrogen bonds with 
16S bacterial RNA, in particular, the phosphate backbone of A1493; such is the strength that it 
locks the skeleton in the ʽʽflipped-outʼʼ form. This leads to reduced binding affinity of cognate 
and non-cognate tRNA codons and as a result codon misreading takes place.12 Paromomycin ring 
I behaves like a nucleotide base, hydrogen-bonding with A1408 (C(6')-OH to N(1) of A1408) 
and stacking on top of the purine ring of G1491 (Figure 8).  
 All studies so far have concluded that paromomycin, and most of the 2-deoxystreptamine 
derived AGAs influence the fidelity of translation of the ribosome by enhancing the 
incorporation of near-cognate tRNAs. Most 4,5- and 4,6-AGAs bind to the decoding A site in a 
similar manner to paromomycin as revealed by various X-ray structures, and lead to a similar 
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loss of translational accuracy.26 The details of how this misreading leads to cell death are not 
well understood, as for example ribosomal mutants with reduced translational accuracy are still 
feasible.27 It has been suggested that AGAs enhance the permeability of cell membranes as a 
result of the incorporation of inaccurate proteins, with the consequence of subsequent saturation 
of the ribosome with AGAs and most likely complete inhibition of protein synthesis.  
 
Figure 9: Decoding site of 30S subunit (Thermus thermophilus) in complex with apramycin 
and pseudo base pair interaction of the bicyclic sugar (II) of apramycin with the A1408 
residue 
 X-ray crystallographic study with the absolutely constituted bacterial ribosome reveals 
that the apramycin bicyclic ring II is bind to the ʽʽflipped-outʼʼ conformation of the bacterial 
ribosomal A site similar way to ring I of the 4,5- and 4,6-AGAs. In particular, the β-face of ring 
II (bicyclic ring) interacts through CH-π interactions with the bacterial ribosomal base G1491; 
the 6'-OH group serves as hydrogen bond donor with N1 of the ribosomal base A1408 and 
another ring oxygen O1' acts as hydrogen bond acceptor with amine group of A1408 (Figure 
9).26 The hydrogen-bonding pattern and location of the apramycin 2-deoxystreptamine ring are 
analogous to those of the 2-deoxystreptamine moiety in the decoding A-site complexes of the 
4,6-disubstituted AGAs. The key hydrogen bonds between apramycin N3 and N7 of G1494; 
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apramycin N1 and O4 of U1495.25,28 The terminal sugar (4-amino-4-deoxy-D-glucose) of 
apramycin forms hydrogen bonds with base pair C1409 and G1491. In addition, 2'''-hydroxy 
group also form hydrogen bonds with G1491 and A1492.28  
 On the other hand, crystallographic studies of apramycin bound to the model sequences, 
which corresponds to the eukaryotic ribosomal A site disclose that the drug binds to a ʽʽflipped 
inʼʼ conformation in which A1492 forms an hydrogen bond to G1408. In this complex bicyclic 
ring II of apramycin is rotated with respect to its orientation in the bacterial complex and does 
not stack with A1491 and 2'-NH2 group of apramycin forms a hydrogen bond to the G1408 O6 
leaving the apramycin 6'-OH exposed to water.29,30  
 In contrast to the other AGAs, apramycin acts initially by blocking the translocation of 
ribosome along mRNA, and as a result, gives only limited codon misreading. One reason could 
be the hydrogen bond interaction between 2''' hydroxyl group of terminal ring III and the ribose 
moiety of A1492, which possibly involve in the switch of nucleotide A1492 to adopt a ʽʽflipped-
outʼʼ conformation as is connected with aminoglycoside-induced misreading. It is consistent with 
the aprosamine (lack of terminal ring), readily induced misreading on bacterial ribosomes.25,28  
1.5. Problems associated with therapeutic usage of AGA's 
 The clinical use of AGAs and their applications into therapeutics is limited because of 
three major problems. The first and foremost problem is associated with two types of toxicity; 
reversible nephrotoxicity and irreversible ototoxicity. In spite of the therapeutic effects of AGAs, 
their use requires careful monitoring of patients as both toxicities are dose-dependent. The 
second problem, as with all antibiotics, is the rise of resistance as a result of overuse and misuse. 
Numerous resistance mechanisms have been elucidated.7 The third problem is the complexity 
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associated with the total and partial syntheses of AGAs. Since the beginning of the AGAs era, 
these problems have limited their therapeutic usage and further development.  
1.5.1. Toxicity of aminoglycoside antibiotics 
 A number of toxicities have been identified with AGAs in medical use, including 
ototoxicity31 (vestibular and auditory), nephrotoxicity32, retinal toxicity, and, infrequently 
neuromuscular blockage. Among these, ototoxicity and nephrotoxicity are of primary concern. 
Inherent toxicity allied with nonspecific binding to RNA a further problem that obstructs wider 
adoption of AGAs. 
1.5.1.1. Nephrotoxicity 
 Kidney damage is called nephrotoxicity. Drug induced nephrotoxicity leads to the body’s 
incapability to eliminate urine and other wastes. If not treated well, it leads to an eventual 
concomitant growth of electrolytes in the blood and consequently permanent kidney breakdown. 
Primarily, AGAs are eliminated by glomerular filtration and excretion in the urine and, 
consequently, accumulation of AGA is observed in the kidneys. Accumulation of about 5% of 
the administrated dose of an AGA in the epithelial cells (one of the four fundamental types of 
animal tissue) of the proximal tubules can be lead to the nephrotoxicity. Significant accumulation 
of an AGA in the renal cortex (outer portion of kidney) tissue is a strong indication of 
aminoglycoside-induced nephrotoxicity.32 Nephrotoxicity is minimized in the clinic by 
administration of a single large daily dose rather than several smaller doses.33 Netilmicin is the 
reportedly the least toxic, whereas gentamicin is considered the most toxic. Amikacin and 
tobramycin are the best tolerated AGAs.34-36  
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1.5.1.2. Ototoxicity 
 Another important obstruction to AGA clinical therapy is ototoxicty, which is mostly 
irreversible and affects ~20% of the patient population.37 Ototoxicity is connected with the 
destruction of the sensory cells of the inner ear. Two types of ototoxicity are presented; cochlear 
toxicity and vestibular toxicity. All AGAs exhibit ototoxicity but differ in toxic potential and 
organ preference, i.e., preferential damage to the cochlea or vestibule.38 Neomycin is believed to 
be highly toxic while gentamicin, tobramycin, and the kanamycins exhibit moderate toxicity. 
Neomycin and amikacin influence mostly the cochlea whereas gentamicin is considered to be 
vestibulo toxic. That AGAs cause ototoxicity can be explained by two mechanisms. In the first 
mechanism, the formation of reactive oxygen species (ROS) is believed to be the initiation step 
that is followed by further events that ultimately lead to cell death. Aminoglycoside antibiotics 
can form complexes with iron present in cells to activate dioxygen, and form the superoxide 
radical (a ROS) and lipid peroxides by reaction with polyunsaturated fatty acids such as 
arachidonic acid. Lipid peroxides can commence a chain reaction of peroxidation (radical 
degradation), and reactive oxygen species can undergo a Fenton-type reaction to form hydroxyl 
radicals. Together these reactions, Fe(II) catalysed reduction of molecular oxygen and an 
subsequent chain reactions with formation of different ROS, result in damage to the cell (Figure 
10).39,40  
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Figure 10: Proposed mechanisms for aminoglycoside-induced ototoxicity 
 Further, Böttger and co-workers proposed, on the basis of genetic studies of 
aminoglycoside interactions with eukaryotic ribosomal RNA, that AGAs inhibit mitochondrial 
protein synthesis which enhances the cochlear toxicity associated with aminoglycosides.41 
Crystallographic analyses of rRNA hybrids of human wild-type, the human A1555G mutant, and 
bacterial decoding A-sites, strongly support the hypothesis that AGA induced deafness is 
affected by genetic factors. Ototoxicity occurs in a couple of ways. i) a random dose dependent 
manner in the common patient population, and ii) in an aggravated type in genetically 
susceptible individuals, with the latter linked to mutations in mitochondrial rRNA, in particular, 
the transition mutations A1555G and C1494U in the A-site of the mitochondrial ribosomal RNA 
subunit.41,42 The sequence differences between the rRNA subunit decoding A sites of the 
eukaryotic and prokaryotic ribosomes are minimum. As a result, competitive AGA binding to the 
human ribosome is expected (Figure 11).  
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Figure 11: Core binding region and secondary-structure comparison of prokaryotic and 
eukaryotic ribosomal decoding site rRNA sequences in the small ribosomal subunit25 
 
 The investigation of interactions between bacterial ribosome and AGAs is not only 
important to understand the mode of action of aminoglycoside, but also to probe the structure 
and function of the ribosomal decoding site. Several methods were developed to study the 
complexes of AGAs and the decoding A site including NMR structural studies of AGAs 
complexed with A site models.43,44 Relatively well resolved crystal structures of the 30S 
ribosomal subunit, in the presence and absence AGAs led to a major breakthrough in 
understanding their mechanisms of action.12,45,46 Besides NMR and X-Ray crystallography 
techniques, several other methods were developed to look into the interactions between AGAs 
and the ribosomal A site.  
 The ribosomal drug susceptibility is studied by in vivo measurement of the minimal 
inhibitory concentration against a single rRNA allelic derivative of the Gram-positive 
eubacerium Mycobacerium smegmatis.47 MIC is defined as the lowest concentration of an 
antibiotic substance that absolutely inhibits the visible growth of a microorganism after overnight 
incubation.48 To determine the susceptibility of microorganisms to antimicrobial agents, MICs 
are considered as the ʽgolden standardʼ. Böttger et al. established cell-free translation assays with 
purified 70S ribosomes of both wild-type and mutant M. smegmatis strains to evaluate the effect 
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of AGAs on the fidelity of translation.14 For that, they constructed a large number manipulated 
mutants with defined alterations in the ribosomal A site (Figure 12 A). 
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Figure 12: A) Secondary structure of the bacterial A site (mutations introduced are shown 
in blue), B) Bacterial hybrid ribosome with a fully functional eukaryotic rRNA decoding 
site 
 The incorporation of the complete decoding A site cassette of human mitochondrial 
(wild-type and recombinant mutants) and cytosolic rRNA into bacterial rRNA has facilitated the 
development of cell-free translation assays, to investigate the AGAs inhibition of mitochondrial, 
cytosolic, and bacterial protein synthesis.49 These assays envisage both AGA antibacterial 
activity as well as drug selectivity at the target level, which leads to the development of potent 
AGAs (Figure 12B). To estimate the antibacterial activity of the aminoglycosides on protein 
synthesis (translation), IC50 values were determined. The IC50 value is the concentration of 
substance (AGA) required to inhibit the bacterial protein synthesis. In particular, antibacterial 
activity is measured against clinical isolates of Escherichia coli (3 strains) and methicillin-
resistant Staphylococcus aureus (4 strains), which were isolated from patients.  
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1.5.2. Resistance 
 AGAs also suffer from severe resistance problems because of their wide-ranging use 
against human and animal pathogens. Both the extended term exposure to low dosage of AGAs 
and the failure to complete a prescription promote more resistant bacterial strains. So far, three 
bacterial resistance mechanisms to AGAs have been identified. The first mechanism involves 
reduction of the intracellular concentration of AGA either by limiting drug uptake or by 
enhancing the activity of active efflux systems. The second mechanism is the alteration of the 
target 16S RNA bacterial ribosomal subunit. Finally, the last and the most important resistance 
mechanism is the enzymatic modification of AGAs or deactivation of AGAs (Figure 13).4,50 
With respect to the latter three classes of aminoglycoside modifying enzymes (AME) are majorly 
affecting the AGAs. They are the aminoglycoside phosphotransferases (APHs), the 
aminoglycoside acetyltransferases (AACs), and the aminoglycoside nucleotidyltransferases 
(ANTs).  
 
Figure 13: Schematic outline of mechanisms of resistance to AGAs 
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1.5.2.1. Reduced uptake and increased efflux  
 The decline of drug uptake and/or activation of drug efflux leads to a reduction in the 
AGA concentration in target bacterial cells.51 This mechanism influences the susceptibility of the 
strain to the entire family of aminoglycoside antibiotics and is a source of intrinsic resistance. 
Even though the exact mechanism of aminoglycoside uptake is still unclear (section 1.4.2), it is 
thought that the process consists of three subsequent steps. The first step is the adsorption of the 
polycationic AGA to the surface of bacteria by electrostatic interactions with the negatively 
charged lipopolysaccharides found on the outer cell membrane of Gram-negative bacteria. The 
two subsequent steps are oxygen dependent, and thus anaerobic bacteria are intrinsically resistant 
to aminoglycosides.52 Energy-dependent bacterial efflux pumps have now been identified as a 
main source of resistance to antibiotics, in particular, in the case of multidrug-resistant pathogens 
accountable for nosocomial infections. Multidrug efflux pumps are active transporters and are 
made up of proteins that are localized in the cytoplasmic membrane of all types of cells. They 
need a source of chemical energy to carry out their function. A few primary active transporters 
use adenosine triphosphate hydrolysis as a source of energy.51 
1.5.2.2. Modification of the target RNA 
 In this mechanism of resistance, the aminoglyocisdes target, the .16S RNA sub unit of the 
bacterial ribosome (Figure 13) is altered by a bacterial modification. Members of the 
actinomycetes group generate inactive aminoglycosides such as partially phosphorylated or 
acetylated ones, which are cleaved during or after their export out of the cell by particular 
enzymes to provide the active antibiotics compounds.51 Streptomyces spp. and Micromonospora 
spp., a class of aminoglycoside-producing organisms are capable of expressing rRNA 
methylases, which can methylate the 16S rRNA at particular positions that are crucial for the 
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binding of the drug.53 Several rRNA methylases have been studied.54 For example, KamA 
isolated from Streptomyces tenjimariensis and KamB isolated from Streptomyces tenebrarius are 
methylation genes; their gene products catalyze the modification of N(1) of A1408 leading to 
elevated resistance to most of the AGAs including kanamycin, sisomicin, tobramycin, and 
apramycin, but not to gentamicin.55 Methylation of A1408 results in the loss of contact with the 
6’-group of the aminoglycosides which is thought to be critical for antibiotic activity. 
1.5.2.3. Enzymatic Modification of the aminoglycoside   
 The enzymatic modification of amino or hydroxy groups of AGAs by specific enzymes, 
is the main cause of aminoglycoside resistance in clinical isolates of Gram-negative and Gram-
positive bacteria. The modified AGAs bind weakly to the target ribosome, resulting in the loss of 
antibacterial activity56 (Figure 14). Three kinds of aminoglycoside-modifying enzymes (AMEs) 
are have been identified:  
• Aminoglycoside Acetyltransferases (AAC) 
• Aminoglycoside Phosphotransferases (APH) 
• Aminoglycoside Nucleotidyltransferases (ANT) 
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Figure 14: Main stream aminoglycoside-modifying enzymes and their effect on kanamycin 
B (a 4,6-2-deoxystreptamine derivative), neomycin B (a 4,5-2-deoxystreptamine derivative) 
and spectinomycin 
1.5.2.3.1. Aminoglycoside Acetyltransferases (AAC) 
 AACs are considered as a main source of resistance in Gram-negative organisms 
(Enterobacteriacae), and are also detected in Gram-positive pathogens (Staphylococci, 
Enterococci).57 Around 50 members of the AAC family have been recognized. Among them, 
four major classes have been identified; AAC(1), AAC(3), AAC(2'), and AAC(6'). These 
enzymes catalyze the regioselective N-acetylation of an amino group of the aminoglycoside 
utilizing acetyl-CoA as a donor. They can alter the 1- and 3-amino groups of the central 2-
deoxystreptamine ring (ring II) and the 2’- and 6’-amino groups of the 6-deoxy-6-aminoglucose 
ring (ring I) Figure 14. 
 The 6’-amino group of the aminoglycosides plays a vital role in rRNA binding to the 30S 
ribosomal subunit. Thus, the 6’-position is the target of one of the numerous classes of 
aminoglycoside- modifying enzymes. AAC(6') enzymes are capable of modifying the majority 
of the clinically significant AGAs. This subclass contains more than 25 members. AAC(6') type-
1 of is cause for resistance to the many useful AGAs.4,7 
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1.5.2.3.2. Aminoglycoside Phosphotransferases (APH) 
 O-Phosphorylation of hydroxyl groups in AGAs by APH enzymes is usually observed in 
Gram-positive bacteria such as S. aureus. As a result of APH action a negative charge is 
introduced into the molecule, which causes a remarkable change in their ability to bind to the A-
site in the ribosome.58,59 Aminoglycoside phosphotransferases, also known as kinases, catalyze 
the regiospecific transfer of the γ-phosphoryl group of ATP to one of the hydroxy groups of the 
aminoglycoside. The various classes and subclasses of APHs are APH(4)-I, APH(6)-I, APH(9)-I, 
APH(3′)-I to -VII, APH(2″)-I to -IV, APH(3″)-I, and APH(7″)-I. APH(3′) enzymes are 
considered to be a major class of the APH family enzymes, which phosphorylate the 3'-hydroxyl 
of the ring-II in many AGAs. The APH(3') enzyme has been extensively used in molecular 
biology as traceable resistance marker (e.g., the neo cassette).60 Phosphorylation of the 
aminoglycosides influences significantly their binding to their target at the A-site of the 
ribosome. From a clinical point of view the APH(2”) enzyme is the most problematic 
aminoglycoside phosphotransferase, because it results in high-level resistance to the majority of 
the clinically used AGAs of the 4,6-class (e.g., gentamicin).61 
1.5.2.3.3. Aminoglycoside Nucleotidyltransferases (ANT) 
 Although the ANTs are a relatively small family of AMEs, but they are believed to be the 
major source of AGA resistance mainly found in Gram-negative clinical pathogens, such as 
Enterobacteriaceae and Pseudomonas, which are common organisms in food poisoning and 
cystic fibrosis.62 The different classes of ANTs are ANT(6), ANT(9), ANT(4′), ANT(3″), and 
ANT(2″). The ANTs have significant therapeutic importance because amikacin, gentamycin and 
tobramycin are influenced by ANT (2''). ANTs catalyze the reaction between Mg-ATP and 
aminoglycosides to form O-adenylylated aminoglycosides.63,64  
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1.5.3. Complexity associated with AGAs chemical syntheses 
 The outstanding activity of the AGAs against Gram-negative pathogens makes them an 
attractive starting point to build novel derivatives to deal with MDR pathogens, which are 
increasingly becoming a health threat. Various synthetic methods allow the specific alteration of 
AGA scaffolds and the generation of new AG analogues that address the AGA resistance by 
AMEs and toxicity mechanisms. Although chemical synthesis is a better way to generate a large 
quantities of AGAs, producing big library of clinically important compounds is often a huge 
task. Because of the multitude of functional groups and structural complexity, the synthesis of 
AGAs or the minor alterations of AGA in particular location, requires multiple protecting group 
manipulations. Thus, these synthetic approaches are quite challenging regardless of how minor 
the modifications to the compounds.4  
1.6. Strategies to overcome problems associated with AGAs 
 The toxicity of aminoglycosides potentially can be minimized by the development of new 
derivatives that are specific for their target rRNA sequences and can differentiate between 
bacterial, viral and human targets. Researchers have suggested two possible ways to avoid the 
resistance due to the presence of aminoglycoside modifying enzymes. One way is to develop 
inhibitors for the modified enzymes, and the other way is to develop analogues of natural 
aminoglycosides that evade modification by the modifying enzymes. The development of new 
analogues of natural aminoglycosides is an appropriate method for the expansion of AGAs and 
can be accomplished by introduction of new functional groups to hinder the recognition and/or 
action of resistance enzymes. The most significant long term strategy is to reduce both overuse 
and misuse of antibacterial agents. The most recently developed AGAs such as amikacin or 
arbekacin are not affected by modifying enzymes, i.e., they retain their antibacterial activity after 
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modification.65 Plazomicin (3) is a next-generation AGA that was obtained through chemical 
synthesis, appending a hydroxy aminobutyric acid substituent at 1-position of the 2-
deoxystreptamine ring and hydroxyethyl chain at 6'-position of sisomicin. Plazomicin belongs to 
4,6-disubstistuted AGA family and is blocked by G-1405 methyltransferase. In addition, it 
confers the ability to evade the all known AMEs except AAC(2')-I. It has completed phase II 
clinical trials in early 2012, till date neither ototoxicity nor nephrotoxicity was reported in human 
studies.66 
1.7. Objective of this project 
 The goal of this project was the development of efficient AGAs that are less toxic (i.e., 
more selective) and that circumvent resistance. Apramycin and paromomycin were considered to 
be ideal substrates from which to develop new derivatives by modifying a certain locations of the 
molecules. Böttger et al have demonstrated that apramycin is the first example of an 
aminoglycoside antibiotic with reduced ototoxicity yet strong antibiotic activity against a range 
of clinical infectious diseases including multidrug resistant Mycobacterium tuberculosis, it 
causes only little hair cell damage and hearing loss,25 as observed in the ex vivo murine cochlear 
explant method and in vivo guinea pig auditory brainstem response model.  
 Further, efforts continue towards finding new active molecules, working with similar 
methods and ended up with increased selectivity by modification at the 4'- and 4',6'- positions of 
potent natural pseudotetrasaccharide paromomycin. The idea behind this work is that the toxicity 
of AGAs is due to the sequence similarity between eukaryotic mitochondrial and bacterial 
ribosomes, both possess an adenosine at position 1408. Thus, paromomycin makes a hydrogen 
bond to N(1) of A1408 by ring I of C(6’)-OH; this is probably the major interaction of 
paromomycin with this base. The insight led us to modify ring I, and particularly C(6’) position, 
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leading to variation in the activity of paromomycin. The goal of this project is generate 
paromomycin analogues by introducing new binding sites at 4' and 6' positions. In particular, this 
meant constructing a fused ring at 4' and 6' positions, which is analogous to bicyclic ring in 
apramycin. 
1.8. Introduction to apramycin and paromomycin 
 Apramycin, a typical aminocyclitol antibiotic, is less ototoxic than many AGAs currently 
in use. It is used to treat many bacterial infections in animals caused by Escherichia coli, 
Pseudomonas aeruginosa, and Klebsiella pneumoniae. It was isolated in 1967 as nebramycin 
component 2 from the fermentation broths of Streptomyces tenebrarius30. It is a structurally 
unique aminoglycoside antibiotic, among all other AGAs, in that it contains the unusual bicyclic 
aminooctodialdose (8 carbon ring), a mono substituted 2-deoxystreptamine unit as a common 
core, in addition to a 4-amino-4-deoxy-D-glucose unit (Figure 15). 
 
 Figure 15: Chemical structure of apramycin and paromomycin 
 Paromomycin is a broad range aminoglycoside antibiotic, active against bacterial strains 
and protozoa strains, first isolated from Streptomyces krestomuceticus in 1950s.67 It is also 
known as monomycin or aminosidine and acts as a protein synthesis inhibitor by binding to 16S 
ribosomal RNA. Paromomycin is a member of the class of 4,5-disubstituted 2-deoxystreptamine 
aminoglycoside antibiotics (Figure 15). It is out of clinical use as an antibiotic due to its toxicity 
but was licensed in 2007 in India for the effective and well tolerated treatment of visceral 
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leishmaniasis (VL) for 21 days (a dose of 11 mg/kg).67 Paromomycin is listed in list of essential 
medicines by WHO in 2013. 
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CHAPTER 2. IMPORTANCE OF THE APRAMYCIN 6'-HYDROXY GROUP AND ITS 
CONFIGURATION FOR ACTIVITY 
 
2.1. Introduction 
 As described in the introduction, apramycin is a potent antibiotic with bacterial protein 
growth inhibitory action against Gram-positive and Gram-negative organisms.68 This chapter 
details the synthesis of apramycin derivatives and the influence of these derivatives on 
antiribosomal and antibacterial activity. 
2.2. Synthetic approaches  
 Apramycin, oxyapramycin, saccharocin and aprosamine derivatives are unique 
aminocyclitol antibiotics, containing an unusual higher-carbon amino sugar based on the 
aminooctodiose framework. This higher carbon sugar adopts a dioxa-trans-decalin skeleton 
(Figure 16),69,70 and, probably as a result of this unique structure, apramycin is less ototoxic than 
most AGAs used currently and also evades most of the AGA inactivating enzymes.  
 
Figure 16: Existing apramycin derivatives 
 Apramycin and oxyapramycin also are known as nebramycin component 2, and 
component 7 respectively, and are produced from fermentation broths of Streptomyces 
tenebrarius as first reported in 1967.71 The skeleton of these AGAs consists of three main 
features: the rigid bicyclic system (ring I), a 2-deoxystreptamine (ring II) and a 4-amino-4-
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deoxy-D-glucose (ring III) as shown in Figure 1. Among the few total syntheses of apramycin, 
Tatsuta et al. reported the first in 1983.72  
2.2.1. Synthesis of octodiose 
 
Scheme 1: Synthesis of octodiose (dioxa-trans-decalin structure) 
 Leading up to the total syntheses, Szarek and co-workers reported the synthesis of the 
octodiose dioxa-trans-decalin structure from methyl-α-glucopyranoside.70,73 The synthesis began 
with selective mono-benzoylation of methyl 2,3-di-O-benzyl-α-D-glucopyranoside. Subsequent 
protection of the secondary hydroxyl group as a methylthiomethyl ether was followed by 
removal of the benzoyl group at the 6-position and furnished compound 22. Aldehyde 23, 
achieved by oxidation of primary alcohol 22, was treated with a Grignard reagent affording the 
epimeric mixture of 24 (in a 5:1 ratio). The major isomer was treated with m-CPBA to generate 
epoxide 26 which, when subjected to a ring opening with sodium azide, gave the epimeric azides 
27. Photolysis of the azide lead to the bicyclic 28,74 which on methanolysis yielded a mixture of 
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glycosides 30. These scaffolds are considered as the first synthetic examples of dialdoses with 
the dioxa-trans-decalin structure (Scheme 1).70,73  
2.2.2. Total synthesis of 4-O-(2-amino-2-deoxyoctodiosyl)-2-deoxystreptamine 
 Later, Szarek et al. reported the first total synthesis of 4-O-(2-amino-2-deoxyoctodiosyl)-
2-deoxystreptamine starting from the disaccharide paromamine 31, which contains the key 
glycosidic linkage between 2-deoxystreptamine and the aminoglycosyl moiety. The synthesis 
began with paromamine 31 which was subjected to N-tosylation, then selective silylation of the 
primary hydroxyl group followed by benzoylation of remaining hydroxyl groups, to give the 
protected paromamine 32 in a 62% overall yield. The silyl group was removed under mild acidic 
conditions to give the 6'-alcohol, which was subjected to dimethyl sulfoxide-based oxidation to 
furnish the key aldehyde intermediate 33 in 85% yield. Treatment of 33 with (ethoxycarbonyl-
methylene)triphenylphosphorane afforded the exclusively E-α,β-unsaturated octuronic ester 34 in 
80% yield. When this ester 34 was subjected to cis-hydroxylation using osmium tetroxide it gave 
ethyl D-threo-D-gluco octuronate 35 in 80-90% yield (3:1 ratio). Ethyl octuronate 34, when 
treated with sodium methoxide, underwent debenzoylation and simultaneous lactonization to an 
octurono-8',4'-lactone 36, with a dioxa-trans-decalin structure. Partial reduction of uronolactone 
36 using lithium aluminium hydride followed by methanolysis gave the corresponding octodiose 
derivative 37 as a 1:1 mixture (anomers at the 8' position). Finally, cleavage of all tosyl groups 
was achieved with sodium in ammonia, after which purification by ion-exchange 
chromatography yielded the free base 38 (Scheme 2).69 
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 Scheme 2: Synthesis of 4-O-(2-amino-2-deoxyoctodiosyl)-2-deoxystreptamine 
2.2.3. Total synthesis of apramycin 
 Tatsuta and co workers reported the first total synthesis of apramycin 6 by a route that 
also allows the synthesis of a variety of structural analogues. The synthesis commenced with the 
preparation of the protected compound 40 from neamine 39, by the following sequence of steps: 
N-benzyloxycarbonylation, N-tosylation and O-cyclohexylidenation in an overall 79% yield.  
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Scheme 3: Synthesis of apramycin 
 Saponification of 40 with a base, then reductive amination of 6'-amino derivative 
followed by oxidation with m-CPBA afforded N-oxide 41 in 83% overall yield. Compound 41 
was treated with benzoyl chloride in the presence of Hünig's base and gave aldehyde 42 in 75% 
yield. Addition of a Grignard reagent to 42 gave a mixture of alcohols (6'S and 6'R), and the 
glycal 44 was achieved in four steps from the 6'S-alcohol.  
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 Azidonitration of 43 gave the 7'-azido derivatives in 4:1 ratio (78% yield), then alkaline 
treatment of the major isomer in methanol afforded methyl β-glycoside 46 in 70% yield. 
Subsequently, the 7'-N-(benzyloxycarbonyl)-methylamino derivative 47 was obtained in a four 
step process from 46. The 3'-deoxy compound 49 was achieved by a three step sequence: 
mesylation, replacement of the labile 3'-mesylate with chloride, and finally radical 
dehalogenation. Epimerization 49 at the 6'-position group was achieved by the treatment with 
sodium acetate to give the oxazolidinone 50. Deprotection of the tosyl groups was accomplished 
with sodium in liquid ammonia, then alkaline hydrolysis and subsequent acidic hydrolysis 
provided the aprosamine 18. Finally, the introduction of the 4-amino-4-deoxy-D-glucosyl 
scaffold was achieved through the glycosylation of the alcohol 51 with glycosyl donor 52 under 
modified Mukaiyama conditions. Hydrogenolysis of 53 followed by resin purification furnished 
apramycin 6 (Scheme 3).72,75  
2.3. Existing modifications of apramycin  
 The existing literature on apramycin covers the influence of modification of functional 
groups at various locations on its antibacterial activity. Numerous patents have been filed for the 
development of new apramycin AGAs that can evade resistance and have limited toxicity. Most 
modifications of apramycin were reported in the 1980s and include 5-deoxy and 5,6-dideoxy 
derivatives,76,77 glycosides at the 5- and 6-positions,78 modification at N1, N2', N7', and N4'',79-82 
modification at the O6'' position,83 and the preparation of aprosamine 18 and its methyl β-
glycoside 20.25,75  
2.3.1. Modification of the 5- and 6- positions of apramycin 
 A novel method for derivatizing apramycin in one regioselective modification is 
highlighted in US patents 1982/4,358,585 and 1983/4,370,475. The synthesis of 5-deoxy and 
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5,6-dideoxyapramycin is achieved by installation and then reductive removal of halogen 
functionality in apramycin. The resulting apramycin analogue had reinforced antimicrobial 
activity against Gram positive and negative bacteria pathogens.  
 
 
Scheme.4: Approaches to the synthesis of 5-deoxy and 5,6-dideoxyapramycin 
 The modification of 5- and 6-positions of apramycin involved a four step sequence to 
achieve 5,6-diol intermediate 54 beginning with the carbamate protection of all amines followed 
by masking of the 5,6-hydroxyl groups with a cyclic acetal. Then, the remaining hydroxyl groups 
were protected as esters followed by acidic hydrolysis of the acetal to give the key 5,6-diol 54. 
Selective 6-O-acetylation was followed by introduction of halogen at the 5'-position; reductive 
removal of the halogen gave 56. Global deprotection by hydrolysis and catalytic hydrogenation 
afforded 5-deoxyapramycin 57. Further, the key intermediate 54 was subjected to sulfonylation 
with methanesulfonyl chloride followed by reaction of sodium iodide and zinc dust to provide 
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the 5,6-dideoxy intermediate 59 with a 5,6-double bond. Hydrolysis and catalytic hydrogenation 
then gave the 5,6-dideoxyapramycin derivative 60 (Scheme 4).76,77 
 In an attempt to maximize activity by incorporating ring II of the 4,5- or 4,6-AGAs, 
Kawaguchi et al. have also reported the synthesis of 5-O-β-D-ribofuranosyl apramycin 65 and 6-
O-(3-amino-3-deoxy-α-D-glucosyl) apramycin derivative 63 (Scheme 5) and these compounds 
were tested for activity against bacterial organisms and strains producing AMEs.78  
 
Scheme 5: Synthesis of 5-O-β-D-ribofuranosyl apramycin and 6-O-(3-amino-3-deoxy-α-D-
glucosyl) apramycin derivatives 
2.3.2. Modification of the N1, N3, N2', N7', and N4''- positions of apramycin 
 Novel methods for derivatizing apramycin by regioselective modification are disclosed in 
various US patents dating from 1982-84. Kirst and co-workers reported that the synthesis of N1, 
N3, and N2'-derivatives of apramycin can be simply achieved by transition metal-directed 
acylations of apramycin and related AGAs.79,80,84,85 They selectively protected amino 
functionality by changing the transition metal cations. Zinc salts are used to achieve regio-
selective acylation and alkylation of N1 of 4-O-substituted-2-deoxystreptamine AGAs in a single 
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reaction. Copper salts are used for the synthesis of N3-acyl derivatives of apramycin in a single 
step. Nickel salts are used to accomplished the regioselective acylation and alkylation of N2' of 
4-O-substituted-2-deoxystreptamine containing AGAs (Scheme 6). These methods were used to 
incorporate numerous alkyl chains including C2-C4 alkyl derivatives. Acyl derivatives were 
subjected to diborane or lithium aluminium hydride reduction to access the corresponding alkyl 
chains. The resulting derivatives were tested for antimicrobial activity against Gram positive and 
negative bacteria pathogens. 
 
Scheme 6: Transition metal directed derivatization  
 A new approach for regioselective derivatization of apramycin, in particular at N4'' 
position was highlighted in the US patent 4,360,665.81 The protection strategy for selective 
modification at 4'' position involves masking of all amine functional groups with a 
benzyloxycarbonyl protecting group, after which the 5,6- and 2'',3''- diols were each protected as 
isopropylidine acetals. Finally, the 6''-hydroxyl group was protected as in the form of C1-C4 
esters. These derivatizations set the stage for the key step of this method, which involves the 
hydrogenation or base hydrolysis to provide the 4''-free amine so that migration of the 6''-O-acyl 
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group can give the 4''-derivative of apramycin. 4''-N-alkyl analogues were then prepared by 
reduction of corresponding acyl derivatives using diborane or lithium aluminum hydride.81 
 The synthesis of 7'-N-alkylapramycin derivatives and their biological activity is reported 
in the US patent 4,458,065.82 1,3,2',4''-Tetra-N-protected apramycin derivatives were accessed by 
first making an apramycin-carbon dioxide complex. Then, the 7'-N-alkyl-1,3,2',4''-tetra-N-
protected apramycin derivatives were prepared by alkylation. General deprotection strategies 
yielded the 7'-N-alkyl derivatives, whose antibacterial activity is similar to that of the parent 
apramycin. 
2.3.3. Modification of the 6''-position of apramycin 
 In US patent 4,379,917,83 the synthesis of apramycin derivatives altered at the 6''-position 
with a range of substituents was reported together with their antibacterial activity. The synthesis 
of 6''-substituted-apramycin antibiotics can achieved by protecting the five amines with 
carbamate protecting groups, and the 5,6- and 2'',3''-diols with cyclohexylidene or isopropylidene 
acetals. The 6''-hydroxyl group is then substituted with by variety of substituents including 
halogen, thio, azido, cyano, etc. Subsequent deprotection, accomplished by either basic 
hydrolysis, acidic hydrolysis or hydrogenation over a palladium catalyst, gave the targeted 6''-
derivatives. 
2.4. Choice of apramycin as parent 
 Cell free translation assays with single point and hybrid ribosomes described by the 
Böttger group predict low toxicity for apramycin, which is borne out in cochlea explant studies 
showing little hair cell loss and eventually in guinea pig models. Furthermore, MIC studies with 
bacteria carrying the various AMEs show apramycin to not be affected by them. Thus, 
apramycin is potentially a excellent AGA except that it generally has weaker activity than AGAs 
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currently in clinical use. Apramycin is relatively unsusceptible to modification by AMEs 
compared with competitor AGAs. Specifically, only the AACs modifying positions N1 and N3 
by acylation are effective. Furthermore, in contrast to most AGAs apramycin is active against 
Enterobacteriacae carrying genes for the 16S rRNA methyltransferases.86 Overall, the findings 
of the lack of ototoxicity and minimal resistance in bacteria carrying AMEs and 
methyltransferases, make apramycin a good lead for further improvement.  
2.5. Rationale  
 
Figure 17: The interactions between apramycin and 16S rRNA nucleotides. (This figure has 
been reproduced from “Matt, T.; Ng, C. L.; Lang, K.; Sha, S.-H.; Akbergenov, R.; Shcherbakov, 
D.; Meyer, M.; Duscha, S.; Xie, J.; Dubbaka, S. R.; Perez-Fernandez, D.; Vasella, A.; 
Ramakrishnan, V.; Schacht, J.; Böttger, E. C., Proc Natl Acad Sci. 2012, 109, 10984-10989”.) 
 
 As described in chapter 1, Section 1.4.2, in X-ray studies with the complete 30S bacterial 
ribosomal subunit the bicyclic ring II of apramycin is bound to the flipped out conformation of 
the bacterial ribosomal A site similar to ring I of the 4,5- and 4,6-AGAs. The β-face of ring II 
interacts through CH-π interactions with the bacterial ribosomal base G1491, and sugar-base-pair 
interactions are formed with the universally conserved A1408 of the bacterial ribosomal A site. 
In particular, the 6'-OH group of AGA serves as hydrogen bond donor to N1 of the ribosomal 
base A1408 and the ring oxygen (O5') acts as hydrogen bond acceptor from the N6 amine of 
A1408 (Figure 17).26 However, crystallographic studies of apramycin bound to a short model 
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sequence corresponding to the eukaryotic ribosomal A site have the drug bound to a flipped in 
conformation in which A1492 forms hydrogen bonds with G1408. In this complex, the bicyclic 
ring II of apramycin is rotated with respect to its orientation in the bacterial complex and does 
not stack with A1491. The 2'-NH2 group of apramycin forms a hydrogen bond to the G1408 O6, 
which is free from any interactions in the bacterial complex (Figure 17). Moreover, apramycin 
O5’ and O6’ bind to three of the six hydration water molecules of a magnesium ion, rather than 
to the base at position 1408 i.e., the apramycin 6'-OH is exposed to water.29,30 There is therefore 
a dichotomy between the modes of binding of apramycin to the complete bacterial 30S subunit 
and the short eukaryotic model sequence, leading to uncertainty about the true binding mode. 
Modification of the 6'- and 7'- positions of apramycin was considered to be a suitable approach 
to address this dichotomy and shed light on the correct binding mode. The following sections 
discus work conducted to modify the 6' and 7' positions and their effect on antiribosomal and 
antibacterial activity.  
2.6. Results and discussion 
 Various modifications can be made at the 6’-position including inversion of the hydroxyl 
group, replacement of hydroxyl group with both inversion and retention by an amine group, 
replacement by a halogen atom and by a hydrogen atom. Modifications can also be made at the 
7'-position including the preparation of analogues in which the methyl group is replaced by 
longer alkyl chains. Other possible modifications at the 7'-position include desamino, desmethyl 
and hydroxyl analogues (Figure 18). 
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Figure 18: Apramycin analogs targeted 
2.6.1. Modification at the 6'-position 
 After several unsatisfactory approaches using carbamate-based strategies, all primary 
amines were protected as azides and the secondary amine as a benzyl carbamate. Initially, the 
5,6- and 2'',3''-trans-vicinal diols were protected as Ley-type bisacetals, but this was found 
difficult to cleave. Eventually, as described below, selective protection of the 6’-alcohol was 
achieved by oxazolidinone formation. 
2.6.1.1. Synthesis of a key apramycin protected intermediate 
 The synthesis commenced with primary amine conversion to azides by copper-catalyzed 
diazotransfer reaction using imidazole-1-sulfononyl azide hydrochloride, also known as Stick's 
reagent,87 a commonly used diazotransfer reagent. Unfortunately, this reagent afforded the 
desired 1,3,2',4''-tetraazido derivative 69 in only 10-15% yield.  
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Scheme 7: Synthesis of azide protected apramycin derivatives 
 On the other hand, reaction of apramycin sulfate 6 with trifluoromethanesulfonyl azide 
gave 1,3,2',4''-tetraazido derivative 69 together with the 7'-demethyl-1,3,2',7',4''-penta-azido 
compound 70 in 50% and 10-20% yield, respectively (Scheme 7).88 Trifluoromethanesulfonyl 
azide, which can be synthesized in situ by reaction of sodium azide and trifluoromethanesulfonic 
anhydride,89 was therefore the reagent of choice. Demethylated compound 70 was separated and 
the influence of its N7'-methyl group on activity of apramycin was analyzed.
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2.6.1.2. Synthesis of 6'-epi, 6'-deoxy and 6'-methyl apramycin intermediates 
 
Scheme 8: Synthesis of protected apramycin intermediate (except 6', 7') 
 Subsequently, carbamate formation at the secondary amine with CbzCl gave 71 in 93% 
yield with a 4:3 ratio of rotamers as determined by 1H NMR. Treatment with sodium hydride 
then provided the 6',7'-oxazolidinone 72 in 87% yield. Benzylation of all the remaining hydroxyl 
groups using benzyl bromide in the presence of sodium hydride gave 73 in 92% yield, and was 
followed by the cleavage of the oxazolidinone ring. This was achieved by heating to reflux with 
sodium hydroxide in aqueous dioxane and led to the common intermediate 74 in 78% that 
allowed the subsequent selective facile modifications at the 6'- and 7'-positions (Scheme 8). 
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Scheme 9: Synthesis of 6'-ketoapramycin intermediate and attempts for oxidation shown 
 Thereafter, reintroduction of the carbamate group on the secondary amine gave 75 in 
90%, with a 3:2 ratio of rotamers according to the 1H NMR data. Afterwards, PCC and SO3-Py 
oxidations did not give encouraging results, prompting a switch to hypervalent iodine oxidation 
to convert the 6'-hydroxy to 6'-keto derivative. IBX was used as an oxidizing reagent but due to 
the harsh conditions (reflux in ethyl acetate), it was replaced with Dess Martin periodinane90 for 
oxidation of 6'-hydroxy group, which afforded the 6'-ketone 76 in 90% yield (Scheme 9). 
 
Scheme 10: Synthesis of 6'-epi-apramycin intermediate 
 
46 
 
 
 
 Ketone 76 was subjected to reduction with sodium borohydride in methanol when it gave 
the 6'-epi-apramycin derivative 77 as a separable 5:1 mixture with 75 in 58% yield (Scheme 10). 
The excellent equatorial selectivity observed in the reduction of the ketone 75 can be explained 
using the Felkin model as shown Scheme 11. With the relatively compact nucleophile 
borohydride the 1,3-diaxial interactions to approach along the axial direction are minimal, 
whereas equatorial approach is disfavored by the developing torsional strain between the 
incipient alcohol and the adjacent substituent: axial attack is therefore preferred and the 
equatorial product predominates (Scheme 11).91,92 
 
 
Scheme 11: Felkin model for hydride reduction of ketone 75 
 The addition reaction of freshly prepared methyl magnesium iodide to ketone 76 at -20 ºC 
proceeded well to deliver a 6'-methyl apramycin derivative 78 as a single isomer in 50% yield. 
Due to the rotamer problem, the configuration of 78 was assigned by conversion to the 
oxazolidinone 79 by treatment with NaH in DMF. The nOe spectrum of 79 showed clear 
enhancement of the resonances for H-5' and H-7' but not of H-8' on irradiation of the 6'-Me 
group (Scheme 12).  
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Scheme 12: Synthesis of 6'-methyl derivative of apramycin 
 The equatorial selectivity of nucleophile addition is explained by the bulk of the 
nucleophile and the 1,3-diaxial interactions it encounters on axial attack, resulting in preferential 
equatorial attack.  
 Triflation of 75 with triflic anhydride in DCM gave 80 in 64% yield, and was followed 
by displacement with sodium iodide which afforded the 6'-deoxy-6'-epi-iodo apramycin 
derivative 81. Attempted conversion of the 6'-deoxy-6'-epi-iodo compound to the 6'-deoxy 
compound using AIBN and tris(trimethylsilyl)silane93 failed because of competing reduction of 
one or more of the azides. Accordingly, the azides were first reduced with trimethylphosphine 
leading to the amino compound 82, which was subsequently treated with 
tris(trimethylsilyl)silane93 and AIBN resulting overall in conversion of the iodo compound into 
the desired 6'-deoxyapramycin intermediate 83 (Scheme 13).  
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Scheme 13: Synthesis of a 6'-Deoxyapramycin intermediate 
2.6.1.3. Synthesis of 6’-trifluoromethyl apramycin derivatives 
 Installation of the trifluoromethyl group was achieved by reaction of 76 with the Ruppert-
Prakash reagent94,95 in the presence of cesium fluoride and gave a 1:3 mixture of the adducts 84 
and 85 in 65% yield. The configuration of the trifluoromethyl compounds 84 and 85 was 
assigned using a 13C,1H scalar coupling method96 that was developed for the purpose, and was 
confirmed following complete deprotection. On exposure to tetrabutylammonium fluoride, 84 
and 85 both gave 80% of the corresponding trifluoromethyl bearing tertiary alcohols 86 and 87 
(Scheme 14).  
 
Scheme 14: Synthesis of 6'-trifluoromethylapramycin derivatives 
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 The introduction of the CF3 group to the ketone 76 proceeds with modest axial selectivity 
which can be explained by the Felkin model similar to that shown for the reduction of the ketone 
(Scheme 11). Thus, when the CF3 moiety attacks on equatorial side, significant torsional strain is 
generated between the newly formed trimethylsiloxyl functionality and the vicinal substituent.97 
As a result, axial attack is preferred although CF3 is a bulkier nucleophile than the methyl 
Grignard reagent. This modest axial selectivity can also explained based on the formation of a 
penta co-ordinate species R2CO-SiMe3-CF3
- in which the bulky silyl complex is oriented in 
equatorial site, as a result axial attack has preference.97  
2.6.1.4. Synthesis of 6'-deoxy-6'-azido and 6'-epi-6'-deoxy-6'-azido apramycin derivatives 
 The 6'-epi-6'-deoxy-6'-azido apramycin derivative 88 was obtained from the 6'-triflate 80 
by displacement with sodium azide in DMF. The 6'-deoxy-6'-azido apramycin derivative 90 was 
accessed from the corresponding inverted 6'-triflate 89, by displacement with sodium azide in 
DMF (Scheme 15). 
 
 
Scheme 15: Synthesis of 6'-deoxy-6'-azido and 6'-epi-6'-deoxy-6'-azido apramycin 
derivatives 
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2.6.2. Modification at the 7'N-position 
 In order to modify the 7’-position the protected apramycin intermediate 74 was used as a 
starting material. Reductive amination of the secondary amine 74 with acetaldehyde and sodium 
cyanoborohydride gave the 7'-N-ethyl derivative of apramycin 91 in 74% yield.98 Subsequently 
N-oxide 92 was accessed by treatment with m-CPBA in 80% yield as an approximately 1:1 
mixture of diastereomers. The N-oxide 92 was subjected to demethylation with ferrous sulfate 
(non-classical Polonovski approach) in methanol, which afforded the 7'N-demethyl-7'N-ethyl 
apramycin derivative 93 in 40% yield (Scheme 16).99  
 
Scheme 16: Preparation of 7'N-ethylapramycin intermediate 
 An alternative demethylation reaction was used to modify at the 7'-position of the 
secondary amine 69. In this reaction 69 was subjected to iodine and sodium methoxide in the 
presence of Tris-base100 resulting in the formation of the 7'N-desmethyl derivative 94 in 58% 
yield. Reductive amination with benzyloxyacetaldehyde and sodium cyanoborohydride afforded 
the 7'-N-desmethyl-7'-N-benzyloxyethyl derivative 95 in 63% yield (Scheme 17).  
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Scheme 17: Preparation of 7'N-desmethyl-7'N-benzyloxyethyl apramycin intermediate 
 Of the two different approaches used to achieve the N-demethylation of apramycin 
(Schemes 16 and 17) the second is preferred as it directly gave the demethylated derivative with 
moderate yield. Moreover, this method has broader scope for derivatization at the 7'-position of 
apramycin.  
2.6.3. Synthesis of aprosamine and 6'-epi-aprosamine 
 Adapting the literature method71,101 removal of the 4-amino-4-deoxy-D-glucopyranose 
(ring III) leads to the aprosamine derivatives. The synthesis of aprosamine commenced with 
acidic hydrolysis of apramycin at 95 ºC providing the aprosamine 18 and 4-amino-4-deoxy-D-
glucopyranose hydrochloride as an inseparable mixture. Subsequently, to separate these 
compounds, all the amines were converted to carbamates. Then, the purification of this mixture 
provided the carbamate protected aprosamine intermediate 51 in 60% yield. Thereafter, 
carbamates were removed by conventional hydrogenolysis over palladium hydroxide on carbon 
at atmospheric pressure in aqueous dioxane in the presence of acetic acid giving aprosamine 18 
as the acetate salt in 63% yield (2:1 ratio of anomers at the 8'-position) (Scheme 18).  
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Scheme 18: Synthesis of aprosamine and 6'-epiaprosamine 
 In the second arm of the scheme, reaction of the aprosamine intermediate 51 with 1,1-
dimethoxycyclohexane in the presence of a catalytic amount of an acid gave the 5,6- protected 
aprosamine intermediate 97 in 77% yield. Selective acetylation of 97 with acetic anhydride in 
pyridine gave 98 in 86% yield, which was subjected to oxidation with the Dess Martin 
periodinane followed by the reduction with NaBH4 to give the 6'-epi-aprosamine derivative 99 as 
a separable 2:1 mixture with 98 in 41 % yield. Total deprotection was achieved by a three-step 
protocol. The cyclohexylidene ketal first was converted to the corresponding diol with acetic 
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acid, then was subjected to deacetylation followed by hydrogenolysis over palladium hydroxide 
on carbon in aqueous dioxane in the presence of acetic acid. This sequence gave the 6'-
epiaprosamine 19 as the acetate salt in 90% yield (5:1 ratio of anomers at the 8'-position) 
(Scheme 18). 
2.6.4. Unmasking of the apramycin derivatives 
 Global deprotection was typically accessed by a two-step protocol. Thus, all azido groups 
were first converted to the corresponding amines with trimethylphosphine and sodium hydroxide 
in hot aqueous THF (Staudinger reaction). Benzyl ethers were then removed by hydrogenolysis 
over palladium hydroxide102 on carbon at atmospheric pressure in aqueous methanol in the 
presence of acetic acid giving the apramycin derivatives 107-115 and 117 (Scheme 19). 
Purification by Sephadex chromatography (CM Sephadex C-25), eluting with deionized water 
and then aqueous NH4OH, afforded the apramycin derivatives in the form of the free bases. 
Finally, lyophilization in the presence of acetic acid gave the products in the form of their acetate 
salts for screening in the biological assays.   
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Scheme 19: Staudinger reaction and hydrogenolysis providing apramycin derivatives 
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2.7. Biological evaluation 
 The above synthesized samples were submitted to the Böttger lab in Zurich, where they 
were screened for selectivity and antibacterial activity. As described in the Introduction the 
ribosomal drug susceptibility is studied by measurement of the IC50 against a single rRNA allelic 
derivative of the Gram-positive eubacterium Mycobacerium smegmatis.103 Rabbit reticulocyte 
ribosomes were used as a source of authentic eukaryotic cytosolic ribosomes. Together with 
apramycin 6 and the 4,5-aminoglycoside antibiotics paromomycin 10 and neomycin B 14 as 
comparators all apramycin analogues were screened for their ability to inhibit ribosomal activity 
in the cell-free translation assays (Table 2). 
Table 2: Antiribosomal activities (IC50, μg/mL) and selectivities* 
Co
mp
d 
Substitutio
n Type 
Bacterial 
activity 
Mit13 
Activity 
(Selectivity) 
A1555G 
Activity 
(Selectivity) 
Cyt14 
Activity 
(Selectivity) 
RRL 
6 apramycin 0.09 67.29 (747) 27.77 (308) 58.65 (652) 
24.25 
(269) 
10 
paromomy
cin 
0.03 
50.54 
(1685) 
5.83 (194) 10.39 (346) 
9.78 
(326) 
14 
neomycin 
B 
0.01 1.62 (162) 0.22 (22) 
17.12 
(1712) 
22.12 
(2212) 
107 6'-deoxy >20 101.15 85.26 103.05 35.74 
108 6'-epi-OH 0.74 
124.21 
(168) 
45.08 (61) 90.01 (122) 
66.34  
(90) 
109 
6'-α-
methyl 
1.24 
185.71 
(150) 
180.95 
(146) 
143.02 
(115) 
45.12 
(36) 
110 6'-α-CF3 >20 >1000 >1000 >1000 n.d. 
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111 
6'-epi-OH-
6'-β-CF3 
>20 >543.33 >1000 >1000 n.d. 
112 
6'-deoxy-
6'-α-amino 
8.60 86.93 (10) 45.61 (5) 61.90 (7) 
44.62 
(5) 
113 
6'-deoxy-
6'-β-amino 
5.15 67.96 (13) 52.24 (10) 71.05 (14) 
22.23 
(4) 
18 
Aprosami
ne 
1.99 56.69 (28) 23.35 (12) 49.19 (25) 
36.08 
(18) 
19 
6'-
epiaprosa
mine 
>10 104.21  36.51 104.25 72.33 
115 
7'-N-
desmethyl 
0.27 
116.57 
(431) 
81.98 (303) 91.95 (340) 
42.26 
(156) 
114 7'-N-ethyl 0.29 
107.53 
(371) 
74.43 (256) 88.50 (305) 
26.94 
(93) 
117 
7'-N-(2-
hydroxyet
hyl) 
1.17 103.47 (88) 57.61 (49) 60.28 (51) 
18.25 
(15) 
*Selectivities are obtained by dividing the eukaryotic activity by bacterial activity. 
 Complete removal of the hydroxyl group at the 6’-position showed significantly reduced 
activity of the AGA. When compared to parent apramycin 6, the 6'-deoxy apramycin derivative 
107 exhibits a >200 fold loss of activity. On the other hand the 6'-epiapramycin derivative 108 
shows an approximately 10 fold loss of activity against bacterial wild-type ribosomes. 
Additionally, the deoxy compound 107 exhibits greater loss of activity (around 100 fold) as 
compared to the 6’-epi-compound 108 (3 to 5- fold loss) against the mitochondrial wild-type, the 
A1555G mitochondrial mutant, the cytosolic hybrid, and rabbit reticulocyte ribosomes (RRL). 
Thus, inversion of stereochemistry at the 6’-position of apramycin has only a small effect on 
ribosomal activity, whereas complete removal of the hydroxyl group has a very significant 
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negative effect on the interaction with ribosomes carrying the eukaryotic decoding A-site 
sequences. Thus, the results reveal the significance of the 6'-hydroxyl group and its configuration 
on the interaction of apramycin with the decoding A site. This is consistent with apramycin 
binding to the flipped-out conformation of the target decoding A-site with a hydrogen bonding 
pattern from the 6'-OH to N1 of A1408 as suggested by X-ray crystallographic studies using the 
complete 30S ribosomal subunit,26 and in disagreement with other NMR and crystallographic 
studies using short models of the decoding A site in which the 6'-OH is exposed to water.30 
Incorporation of a methyl group at the 6'-position (109) or of a trifluoromethyl group in either 
configuration (110 and 111) is detrimental to antiribosomal activity in the bacterial wild-type and 
to a slight lower level in the eukaryotic hybrid ribosomes. These results also emphasize the 
greater influence of the 6’-hydroxy group and its configuration on binding to the bacterial rRNA 
A-site rather than to either of the eukaryotic ribosomes. 
 Further, the substitution of the 6'-hydroxyl group apramycin by an amino group is 
strongly detrimental to antiribosomal activity (112 and 113) and reduces the selectivity over the 
hybrid mutant ribosomes. This is presumably because protonation of one of the two amines in 
the vicinal diamine function precludes protonation of the second one,104 and in doing so 
eliminates key interactions with the ribosome. For example, protonation of the 7'-amine would 
not allow protonation of the 6'-amine, which would greatly weaken the pseudobase pair 
interaction with A1408. 
 Removal of the 4-amino-4-deoxy-D-glucopyranose (ring III) from apramycin gave 
aprosamine 18, which showed a ~20 fold loss of activity against bacterial wild-type ribosomes as 
well as hybrid mutants. On the other hand, 6'-epiaprosamine 19 also drastically lost activity 
against all tested ribosomes. This may be a consequence of the lack of hydrogen bonding 
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between C1409-G1491 base pair and the 5''O and 6''-OH positions of ring III. Overall, this 
situation is consistent with the pattern seen with apramycin and 6'-epiapramycin. 
 Simple removal of the methyl group from N7' (115), or its replacement by an ethyl group 
(114), results in a three-fold loss of inhibitory activity for all ribosomes. These modifications are 
affecting the bonding character between N7' and phosphate back bone of A1492, A1493 bases of 
bacterial rRNA. Finally, the replacement of methyl group by hydroxyethyl group 117 reduced 
the activity against the wild-type bacterial ribosomes. 
Table 3: Compound interaction with polymorphic residues in the drug binding pocket 
(IC50, μg/ml) 
  Bacterial A Site 
Compd 6'-Substitution Type Wild Type G1491C G1491A A1408G 
6 apramycin 0.09 31.21 (347) 5.00  (55) 128.9 (1425) 
10 paromomycin 0.03 10.42 (347) 0.57 (19) 0.26 (9) 
14 neomycin B 0.01 0.67 (67) 0.06 (6) 17.51 (1751) 
108 6'-epi-OH 0.74 89.66 (121) 16.01(21) 86.88 (117) 
115 7'-N-desmethyl 0.27 
152.90 
(566) 
44.86 (166) 133.86 (496) 
114 
7'-N-desmethyl-7'-N-
ethyl 
0.29 
117.16 
(403) 
21.56 (73) 189.50 (653) 
*Selectivities are obtained by dividing the single mutant activity by bacterial activity. 
 In an attempt to gain further understanding, the antiribosomal activity of the better 
compounds 108, 114 and 115 towards bacterial ribosomes carrying single point mutations in the 
decoding A site was determined. The study is focused on the comparison with parent compound 
apramycin (6), and the comparators paromomycin (10), and neomycin B (14) and their ability to 
inhibit the bacterial wild-type ribosome in contrast to its A1408G, G1491C and G1491A mutants 
(Table 3).  
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 From this study, it is clear that the apramycin and neomycin B exhibit superior selectivity 
for the wild-type over the A1408G mutant than 6'-epi-apramycin and the other compounds. The 
reason could be the outcome of the imposed gg-conformation of the apramycin C5'-C6' bond 
disfavouring pseudo-base pair formation of the AGA O5' and 6'-OH groups with N1 and N2 of 
G1408.105,106 When compared with the 1408-ring I interaction, the 1491-ring I interaction is 
probably less susceptible to inversion of configuration at the apramycin 6'-position. The 
relocation of the axial 6'-hydroxyl group from the β-face of the bicyclic apramycin ring I to the 
equatorial position on the α-face (6'-epiapramycin) similarly affects the drug binding pockets 
both containing the C1491=G1409 Watson-Crick pair and mutants with C1491●C1409 and 
A1491●C1409 non-canonical base pairs. 
Table 4: Minimal inhibitory concentrations (MIC, μg/ml) of clinical isolates 
Compd 
Strain 
Staphylococcus aureus (MRSA) Escherichia coli 
AG 038 AG 039 AG 042 AG 044 
 
AG 001 AG 055 AG 003 
6 8 8 8 16 
 
16 8 8-16 
10 4 >128 >128 4-8 
 
16-32 8 8-16 
14 0.5-1 nd 128 0.5-1 
 
8-16 nd 4 
107 >128 >128 >128 >128 
 
>128 >128 >128 
108 32-64 64 64 32-64 
 
32 32 32 
109 ≥64 ≥64 ≥64 ≥64 
 
32-64 32-64 32-64 
110 >64 >64 >64 >64 
 
>64 >64 >64 
111 >64 >64 >64 >64 
 
>64 >64 >64 
112 >128 >128 >128 >128 
 
>128 128 128 
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113 >128 >128 >128 >128 
 
>128 >128 >128 
18 32-64 32-64 32 32 
 
64-128 64-128 32-64 
19 >128 >128 >128 >128 
 
>128 >128 >128 
115 16-32 32 16-32 16 
 
16-32 16-32 16 
114 16 8-16 16 8-16 
 
8-16 8-16 8-16 
117 64 ≥64 64 ≥64 
 
32-64 32-64 32-64 
 
 All apramycin derivatives prepared, together with the parent apramycin 6 and other 
comparators 10, and 14, were screened for antibacterial activity against clinical isolates of 
Escherichia coli and methicillin-resistant Staphylococcus aureus (Table 4). Most synthetic 
apramycin derivatives exhibit significantly reduced activity compared to parent apramycin and 
the comparators 10 and 14, which was anticipated on the basis of their cell-free ribosomal 
translation assays data (Tables 2.2). The 6'-epiapramycin 108 showed moderate to good activity 
against some strains of S. aureus and/or E. coli, whereas 6-α-methylapramycin 109 was 
moderately active only against E. coli. Aprosamine 18 exhibits moderate activity and 6'-
epiaprosamine 19 completely lost activity against all strains studied. The 7'-N-desmethyl 
apramycin derivative 113 and the 7'-N-desmethyl-7'-N-ethyl derivative 114 have moderate to 
good activity, in some cases comparable with apramycin, against all strains tested. The 7'-N-
hydroxyethyl derivative 117 is less effective against all strains, as compared to substitution by a 
simple ethyl group 114. 
 Overall, the inversion of the stereochemistry of 6'-hydroxy group of apramycin lessens 
the antiribosomal and antibacterial activity of this AGA; while deletion of the 6'-hydroxy group 
substantially diminishes all activity. Also, the replacement of the 6'-hydroxy group by an amino 
group is detrimental to activity. The overall results point to changes at the 6'-position of 
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apramycin having a greater influence on binding to the wild-type bacterial ribosomes than drug 
binding pockets of the eukaryotic ribosomes. The results are consistent with apramycin adopting 
the standard binding mode of the 4,5- and 4,6-aminoglycosides in the decoding A site of the 
bacterial ribosome as opposed to the alternative binding mode proposed in some studies. 
2.8. Conclusion  
 A series of aminoglycoside antibiotic apramycin derivatives have been prepared by 
modifying the 6'- and N7'-positions and were screened for antiribosomal activity in cell-free 
translation assays with a series of wild-type and mutant ribosomes, as well as for antibacterial 
activity against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and 
Escherichia coli (E coli). All apramycin derivatives prepared showed a greater loss of activity 
against the bacterial wild-type ribosome than against the hybrid mutants of the human 
mitochondrial and cytosolic ribosomes. The existence and its exact stereochemical location of 
the hydroxyl group at the 6'-position is more critical for binding to the bacterial decoding A site 
than to either of its mitochondrial or cytosolic ribosomes. These studies about activity changes 
between the various ribosomes contribute to the current understanding of the mode of interaction 
of AGAs with the bacterial ribosomsal decoding A site and should support future design and 
development of more active and less toxic aminoglycoside antibiotics. 
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CHAPTER 3. SYNTHESIS AND BIOLOGICAL EVALUATION OF PAROMOMYCIN 
ANTIBIOTICS CARRYING AN APRAMYCIN-LIKE RING I 
 
3.1. Introduction 
 Paromomycin is a representative of the 4,5-disubstituted 2-deoxystreptamine 
aminoglycoside antibiotics. It is an effective antibiotic against Gram-negative and several Gram-
positive bacteria but is no longer used in North America as an antibiotic due to its poor 
therapeutic index. Paromomycin is licensed as an effective, well tolerated treatment for visceral 
leishmaniasis (kala-azar) in India.107 This chapter describes the synthesis of paromomycin 
analogues carrying an apramycin-like scaffold in place of ring I and the influence of these 
modifications on antiribosomal and antibacterial activity.  
3.2. Existing modifications of paromomycin ring I 
3.2.1. Modification of the 2',3' & 4'-positions of paromomycin 
 Researchers have invested considerable effort towards generating new paromomycin 
analogues by modifying its key functional groups. Modifications of ring I of paromomycin to 
produce the new antibiotics are surveyed here. The modification of ring I of paromomycin was 
first attempted with the synthesis of 2'-N-ethylparomomycin in the 1980s. The key intermediate 
1,3,2''',6'''-tetra-N-acetylparomomycin 118 was obtained from paromomycin 10 using acetic 
anhydride in aqueous methanol. Subsequently, reductive alkylation of 118 with acetaldehyde and 
sodium borohydride followed by deacetylation afforded 2'-N-ethylparomomycin 119. This 
compound showed comparable activity with the parent paromomycin against selected 
microorganisms.108 Carbamate protection of 1,3,2''',6'''-tetra-N-acetylparomomycin 118 at the 
N2'position, per-acetylation followed by hydrogenolysis of the benzyloxycarbonyl afforded the 
1,3,2''',6'''-tetra-N-acetyl-octa-O-acetyl-paromomycin 120. Deamination of 120 with nitrous acid 
gave pseudotrisaccharide 121, which was used for the replacement of ring I of paromomycin 
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with various glycosides (Scheme 20).109 Among these ring I analogues of paromomycin, only the 
6'-amino-6'-deoxy-glucopyranosyl derivative 122 exhibited slightly reduced activity; the galacto- 
(123) and manno- (124) derivatives had dramatically lower activity when compared with 
paromomycin.109 
 
Scheme 20: Synthesis of 2'-N-ethylparomomycin and ring I analogues of paromomycin 
 Modification of the 3' and 4'-positions of paromomycin involved a 5 step sequence to 
achieve 4'-hydroxyl intermediate 125 starting with the carbamate protection of all amines 
followed by benzylidene protection of the 4',6'-diol. After that, the remaining hydroxyl groups 
were protected as acetates and cleavage of the benzylidene ring followed by selective 6-O-
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benzoylation gave the 4'-hydroxyl intermediate 125.110 Reaction of 125 with sulfuryl chloride 
provided the 4'-epichloro-4-deoxy derivative 126, which gave 4'-deoxyparomomycin derivative 
127 by reductive removal of the halogen using tributyltin hydride (Scheme 21). 
 
Scheme 21: Synthesis of 3',4' modified paromomycin derivatives 
 O-Mesylation of compound 125 at the 4'-position and subsequent treatment with sodium 
methoxide provided the 3',4'-β-epoxide 130. The reaction of 130 with sodium iodide in acetone 
afforded an iodohydrin which on treatment with methanesulfonyl chloride in pyridine gave the 
unsaturated paromomycin derivative 131. Similarly, the reaction of 130 with sodium azide lead 
to the 4'-azido-4'-deoxy intermediate 133. All these intermediates were subjected to conventional 
deprotection methods to give the corresponding paromomycin derivatives (Scheme 21). Among 
these molecules the 4'-deoxy 129 and 3',4'-dideoxy 132 paromomycin derivatives exhibited 
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slightly improved activity against a number of bacterial strains, while the deoxy amine 134, 
showed comparable activity in ribosomal assays.110,111 In contrast Vasella and coworkers later 
reported that the 4'-amino-4'-deoxy derivative 134 and the 4'-deoxy derivative of paromomycin 
129 show slightly less activity than the parent antibiotic. These workers also confirmed that the 
galacto configured ring I derivatives 135 & 136 exhibit lesser activity than the corresponding 
gluco-configured analogues (Figure 19).112 
 
Figure 19: Some 4'-modified paromomycin derivatives 
3.2.2. Modification of the 4' & 6'-positions of paromomycin 
 In recent years, researchers have focused on modification of the 4' and 6'-positions of 
paromomycin. Various crystallographic studies and existing literature on paromomycin revealed 
the role of the 6'-hydroxyl group in binding to the bacterial ribosomal RNA. Consequently 
Vasella and coworkers investigated the importance of the 6'-hydroxyl group by replacing it with 
fluorine and by complete exclusion of hydroxyl group as shown in Scheme 4. Regioselective 
ring opening of the benzylidene ring of 137 followed by radical dehalogenation afforded the 6'-
deoxyparomomycin 139. After that, treatment of 137 with aq. acetic acid gave the 4',6'-diol 141, 
which was subjected to the fluorination of the 6'-hydroxyl group using DAST giving 6'-fluoro-6'-
deoxyparomomycin 142. Deacetylation followed by removal of the Boc groups gave 6'-deoxy 
140, and 6'-fluoro-6'-deoxyparomomycin 143, which were 16 to 32 times less active than the 
original paromomycin (Scheme 22).113 
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Scheme 22: Synthesis of some 6'-paromomycin derivatives 
 
Scheme 23: Synthesis of 4',6'-O-benzylidene derivatives of paromomycin  
 In the European patent 1,953,171 the synthesis of paromomycin derivatives altered at the 
4',6'-position with a range of substituents was reported together with their antibacterial 
activity.114 The synthesis of 4',6'-O-benzylidene substituted paromomycin antibiotics can 
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achieved in six synthetic steps. Paromomycin was subjected to the copper-catalyzed diazo 
transfer reaction using triflyl azide to give penta azide 144. Subsequently, benzylidenation 
followed by acetylation of remaining hydroxyl groups provided the fully protected intermediate 
145. Cleavage of the 1, 3-dioxanyl ring of 145 with PTSA gave the 4',6'-diol intermediate 146. 
Then, the reaction of 146 with a range of aromatic aldehydes or acetals gave the desired 4',6'-O-
benzylidenated intermediates. Finally, the unmasked 4', 6'-benzylidenated paromomycin 
compounds were achieved after deprotection (Scheme 23).114  
 
Scheme 24: Regioselective opening of the 1, 3-dioxanyl ring of 148 
 Furthermore, Vasella and coworkers reported the regioselective opening of the 1,3-
dioxanyl ring of 148 under two sets of conditions to give regioisomeric products (Scheme 24). 
This approach is useful for selective modification at the 4' and 6'-positions of paromomycin. 
Using these two strategies, a library of paromomycin derivatives including the 4'-O-alkyl, 4'-O-
aralkyl and the 4',6'-acetals24,114,115 were synthesized and their ribosomal activity profile was 
reported. These molecules retained their activity against a range of clinical isolates and showed 
improved selectivity in evasion of mitochondrial and cytoplasmic ribosomes when compared to 
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the parent paromomycin. Recently, Crich group has explored the 4'-position of paromomycin 
further by adding an additional ring using glycosylation. Thus, a range of 4'-O-glycosyl 
paromomycin analogs and a 4'-O-(glucosyloxymethyl) derivative were synthesized and the 
influence of the glycosyl moiety on their protein synthesis inhibitory action by bacterial, 
mitochondrial and cytosolic ribosomes was studied (Scheme 25).116,117 
 
Scheme 25: Various modifications at the 4' and 6'-positions of paromomycin 
 Overall, several strategies have been reported to synthesize new paromomycin analogues 
by modification of ring I with emphasis on the 4’-position or both the 4'- and 6'-positions. 
Modifications of interest include 4'-O-alkyl chains, 4',6'-O-acetals as they displayed interesting 
biological profiles in terms of activity and selectivity. 
3.3. Design of new paromomycin antibiotics 
 According to the existing data, rings I and II of the 4,5- and 4,6-disubstituted 2-
deoxystreptamine class of aminoglycosides are mostly accountable for drug binding to the 
bacterial 30S ribosomal A site. It is established that the glucopyranosyl ring (ring I) of these 
AGAs takes part in a pseudo-base pair interaction with the A1408 nucleotide. In particular, N1 
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and N6 of A1408 base form hydrogen bonds with the 6'-substituent (OH in paromomycin 10 or 
NH2 in neomycin 14) and the ring I oxygen (O5') of the AGA,
12,24,26,118 as described in detail in 
chapter 1, section 1.42. In these type I interactions complexes the glucopyranosyl side chain 
consistently adopts the gauche, trans (gt) conformation119 (Figure 20B). This is to be contrasted 
with the apramycin ring I-A1408 interaction,120,121 where the 6’-hydroxy group is locked in the 
gauche, gauche (gg) conformation leading to a type II interaction with the ribosome (Figure 
20B). 
 
Figure 20: A) Side chain conformations of ring I and estimated populations based on 
methyl α-D-glucopyranoside and methyl 6-amino-6-deoxy-α-D-glucopyranoside, B) Type I 
and II Pseudo-base Pairs 
 Additionally, the existing literature of 4’-O-alkyl paromomcyin derivatives shows that an 
alkyl chain length of 2 or 3 carbons is ideal to afford the optimum reduction in mitoribosomal 
activity with the minimum loss of anibacterioribosomal activity. In the 4’,6’-O-alkylidene 
paromomycin derivatives the ethylidene derivative 153 had a better activity profile than the 
analogous methylidene derivative 151, which also suggests a 2 carbon alkyl chain on O4’ to be 
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optimal.115 Furthermore, it is known that the unusual monosubstituted 2-deoxystreptamine AGA 
apramycin 6 is not ototoxic in animal models consistent with predictions, based on cell free 
translation assays of mitochondrial ribosomes.25 Taking all of these factors into consideration 
paromomycin-apramycin hybrids were designed to improve the antibacterial activity and reduce 
the toxicity profile of paromomycin.  
 
Figure 21: Design of the new class of paromomycin analogs 
 The designed paromomycin-apramycin hybrids consist of paromomycin derivatives in a 
trans-dioxadecalin-like structure replaces ring I of the parent. The new bicyclic ring carries a 
methyl substituent placed so as to resemble the ethylidene acetal 153. The bicyclic ring also 
carries either an equatorial or axial amine located in such a way as to participate in a type I or 
type II pseudobase interaction with A1408 (Figure 21). The following sections discuss work 
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conducted to synthesize the target molecules (153-157) and their effect on antiribosomal and 
antibacterial activity.  
3.4. Results and discussion 
3.4.1. Synthesis of a paromomycin 4',6'-diol intermediate 
 
Scheme 26: Synthesis of a protected paromomycin 4',6'-diol derivative 
 The synthesis began by diazo transfer to paromomycin sulfate 10 with imidazole sulfonyl 
azide (Stick's reagent)87 which afforded the known 1,3,2',2''',6'''-pentaazido derivative 144 in 
62% yield. Subsequent acid catalyzed benzylidene protection of 144 at the 4' and 6' hydroxyl 
groups gave 158 in 60% yield. Benzylation of all the remaining hydroxyl groups using benzyl 
bromide in the presence of sodium hydride gave 159 (73%) and was followed by the cleavage of 
benzylidene ring, which was achieved by reaction with p-toluenesulfonic acid in methanol 
affording the common intermediate 160 in 84% yield. This intermediate allows the subsequent 
selective facile modifications at the 4'- and 6’-positions (Scheme 26).  
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3.4.2. Synthesis of a 6'-allylparomomycin derivative 
 
 
Scheme 27: Synthesis of a 6'-allylparomomycin derivative 
 The diol 160 was subjected to selective oxidation using TEMPO and BAIB in DCM,122 
and, without purification, the resultant aldehyde was subjected to the allylation (Scheme 27). 
Numerous conditions for allylation were tried leading to the results presented Table 5.  
Table 5: Allyllation of aldehyde 161 
Entry  Conditions Remarks [162R & 162S-isomers] 
1 
Allyltributyltin 
BF3OEt2, DCM
123 
30%, 28% (1:1 ratio) 
 
2 
(+)-Ipc2Allyl/Diethylether, 
3N NaOH/30% H2O2
124 
200 mg Scale: 40% & 3% (1:0.1) 
2.0 g Scale: 25% & 28% (1:1) 
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3 AllylTMS, TiCl4, DCM
125 1:1.3 ratio* 
4 AllylMgBr in Et2O
125 Starting material decomposed 
*Not isolated 
 First, aldehyde 161 was treated with allyltributyltin and boron trifluoride diethyl etherate 
in DCM which gave the 6'-allylated derivative 162R in 30% yield and the S-isomer 162S in 28% 
yield, whose configurations were determined as described below. To improve 
diastereoselectivity of the allylation reaction Brown allylation was attempted. Thus , B-
allyldiisopinocampheylborane was synthesized from (-)-α-pinene in three steps according to the 
literature protocol.124 On a smaller scale the use of this reagent gave a percentage of the desired 
R-alcohol, but upon the increasing the scale of the reaction inconsistent results were observed. 
Allylation with allyltrimethylsilane in the presence of titanium tetrachloride also gave 1:1.3 ratio 
of R and S-alcohols. On the basis of this brief survey, allyltributyltin was selected as the 
preferred reagent. 
 The absolute configuration of the newly formed ring in compound 162R was confirmed 
by conversion to its benzylidene derivative 163 by treatment with benzaldehyde dimethylacetal 
in the presence of catalytic amount acid in acetonitrile. The nOe spectrum of 163 showed clear 
enhancement of the resonances for H-4' and H-6' on irradiation of the benzylidene proton 
(Scheme 28). 
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Scheme 28: Synthesis of 4',6'-O-benzylidene derivative of 162R 
3.4.3. Synthesis of a bicyclic ring I for paromomycin  
 The 6'-allylparomomycin derivative 162R was subjected to bromocycloetherification 
using N-bromosuccinimide in acetonitrile to give the cyclized product 164 in 38% yield along 
with two furanosyl derivatives 165 and 166 in 20% and 22% yields, respectively (Scheme 29). 
The axial location of the alcohol in 164 confirmed the assignment of configuration of the 
substrate. The relative configurations of the two furanosyl products were assigned following 
complete deprotection. The mechanism of formation of 164-166 involves the reversible 
formation of two diastereomeric cyclic bromonium ions A and B, which are in equilibrium with 
the substrate126,127 as shown in Scheme 10. The formation of cyclic product 164 involves the 
attack of the 4'-hydroxyl group on cyclic bromonium ion A in a 6-exo fashion. The formation of 
165 and 166 involves the participation of the ring oxygen to open the cyclic bromonium ions A 
and B in a 5-exo approach, respectively. The cyclized product 167, arising from attack of the 4’-
hydroxy group on bromonium ion B, was not formed probably due to severe 1,3-diaxial 
repulsions between the hydroxyl group and bromomethyl group.  
 Bromocycloetherification of the diastereomeric homoallyl alcohol 162S gave only 
furanosyl derivatives. The contrast in results between diastereomers 162R and 162S results can 
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be explained by analysis of the respective side chain conformations. In case of isomer 162R, 
both the gg and the gt conformations are expected to be populated and leading to the bicyclic 164 
and the two furanosides 165 and 166, respectively. With isomer 162S the preferred conformation 
will be the gg, which will lead to furanoside products (Figure 22).  
 
Scheme 29: Synthesis of ring I modified cyclic derivatives of paromomycin 
 
76 
 
 
 
Figure 22: Side chain conformations of ring I of 162R and 162S  
3.4.4. Derivatization of the 6'-position of bicyclic paromomycin  
 Bicyclic compound 164 was subjected to the oxidation with Dess Martin periodinane90 
reagent which afforded the 6'-ketone. This was further subjected to the reduction with sodium 
borohydride in methanol to give the bicyclic 6'-equatorial hydroxy paromomycin derivative 170 
as a separable 3:1 mixture with 164 in 58% yield. The bicyclic 6'-equatorial azido paromomycin 
derivative 169 was accessed from the corresponding inverted 6'-triflate 168 in 49% yield by 
displacement with sodium azide in DMF. The bicyclic 6'-axial azido paromomycin derivative 
172 was achieved from the corresponding inverted 6'-triflate 171 in 67% yield, by displacement 
with sodium azide in DMF (Scheme 30).  
3.4.5. Deprotection of the paromomycin-apramycin hybrid analogues  
 
77 
 
 
 
 
Scheme 30: Preparation of bicyclic 6'-equatorial hydroxy, 6'-equatorial and 6'-axial azido 
derivatives of paromomycin 
 Global deprotection was achieved in one pot by hydrogenolysis. Thus, all benzyl ethers, 
azido groups and the bromine atom were removed by hydrogenolysis over palladium on carbon 
at 40 psi in aqueous 1,4-dioxane in the presence of acetic acid. In this manner the paromomycin 
derivatives 154-157 with the apramycin-like scaffold for ring 1 together with the furanosyl 
derivatives 173, 174 (Scheme 31) were obtained in the form of their acetate salts after 
purification by Sephadex resin column. These compounds were used for screening in biological 
assays. The relative configuration of the furanosyl derivatives 173, 174 was assigned based on 
the 1H, and13C chemical shifts and coupling constants (Table 6), which confirmed that the both 
derivatives as 1,2-cis-glycosides.128 In addition, the nOe spectrum of 173 showed mutual 
enhancement of the resonances for H-6' and H-9' on irradiation of the other proton. In contrast 
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the nOe spectrum of 174 showed enhancement of the resonance for H-6' on irradiation of the 8' 
proton.  
Table 6: 1'-H NMR data of 173 and 174 derivatives 
Compound 1H Chemical shift and 
coupling constant of 1'-H 
13C chemical shift of 1'-C 
173 5.61 (5.14 Hz) 101.23 
174 5.66 (5.14 Hz) 101.1 
  
 
Scheme 31: Global deprotection by hydrogenolysis 
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3.5. Biological results  
 The above synthesized samples were submitted to the Böttger lab in Zurich, where they 
were screened for antiribosomal and antibacterial activity. The methods were identical to the 
ones applied in the apramycin series (Chapter 2) for the study of ribosomal susceptibility to the 
drug.  
3.5.1. Discussion of antiribosomal activity  
Table 7: Antiribosomal activities (IC50, μg/mL) and selectivities* 
Com
pd 
Substitution 
Type 
Bacterial 
Activity 
Mit13 
Activity 
(Selectivity) 
A1555G 
Activity 
(Selectivity) 
Cyt 14 
Activity 
(Selectivity) 10 Paromomycin 0.03 50.54 (2509) 5.83 (194) 10.39 (470) 
18 Apramycin 0.09 67.29 (747) 27.77 (308) 58.65 (651) 
14 Neomycin B 0.02 1.62 (162) 0.22 (22) 17.12 (1712) 
106 
6'-
epiapramycin 
0.74 124.21 (168) 45.08 (61) 90.01 (122) 
153 
4',6'-O-
Ethylylidene  
0.12 
226.38 
(1889) 
76.97 (641)       -- 
154 
Bicyclic 6'- 
axial hydroxy  
0.47 193.33 (411) 213.00 (453) 169.16 (360) 
155 
Bicyclic 6'-
equatorial 
hydroxy 
0.02 
231.85 
(11593) 
11.82 (591) 15.07 (753) 
156 
Bicyclic 6'-
axial amino 
0.37 2.99 (8.1) 1.66 (4.5) 10.31 (28) 
157 
Bicyclic 6'-
equatorial 
amino  
0.08 1.15 (14) 0.18 (2.3) 12.03 (150) 
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173 
Furanosyl 
derivative-1 
128 190.47 190.95 172.78 
174 
Furanosyl 
derivative-2 
>128 273.31 431.01 312.40 
*Selectivities are obtained by dividing the eukaryotic activity by bacterial activity. 
 The bicyclic paromomycin derivative 155 with the equatorial 6’-hydroxy group shows 
greater activity against wild-type bacterial ribosomes than the parent paromomycin 10. In 
contrast the epimer 154 with the axial hydroxyl group is significantly less active. Overall it is 
clear that the bicyclic derivatives benefit significantly from the presence of an equatorial 
hydroxyl group at the 6’-position. This is because an equatorial 6'-hydroxyl group is 
preorganized in the gt conformation needed for binding to A1408 in the type I pseudo base pair 
(Figure 23). This preorganized hydrogen bond is sufficient to overcome any loss of affinity 
caused by additional hydrophobic ring and the simultaneous loss of the hydrogen bond between 
the 4'-hydroxyl of paromomycin and the backbone phosphate linking G1491 to A1492. 
 In the analogous 6'-amino series the difference in activity between the two epimers is 
much smaller. Furthermore the most active of the two isomers 157, with its equatorial group, 
does not rise to the level of activity of the parent paromomycin. Preorganization into the gt 
conformation is therefore less beneficial for the amine than for the alcohols.  
 This discrepancy is explained by consideration of the ground state conformations of the 
ring I side chains in 6'-hydroxy and 6'-aminopyranosides and the correspondingly different 
energetic penalties paid on binding to the bacterial decoding A site in the gt conformation. Thus, 
based on comparison with α-D-glucosides, in aqueous solution the hydroxymethyl group of 
paromomycin exists as a 60:40:0 gg:gt:tg mixture of conformers; an energetic penalty is 
therefore paid when the gt conformer is imposed in the type I pseudo-base pair interaction. This 
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energetic penalty is removed in the bicyclic derivative 155 and binding is correspondingly 
enhanced. On the other hand the protonated aminomethyl side chain of neomycin is expected to 
exist as a 10:90:0 mixture of the gg, gt and tg conformers (Figure 20A) based on comparison 
with 6-amino-α-D-glucosides.119 The aminomethyl group of neomycin is therefore already 
preorganized for formation of the type I pseudo-base pair and there is no advantage to be gained 
from enforcing it in a bicyclic derivative. 
 
Figure 23: Binding pattern of bicyclic bicyclic 6'-equatorial paromomycin 155 with A1408 
base and apramycin with A1408 
 Furthermore, the 6'-equatorial hydroxyl paromomycin derivative 155 exhibits remarkable 
selectivity against the eukaryotic mitochondrial ribosome and better selectivity over the A1555G 
mitochondrial mutant ribosome which is highly susceptible to AGA induced ototoxicity. Such 
dissimilarities in affinity for the prokaryotic and mitochondrial ribosomes are consequence of the 
differing interactions of the β-face of ring I with the nucleotide bases at the bottom of the target 
decoding A site. Therefore, the base pair G1491=C1409 at the bottom of the bacterial A site, in 
particular, the affinity between G1491 and the β-face of the AGA ring I through the CH-π 
interactions compensates for any kind of loss due to the introduction of the hydrophobic bicyclic 
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moiety. Conversely, the mitochondrial ribosome built with two consecutive non Watson-Crick 
pairs (C1491•C1409 and A1490•C1410) cannot compensate as much for the introduction of a 
hydrophobic bicyclic ring I. On the other hand, the both isomers of the 6'-amino analogues 156, 
157 strongly inhibit the mitochondrial ribosome and its A1555G mutant, which is similar to the 
parent neomycin. 
 Further, the 6'-equatorial hydroxyl paromomycin derivative 155 displays better 
selectivity than the 6'-axial analogue 154 over the eukaryotic cytoplasmic ribosomal A site 
whereas, the analogous 6'-amino compounds exhibit lower affinity towards the cytoplasmic 
decoding A site. This is due to the mutation A1408G that does not permit the pseudo-base pair 
with the 6'-amine of the ring I AGA, due to repulsions between protonated amines.129 
 Finally, both the unusual five membered furanosyl derivatives (173, 174) display total 
loss of activity against all ribosomes, which is probably due to the fact that the two five 
membered rings cannot be accommodated in the drug binding pockets.  
 Overall, based on the antiribosomal data, it is confirmed that the rigid bicyclic derivatives 
of paromomycin with equatorial 6'-hydroxyl 155 and 6'-amino compound 157 bind tighter to the 
ribosomal decoding A site than their axial analogues 154 and 156. These observations are in 
contrast with the unusual bicyclic AGA apramycin, with the axial 6’-hydroxy group, which binds 
more tightly than the equatorial isomer (Chapter 2). The origin of the differences between the 
bicyclic paromomycin derivatives described in this chapter for which an equatorial 6’-hydroxyl 
group is clearly preferred and the apramycin series when the axial isomer await further 
investigation. 
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3.5.2. Discussion of antibacterial activity  
 All paromomycin derivatives prepared, together with the parent paromomycin 1 and 
other comparators apramycin, and neomycin, were screened for antibacterial activity against 
clinical isolates of methicillin-resistant strains of the Gram-positive bacterium Staphylococcus 
aureus and clinical isolates of the Gram-negative bacterium Escherichia coli. Consistent with the 
promising results in the cell-free translation assays, the bicyclic 6'-epiparomomycin derivative 
155 displayed greatest activity against all clinical strains of MRSA and/or E coli. Replacement of 
the 6'-hydroxyl group with an amine 156, leads to significant activity against all strains of S 
aureus and/or E coli, with even better values observed than parent compounds, while the axial 
isomer 157 is much less active. Further, the unusual 5-membered compounds displayed no 
activity against all tested strains (Table 8). Overall, with the exception of 157 all bicyclic 
derivatives (154, 155, 156) display good activity against two clinical strains of MRSA (AG039, 
AG042), that are resistant to the parent antibiotic. This activity enhancement is a result of 
interfering with the resistance mechanism of two MRSA strains by drug modification of either 
ANT (4') or APH (3') AMEs.  
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Table 8: Antibacterial Activities (MIC, μg/mL) 
Compd 
MRSA  E coli 
AG038 AG039 AG042 AG044  AG001 AG055 AG003 
Paromomycin 4 >256 >256 4-8  16-32 8 8-16 
Neomycin 0.5-1 128 128 0.5-1  8-16 4 4 
Apramycin 8 8 8 16  16 8 8-16 
106 32-64 64 64 32-64  32 32 32 
153 32 64 32 32  >128 - 64-128 
155 8-16 8 8 4  8 8 8 
154 32 32-64 16-32 32  ≥128 64-128 64-128 
156 4 4 4 2  2 2 2 
157 >128 >128 128 128  >128 >128 >128 
173 >128 >128 >128 >128  >128 >128 >128 
174 >128 >128 >128 >128  >128 >128 >128 
 
3.6. Conclusions 
 A new class of paromomycin antibiotics was designed based on the existing active 
molecule library. This new design focused on the modification of ring I at the 4' and 6'-positions. 
It consists of an apramycin-like bicyclic scaffold and a key hydroxy group or amine at 6'-position 
to bind to the RNA bases. All these new targets of paramomycin antibiotics were synthesized 
and screened for antiribosomal activity in cell-free translation assays with a series of wild-type 
and human mitochondrial and cytosolic ribosome models, as well as for antibacterial activity 
against clinical isolates of E-coli and methicillin-resistant Staphylococcus aureus. A bicyclic 
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derivative with a 6'-equatorial hydroxyl displays better activity against the bacterial wild-type 
ribosome than the original paromomycin. The information from the trend of activity changes 
between locked systems and free side chain models contributes to the understanding of binding 
pattern of AGAs with the bacterial A site and will be helpful for the future drug design.  
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CHAPTER 4. INFLUENCE OF THE ISOTHIOCYANATO MOIETY ON THE 
STEREOSELECTIVITY OF SIALIC ACID GLYCOSIDES FORMATION AND ITS USE 
IN SUBSEQUENT DIVERSIFICATION 
 
4.1. Introduction to sialic acids 
 Sialic acids are higher carbon sugars found at the outer most position of the glycoprotiens 
and glycoconjugates where they play an important role in various biological process.130 They are 
a group of nonulosonic acids featuring an anomeric carboxylic acid and a deoxygenated C-3 
methylene group. The sialic acids are linked to glycan chains via specific glycosidic linkages.131 
Naturally occurring sialic acids exist in different forms varying in the substitution of the 
pyranose skeleton, by modifications of the hydroxyl groups, and through the anomeric sialyl 
linkages affixing them to different types of glycans. Mostly, three common forms of sialic acids 
are available; N-acetyl neuraminic acid 175, N-glycolylneuraminic acid 176 and keto-deoxy-
nonulosonic acid 177. Neu5Ac 175 is a nine carbon deoxy sugar with an acetamido substituent at 
the C-5 position; it is the most abundant sialic acid and is extensively distributed in nature.130  
 
Figure 24: Naturally existing sialic acids 
 In addition, post translational alterations of the sialic acids, such as acetylation and 
phosphorylation at C-9 and methylation and sulfation at C-8, expand the diversity of these 
molecules to the extent that more than 50 sialic acid derivatives have been found in nature.132 
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Pseudaminic acid 178 and legionaminic acid 179 are two 9-deoxy-7-amino derivatives of the 
sialic acid scaffold found in bacteria, generally at the non-terminal positions of bacterial glycans 
(Figure 24).133 
4.2. Linkage diversity and biological importance of sialic acids 
 Mammalian sialic acids occur in limited linkage modes and their linkage diversity is well 
documented.132 The naturally existing equatorial sialic acid glycosides are classified as the α-
anomers, while the artificial axial glycosides are classified as the β-anomers. Sialic acids are 
most commonly α-linked to the 3- and 6- positions of galactopyranose or the 6-position of 
galactosamine. Another important linkage form of the sialic acids is the homopolymeric form, 
which observed in bacteria when multiple residues are joined to each other in the α(2→8) or 
α(2→9) fashions. The anomeric carboxylic group of the sialic acids confers negative charge on 
molecule into which they are incorporated under physiological conditions, but is also found 
lactonized with hydroxyl groups on the adjacent residues as in compound 183 (Figure 25).134 The 
CMP-sialic acid sugar nucleotide 184 is used as a glycosyl donor by the sialyltransferases in the 
biosynthetic pathway of the sialyl glycans and is the only sialoside with a β-linkage in mammals. 
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Figure 25: Diversity in the naturally existing sialic acid linkages 
 Sialic acids perform a multitude of biological functions. In particular, Neu5Ac and KDN 
are two sialic acids found in the human biological regime.135 These sialic acids execute functions 
ranging from normal physiochemical effects on the cellular environment to specific phenomena 
relating to molecular and cellular recognition, as a function of their charge, size and hydrophilic 
nature.135 Sialic acid functions can be divided into two groups; firstly, they can act as a biological 
recognition sites or receptors as in their binding of viral influenza causing lectins.136 Secondly, 
they can also act as biological masks by shielding the recognition sites such as penultimate 
sugars of glycan.137 Sialic acids can prevent erythrocytes from degradation by masking the 
subterminal galactose residues. 
 The sialidase enzymes remove the terminal sialic acid from cell surface glycans. This is a 
key step in the replication cycle of influenza viruses and which gives importance to the sialidase 
inhibitors as antiviral drugs. They are associated with different pathological processes like 
cholera, influenza and Salla disease.138 Increased understanding of the bacterial and viral 
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neuraminidases has led to the rational design and synthesis139 of sialic acid based drugs like 
Zanamavir and Tamiflu.140  
4.3. Synthesis of sialic acid glycoconjugates 
 The sialome, which is a subclass of the glycome, is defined as the complete study of the 
sialic acids, their linkages and modes of action. The current understanding of the sialome, in 
particular of the vast number of roles played by sialic acids in vertebrates, leaves many 
challenges in the development of methods to obtain well characterized sialic acid containing 
glycoconjugates.141 The study of the biological functions of the sialylglycans requires 
structurally defined homogeneous molecules, but the isolation of pure forms of glycans from 
natural sources is very difficult owing to the heterogeneity and diversity of these molecules. 
These circumstances highlight the importance of the development of efficient enzymatic or 
chemical methodologies for the synthesis homogenous glycans.134 Although chemoenzymatic 
methods offer high substrate promiscuity in the synthesis of sialyl glycoconjugates, the 
development of synthetic chemical methods enjoys a lead role due to the more significant 
quantities it can provide as well as the ability to access non-natural linkages.  
 The chemical synthesis of the naturally occurring α-linked sialosides involves many 
challenges. These challenges arise primarily from the presence of the electron withdrawing 
carboxylic acid functionality at the anomeric position and the lack of functionality at the 3-
position, which together lead to a number of complications on activation. These complications 
include the formation of the 2,3-eliminated product 189 following oxocarbenium ion 187 
formation (Scheme 32). As with all equatorial glycosides the anomeric effect has to be 
circumvented in the formation of the α-sialosides. This is complicated by the absence of a 
functional group at the 3-position precludes the possibility of any kind of stereodirecting 
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participation from that position unless significant modifications are made to the donor. As a 
result of the combination of these factors, glycosylation reactions of sialic acids are often low 
yielding and poorly selective. 
Scheme 32: General glycosylation or sialylation reaction 
 The chemical synthesis of the α-sialic acid linkages has long been of considerable 
synthetic interest, which is reflected in the numerous strategies that have been developed toward 
the establishment of high-yielding and highly α-selective chemical sialidation reactions. The 
various approaches that have been employed to overcome this problem can be categorized into, 
i) auxiliary group assisted sialylation, ii) modification of the natural N-5 acetyl group by 
installation of electron withdrawing groups, and iii) use of cyclic protecting groups. 
4.3.1. Auxiliary group assisted sialylation  
 Neighboring group assisted glycosylation is a popular technique and widely used to 
control stereoselectivity.142 Modification of sialyl donors by incorporation of auxiliary groups at 
the C-1 and C-3 positions to improve the glycosylation reaction profile is an important strategy 
in the field. C-1 auxiliaries have been explored by the Gin143 (Scheme 33) and Takahashi144 
groups who used N,N-dimethylglycolamide and 2-thioethyl ester participating groups, 
respectively.  
91 
 
 
 
 
Scheme 33: C-1 auxiliary glycosylation (Gin's approach) 
 Gin's sialylation using an N,N-dimethylglycolamide auxiliary 190 (Scheme 33) was 
somewhat selective for primary alcohol acceptors, but it showed only modest α-selectivity with 
hindered secondary alcohol acceptors. 143 The related Takahashi approach, with participation by 
a thioether gave only very modest selectivity.144 The use of auxiliaries at the 3-position is 
complicated due to need to installation and eventually remove the auxiliary on a methylene 
group. Examples of the class include halides, acetoxy groups, thioethers and phenyl selenides 
(195) with some affording α-sialosides successfully albeit in a leaving group dependant manner 
(Scheme 34).145 Although these methods are useful in that they give modest α-selectivity, they 
are considered less attractive due to the further steps required to remove the auxiliary groups.  
 
Scheme 34: C-3 auxiliary supported glycosylation  
4.3.2. Replacing the N-5 acetamide by electron withdrawing groups 
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Scheme 35: General scheme for the modification of N-5 substituent followed by the 
sialylation  
 
 The chemical modification of C-5 position by the introduction of various protecting 
groups results in a change of reactivity and stereoselectivity of the glycosylation reaction.146 In 
particular, the incorporation of electron withdrawing groups at C-5 position has great influence 
on the stereoselectivity of sialylation. The introduction of a further acetyl group on Neu5Ac, as 
in the acetimide 200, is achieved by the simple acetylation of fully deprotected Neu5Ac with 
concomitant O-acetylation. The higher reactivity of the 200 in comparison with the mono-N-
acetylated donor 199 was reported for the synthesis of α-(2→3) linked disaccharides and α-
(2→8) linked dimers.147,148 Also, Crich et al. shown that the challenging α-sialylation with 5-N-
acetylacetamido derivative 200 can be efficiently performed by using the diphenyl 
sulfoxide/trifluoromethanesulfonic anhydride activation system in the absence of acetonitrile. 
With this glycosylation method, the Neu5Ac α(2→6) Gal glycosidic linkages can be installed 
with excellent yield and selectivity.149 5-Azido derivatives of neuraminic acid 201 have been 
obtained by the biosynthetic method150 and by chemical methods.151 Higher stereoselectivities 
have also been reported for the synthesis of α(2→6) and α(2→9) dimers with the 5-azido 
donors.152-155 Higher stereoselectivity with the 5-trifluoroacetamido donor 202 has also been 
reported in the synthesis of α(2→8) and α(2→9) linked dimers and oligosaccharides.154,156-158 
Similarly, the replacement of the acetamide group with other electron withdrawing groups as in 
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the 5-N-Troc 203,159-161 5-N-phthalimido 204,162-165 N-glycolyl,166 N-t-butyloxycarbonyl 
(Boc),167 N-benzyloxycarbonyl (Cbz),168 N-t-butyloxycarbonylacetamido (NAcBoc),169,170 and 
N-Fmoc, N-Alloc, and trichloroacetyl160,171 groups has been shown to increase α-selectivity in 
the synthesis of oligosaccharides (Scheme 35). Overall the placement of an electron withdrawing 
group at the C-5 position has a significant impact on the α-selectivity with primary alcohol 
acceptors. Nevertheless many of these methods are associated with limitations to the use of 
unhindered primary alcohol acceptors. 
4.3.3. Use of cyclic protecting groups to attain α-selectivity 
 
 
Figure 26: 4O, 5N cyclic protected sialyl donors  
 A significant breakthrough in the area of α-selective sialylation arose from the 
introduction of cyclic protecting groups spanning 4O and 5N of sialyl donors. Crich et al. 
developed a α-sialylation donor which features a trans-fused N-acetyl 5N,4O-oxazolidinone 
protected phenylthio sialoside 205 or the thioadamantyl sialoside 206. These donors offer 
excellent stereochemical control of glycosylation as well as excellent yields under the NIS/TfOH 
in situ activation conditions.172,173 These donors can be directly used for glycosylation, without a 
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need of any auxiliary functionality to control the stereo selectivity. The advantage of the extra N-
acetyl group in the Crich method arises from the mild conditions used for the cleavage of the N-
acetyl 5N,4O-oxazolidinone with direct regeneration of the native C-5 acetamide 212 (Scheme 
36). This is to be contrasted with the otherwise excellent donors from the Takahashi174 and De 
Meo175 laboratories based on the simple 5N, 4O-oxazolidinones 207 and 208, which require 
harsh conditions for cleavage of the 4,5-O,N-oxazolidinone ring. 
Scheme 36: Glycosylation followed by Zemplen deacetylation of Crich's N-acetyl 
oxazolidinone sialosides 
 The Crich group also extended the outstanding stereoselectivity of the N-acteyl 
oxazolidinone donor 206 to the analogous N-glycolyl oxazolidinone donor 209, and reported a 
one-pot glycosylation method to construct oligosaccharides containing Neu5Gc at the terminal 
position.176 Further, the same group reported the synthesis of C- and S- α-sialosides177,178 using 
Wong's N-acteyl oxazolidinone protected sialyl phosphate 210179 using the milder TMSOTf 
conditions for activation thereby enabling the synthesis of unnatural sialosides with excellent α-
selectivity.  
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Scheme 37: Synthesis of 5N,4O-Oxazolidinthione and isothiocyanate derivatives  
 Seeking to extend the concept of cyclic protecting groups to the more strongly electron 
withdrawing N-acetyl oxazolidinthione protected system 217 Crich and coworkers found that 
higher temperatures were required for activation, resulting in lower selectivities overall.180 The 
synthesis of N-acetyl oxazolidinthione-protected sialyl thioglycoside 217 was accomplished from 
the known neuraminic acid intermediate 213 by treatment with HCl in ether to give 214, 
followed by treatment with phenyl thionochloroformate and sodium hydrogen carbonate in 
aqueous acetonitrile yielding intermediates 215 and 216. Further acetylation with sodium hydride 
and acetyl chloride then furnished donor 217. This synthesis provided a byproduct, the 
isothiocyanate 218, which arises from the incomplete cyclization of the intermediate phenyl 
thionocarbamate (Scheme 37).  
 This chapter describes the exploration of the isothiocyanate 218 as a sialyl donor, and 
subsequent work taking advantage of the diverse reactivity of the isothiocyanate for the 
preparation of sialosides diversely functionalized at the 5-position.  
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4.4. Results and Discussion 
4.4.1. Synthesis of an isothiocyanate protected donor  
 As described above, the peracetyl adamantanyl thiosialoside 218 protected by an 
isothiocyanate group at the N-5 position was initially isolated as a by-product in the synthesis of 
the N-acetyl-4-O,5-N-oxazolidinthione protected sialyl donor 217.180 In an improved synthesis, 
the β-S-adamantanyl thiosialoside 213 was treated with HCl in diethyl ether, followed by phenyl 
chlorothionoformate and aqueous sodium bicarbonate at room temperature, and finally acetic 
anhydride in pyridine to give the target 218 in 59 % yield (Scheme 38). Isothiocyanate 218 is a 
stable white crystalline solid, which can be readily handled and stored. 
 
Scheme 38: Synthesis of the isothiocyanato donor 218 
4.4.2. Sialylation using isothiocyanato donor 218 
 To study the influence of the isothiocyanate group on the stereoselectivity of sialylation, 
a series of reactions were performed using isothiocyanate donor 218 and a range of acceptors. 
Activation of  218 in the presence of 1.2 equiv. of various acceptors using NIS/TfOH activation 
system afforded the corresponding glycosides, exclusively as the α-anomers (Scheme 39, Table 
9). The glycosylation of monosaccharide acceptors such as the galactopyranosyl 6-ol 219, the 
galactopyranosyl 3,4-diol  220, and the galactopyranosyl 3-ol 221 with 218 using standard 
glycosylation conditions gave the disaccharides 224, 225 and 226, respectively, in a highly 
stereoselective manner and excellent yield. In particular, the glycosylation of the 4-O-protected 
galactopyranosyl 3-OH acceptor (Entry 3, Table 9) is noteworthy as it gave the coupled product 
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as a single anomer 226. This is be contrasted with the typically poorly selective coupling of 221 
to other sialyl donors, including the N-acetyl oxazolidinones. The isothiocyanate donor 218 was 
also coupled with the di- and tri- saccharyl acceptors 222 and 223 and gave the α-anomers of the 
products in 55% and 58% yields, respectively (Entry 4 and 5, Table 9). Overall, these 
experiments showed that the isothiocyanato donor 218 is highly beneficial in imparting α-
selectivity. The anomeric configuration of the resulting glycosides was assigned on the basis of 
the heteronuclear 3JC1,H3ax coupling constant method as discussed below.
181-185 
 
Scheme 39: Glycosylation with isothiocyanate 218 
Table 9: Glycosylation with per-acetylated isothiocyanate donor 
Entry 
 
Acceptor 
 
Product 
Yield & 
Selectivity 
Coupling 
constant 
(3JC1-H3ax) 
1 
 
 
80% 
(α-only) 
6.7 Hz 
2 
 
 
79% 
(α-only) 
7.5 Hz 
98 
 
 
 
3 
 
 
87% 
(α-only) 
7.0 Hz 
 
4 
 
 
 
 
55% 
(α-only) 
6.5 Hz 
5 
 
 
 
 
58% 
(α-only) 
6.5 Hz 
 
4.4.3. Assignment of anomeric configuration for coupled products 
 The commonly used NMR methods for the assignment of anomeric configuration of 
glycopyranosides, such as the evaluation of 3JH1-H2 and 
1JC1-H1 NMR coupling constants,
186 are 
not be suitable for the sialic acid glycosides due to the absence of an anomeric proton. For this 
reason numerous alternative methods have been reported in the literature to determine the 
anomeric configuration of sialosides based on i) the chemical shift of the H-3eq,
187 and H-4188,189 
resonances, ii) the Δvalue of the resonances for H9a-H9b,190 iii) the values of H-7 and H-
8,189,190 and the measurement of 3JC-1, H3ax heteronuclear coupling constants.
181-185 Among these 
methods, the measurement of 3JC-1, H3ax coupling constant is the most reliable as it is based on the 
correlation of coupling constants with torsional angles and not on the interpretation of chemical 
shift differences which are affected by many factors. Thus, the method differentiates between α 
99 
 
 
 
and β-sialosides on the basis of the respective numerical values of 5-7 Hz and 0-2 Hz of the 3JC-1, 
H3ax coupling constant. This difference in the coupling constants can be explained based on the 
Karplus relationship for 3JC-1, H3ax of the sialoside anomers. In the 
2C5 chair form, the dihedral 
angles of C1-C2-C3-H3ax of the α and β-anomers are 180º and 60º, respectively (Figure 27).182  
Figure 27: Dihedral angles of α and β-anomers of sialosides 
 The practical implementation of the method is illustrated for 228 in Figure 28 where three 
NMR experiments were used to measure the 3JC-1, H3ax coupling constants. First, the standard 
broad band proton decoupled carbon spectrum shows 10 carbonyl signals in the down-field 
region (164_172 ppm). Second, a spectrum recorded with the broadband decoupler turned off 
gives the complete proton coupling profile for all of the carbonyl carbons. Finally, a 13C NMR 
spectrum obtained with selective decoupling of the C-1 methyl ester protons which reveals the 
residual doublet nature of the C-1 signal at δ 167.5 owing to coupling to the axial hydrogen at 
C3. The observed coupling constant of 6.5 Hz for this doublet leads indicates C-1 and H3ax to 
have an antiperiplanar relationship and consequently the glycoside to have the α-configuration.  
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Figure 28: Sialoside 228 stereochemical assignment using the 3JC-H coupling constant 
method  
4.4.4. Selectivity 
 In order to explain the selectivity of the isothiocyanate 218, two possibilities can be 
considered. First, it is possible that the isothiocyanate simply acts as a strongly electron-
withdrawing group and promotes SN2-like glycosylation as has been proposed
 for the 
oxazolidinone system on the basis of mass spectrometric fragmentation studies.191 In this respect 
it is noteworthy that the isothiocyanate group is considerably more polar than the azido and 
isocyanate groups (dipole moments of C6H5N3, C6H5N=C=O, and PhN=C=S in Debye units, 
respectively: 1.82, 2.43, 2.69).192,193 Alternatively, an explanation can be advanced based on 
through space stabilization of glycosyl oxocarbenium ions in an inverted conformation.194,195 In 
this second possibility the transient intermediate sialyl oxocarbenium ion 229 is considered to 
adopts the 5H4 conformation preferentially to take advantage from stabilization by the 
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pseudoaxial 4-O-acetate and the C-5 isothiocyanate groups. In such a conformation the 
isothiocyanate would provide significant steric shielding to the β-face of the oxocarbenium, 
leading to enhanced α-selectivity (Figure 29). 
 
Figure 29: Structure of the Oxocarbenium ion  
 A competition experiment was designed to probe the relative reactivity of the 
isothiocyanate 218 and the N-acetyloxazolidinone 206 and thus indirectly the relative electron 
withdrawing effects of the protecting groups in the two systems. Accordingly, an equimolar 
mixture of 218, 206 and acceptor 221 were activated with NIS/TfOH, -78 ºC followed by the 
standard work up leading to the isolation of the coupled products 226 (α-only) and 230 (α/β=4:1 
mixture) in 3 and 51% yields, respectively. Clearly the reactivity of the isothiocyanate donor 218 
is lower than that of the N-acetyloxazolidinone 206, which is consistent with the highly electron-
withdrawing nature of the isothiocyanate moiety (Scheme 40). 
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Scheme 40: Competition experiment to estimate the relative reactivity of donors 218 and 
206 
4.4.5. Synthesis and fragmentation studies of sialyl phosphates 
 The study of different leaving groups at the anomeric position plays a major role in the 
development of sialic acid donors for efficient α-sialylation methods. Apart from the 
thioglycosides, sialyl phosphates have been demonstrated to be an important class in the 
glycosylation reaction particularly used in conjunction with the oxazolidinone–type protecting 
groups.179 Sialylation with sialyl phosphate donors has several advantages including high 
reactivity but more especially the mild reaction conditions. Indeed, the mild conditions were 
critical in the Crich group’s demonstration of the efficient synthesis of C α-sialosides using 
sensitive allylstannanes and silyl enolethers as nucleophiles.177 In view of this, the conversion of 
the isothiocyanate protected sialyl donor 218 to the corresponding sialyl dibutyl phosphate was 
investigated and the use of this novel donor in sialylation reactions and as a mass spectrometric 
probe were explored. 
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Scheme 41: Formation of sialyl phosphates 231 
 Thus, thioglycoside 218 was treated with dibutyl phosphoric acid in the presence of the 
NIS/TfOH activating system in DCM at 0 ºC, resulting in the isolation of the desired 
isothiocyanate containing sialyl phosphate 231 in 76 % yield (Scheme 41) as a 3:2 α/β mixture. 
Subsequently, a series of sialylations were performed using the new donor and a range of 
acceptors. Glycosylation reactions were conducted with 231 in the presence of 1.2 equiv. of 
various acceptors using TMSOTf as the activation system at -78 ºC The corresponding 
glycosides were obtained exclusively as the α-anomers in moderate yields (Scheme 42, Table 
10). Overall, these experiments showed that the stereoselectivity already evident with the 
thiosialoside 218 is also operative with the sialyl phosphate 231. Yields, however, were generally 
lower with the phosphate donor (Table 10) than with the thiosialoside (Table 9) due to the 
competing formation of the 2,3-glycal by-product 232 as judged by mass spectrometric analysis 
of the crude reaction mixtures. 
  
Scheme 42: Glycosylation with sialyl phosphate 231 
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Table 10: Glycosylation with sialyl phosphate donor 
Entry 
 
Acceptor 
 
Product 
Yield & 
Selectivity 
1 
 
 
52% 
(α-only) 
2 
  
43% 
(α-only) 
3 
 
 
55% 
(α-only) 
 
4 
 
 
 
 
55% 
(α-only) 
 
 4.4.6. Mass spectral fragmental studies of sialyl phosphates 
 The isothiocyanate containing sialyl phosphate 231 was subjected to the in-source 
fragmentation experiment in order to determine the influence of the isothiocyanate on the 
formation of the oxocarbenium ion. 196 The technique used, is a cone-voltage induced 
fragmentation performed on an ESI mass spectrometer and derives from the work of Denekamp 
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and Sandlers on the use of threshold fragmentation energies to probe the influence of protecting 
groups on the stability of glycosyl oxocarbenium ions.197,198 The Crich group previously utilized 
this strategy in the study of the influence of other protecting groups on the formation of sialyl 
oxocarbenium ions.196 The ESI fragmentation of the phosphate probably occurs by the expulsion 
of dibutyl phosphate to give the corresponding oxocarbenium ion, which then undergoes 
deprotonation to give the observed 2,3-glycal fragment ion. Experimentally, various 
combinations of differentially protected sialyl phosphates196 were injected in to the ESI 
spectrometer and the cone voltage gradually increased until fragmentation began, with the 
minimum detection level set to 2% of the TIC. The results reveal that compounds carrying cyclic 
protecting groups (210, 235) required more energy to attain the corresponding oxocarbenium 
ions when compared to those with acyclic protecting groups (233, 231 and 235). However, it was 
not possible to distinguish between the threshold energies for the fragmentation of 231, 233 and 
234 due to problems with reproducibility. The higher energy required for the fragmentation of 
the the oxazolidinones 210 and 235 compared to the isothiocyanate 231 are inconsistent with the 
results of the competition experiment discussed in section 4.4.3. The reasons for this 
inconsistency are not yet clear and are the subject of further investigations in the Crich 
laboratory (Figure 30). 
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Figure 30: Comparison of ESI cone voltages required to induce fragmentation of various 
sialyl phosphates 
4.4.7. Post-glycosylation derivatization 
 The isothiocyanate group has very versatile chemistry and has found application in many 
areas of chemistry.199,200 In view of the excellent selectivity of donor 218 in sialylation reactions, 
the adaptation of some of this chemistry promised to afford a range of sialosides carrying novel 
functional groups at C-5. The implementation of this idea is covered in the following section.  
4.4.7.1. Radical deamination of sialyl glycosides 
 Radical deamination was achieved by treatment of the disaccharide 226 with 
tris(trimethylsilyl)silane and azobisisobutyronitrile (AIBN) in toluene at the reflux affording the 
5-deamino-α-sialoside 236 in 78% yield (Scheme 43).201,202 Further, acetylation of the residual 
alcohol in 225 followed by AIBN-initiated reaction with allyltris(trimethylsilyl)silane203,204 in 
toluene at reflux gave the 5-deamino-5-allyl-α-sialoside 238 in 45% yield as a single isomer 
(Scheme 43). The selectivity observed in this radical reaction is consistent with that seen in the 
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analogous C-4 glucopyranosyl radicals,205,206 at and is a function of the face selectivity of radical 
239. As with conformationally locked cyclohexyl radicals207 trapping of 239 occurs 
preferentially from the equatorial direction, presumably to avoid 1,3-diaxial interactions with the 
incoming radical trap. The equatorial preference for trapping of 239 is enhanced by the location 
on the axial face of the flanking substituents and especially by the conformation of the side 
chain185 in which the 7-O-acetyl groups severely hinders approach from the axial direction.  
 
Scheme 43: Formation of desamino sialosyl disaccharides disaccharide and structure of 
radical 239 
4.4.7.2. Transformation of the isothiocyanate to amides 
 The reaction of thioacids with isothiocyanates is known as a useful amide-forming 
reaction.208 Thus, the reaction of isothiocyanato sialosides with thioacids was investigated. Two 
thioacids, 242 and 243 were prepared by the coupling reaction of corresponding acids with 9-
fluorenylmethanethiol under standard carbodiimide conditions to give the 9-fluorenylmethyl 
thioesters 241 and 244, respectively. Treatment of these thioesters with piperidine in DMF at 
room temperature gave the corresponding thioacids 242 and 245, respectively (Scheme 44).208,209  
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Scheme 44: Formation of thioacids  
 Then, the sialyl disaccharide 221 was reacted with the thioacids 242 and 245 in DCM at 
40 oC leading to the isolation of the amides 246 and 247 in moderate yield. In a further example 
of the class the residual alcohol in the disialoside 228 was acetylated and the product 248 was 
allowed to react with benzyloxy thioacetic acid (242) in DCM at 40 oC to provide the disialoside 
249 containing a protected glycolyl amide (Scheme 45).  
 
 
Scheme 45: Formation of amido derivatives from isothiocyanate sialosides 
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4.4.7.3. Synthesis of guanidine derivatives 
 In a further demonstration of the power of isothiocyanate chemistry the isothiocyanate-
protected disaccharide 226 was converted to a guanidine group. In this sequence disaccharide 
226 was treated first with 2-phenylethylamine to give the thiourea 250 in 90% yield. Subsequent 
reaction with methyl iodide gave an isothiourea 251, which on treatment with ammonia in DMF 
at 130 ºC gave 252 in 49% yield (Scheme 46). 
 
Scheme 46: Synthesis of thiourea and guanidine derivatives 
4.4.7.4. Deprotection of the sialosides 
 
Scheme 47: General scheme for deprotection of disaccharides  
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 A two-step protocol was developed for the deprotection of selected disaccharides. This 
approach involved the saponification of all esters followed by hydrogenolysis of benzyl ethers 
over palladium-charcoal in aqueous buffer (Scheme 47 and Table 11). It provides access to novel 
sialosides including those with a complete lack of substitution at the 5-position (253), or ones in 
which the acetamido function has been replaced by an alkyl chain (254), for the first time. In 
addition, a variety of C5 amides of the sialosides are accessible by this method, as illustrated by 
the N-glycoyl sialoside 255 and by the guanidine 256. 
Table 11: Deprotection of selected disaccharides 
Entry Substrate Product Yield 
1 236 
 
91% 
2 238 
 
93% 
3 242 
 
91% 
4 252 
 
52% 
 
4.5. Conclusion 
  A crystalline sialyl donor (218) in which the nitrogen function is protected as an 
isothiocyanate has been prepared and demonstrated to be an excellent donor toward a variety of 
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primary and secondary glycosyl acceptors giving excellent selectivity and high yield in all cases. 
The corresponding sialyl phosphate 231 also gives excellent selectivity when used as a glycosyl 
donor, but yields are lower due to competing elimination. The presence of the isothiocyanate 
group facilitates direct introduction of a range of novel functionalities at the 5-position post-
glycosylation. 
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CHAPTER 5. CONCLUSIONS 
 To improve the potential of apramycin as an antibiotic and resolve the uncertainty in its 
binding mode with bacterial and eukaryotic rRNA, a number of apramycin derivatives have been 
prepared by modifying the 6'- and N7'-positions. These derivatives were screened for 
antiribosomal activity in cell-free translation assays with a series of wild-type and mutant 
ribosomes, as well as for antibacterial activity against clinical isolates of methicillin-resistant 
Staphylococcus aureus (MRSA) and Escherichia coli (E coli). Unfortunately, all modifications 
of apramycin at 6' and 7' positions ended up with greater loss of activity against the bacterial 
wild-type ribosome than against the hybrid mutants of the human mitochondrial and cytosolic 
ribosomes. In particular, the modifications at the 6'-position including the inversion of the 
stereochemistry of 6'-hydroxy group, replacement of the 6'-hydroxy group by an amino group 
and complete removal of hydroxyl group had a significant influence on binding to the wild-type 
bacterial ribosomes. Thus, the inclusion and proper placement of a hydroxyl group at the 6'-
position is significant for binding to the bacterial decoding A site. These results are consistent 
with apramycin adopting the standard binding mode of the 4,5- and 4,6-aminoglycosides in the 
decoding A site of the bacterial ribosome and are not in favor of the alternative binding mode 
proposed in some studies. 
 A series of novel paromomycin antibiotics were designed by focusing on the 
modification of ring I at the 4' and 6'-positions. The modifications consist of the introduction of 
an apramycin-like bicyclic scaffold containing a key hydroxy group or amine at the 6'-position to 
assist in binding to the ribosomal RNA. These newly designed paramomycin antibiotics were 
synthesized and screened for antiribosomal activity as well as for antibacterial activity. The 
bicyclic paromomycin derivative 155 with the equatorial 6’-hydroxy group displays better 
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activity against the bacterial wild-type ribosome than paromomycin itself; the epimer 154 with 
the axial hydroxyl group is significantly less active. The comparable amine derivatives are not as 
active as the parent paromomycin.  
 A novel sialyl donor with a highly electron withdrawing isothiocyanate functionality at 
the C-5 position (218) has been prepared and was demonstrated to be an excellent donor toward 
a variety of primary and secondary glycosyl acceptors giving outstanding stereoselectivity and 
high yields. The corresponding sialyl phosphate donor 231 also gives excellent selectivity in 
glycosylation reaction, but yields are lower due to competing elimination. The versatile 
isothiocyanate chemistry allows the isothiocyanate bearing saccharides to serve as precursors for 
the introduction of a range of novel functionalities at the 5-position post-glycosylation, which 
opens up access to new chemistry and potentially new biology at the 5-position of thesialyl 
glycosides. 
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CHAPTER 6. EXPERIMENTAL SECTION 
General  
 All reagents and solvents were purchased from commercial suppliers and were used 
without further purification unless otherwise specified. All organic extracts were dried over 
sodium sulfate and concentrated under vacuum. Chromatographic purifications were carried out 
over silica gel, Sephadex G-10, Sephadex C-25 and Dowex 50WX8-100 sodium ion exchange 
resin. Analytical thin-layer chromatography was performed with pre-coated glass backed plates 
(w/UV 254) and visualized by UV irradiation (254 nm) or by staining with 25% H2SO4 in EtOH 
or ceric ammonium molybdate solution. Specific rotations were obtained using a digital 
polarimeter (Autopol III) in the solvent specified. High resolution mass spectra were recorded 
with an electrospray source coupled to a time-of-flight mass analyzer (Waters). 1H, 13C, 19F, 31P 
and 2D NMR spectra were recorded on 600 MHz (Agilent), 500 MHz and 400 MHz (Varian) 
instruments. Stereochemical assignments of coupled sialosides are based on 3JC1-H3-ax values. 
Ammonical methanol was prepared by using ammonium hydroxide solution (28% in water) and 
methanol in 1:9 ratio.  
Chapter 2:  
 1,3,2′,4′′-Tetraazidoapramycin (69) and 1,3,2′,4′′,7'-Pentaazido-7’-
demethylapramycin (70): Trifluoromethanesulfonyl azide was prepared fresh for each reaction 
as described here. Sodium azide (14.0 g, 0.21 mol) was dissolved in water (40.0 mL) and an 
equal volume of dichloromethane (40.0 mL) was added while stirring at room temperature. The 
resulting suspension was cooled to 0 ºC and Tf2O (30.0 g, 0.11 mol) was added drop wise over 
45 min with vigorous stirring. The mixture was stirred at 0 ºC for 3 h before sat. NaHCO3 (45.0 
mL) was added to quench the reaction. The organic layer was separated and the aqueous layer 
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was extracted with dichloromethane (10.0 mL). The organic layers were combined (triflyl azide 
solution) and kept at 0 ºC until needed.  
 In a 500 mL round bottom flask, apramycin sulphate (6) (5.0 g, 0.0078 mol), NaHCO3 
(12.0 g, 0.142 mol) and CuSO4.5H2O (0.3 g, 0.0013 mol) were dissolved in H2O (50.0 mL) and 
cooled to 0 ºC. Triflyl azide solution (freshly prepared dichloromethane solution) was added 
slowly to the reaction mixture at 0 oC over 0.5 h, followed by drop wise addition of MeOH (85.0 
mL) over 0.5 h. The reaction mixture was allowed to come to room temperature and was stirred 
for 8 h before butylamine (1.2 g, 0.015 mmol) was added to quench the excess TfN3. The solvent 
was evaporated under vacuum and the residue was purified by column chromatography over 
silica gel (eluent: gradient of 4% to 8% to 12% to 16% of ammonical methanol in 
dichloromethane) to give 69 (2.6 g, 50%) as a white solid and 70 (0.720 g, 15%) as a gum.  
 69: Rf= 0.47 (30% ammonical MeOH in EtOAc); mp: 112-114 oC; [α]D25= +228.2 
(c=0.93, MeOH); 1H NMR (600 MHz, CD3OD): δ 5.59 (d, J = 3.3 Hz, 1H, H-1'), 5.28 (d, J = 3.7 
Hz, 1H, H-1''), 4.87 (br s, 1H, H-8'), 4.20 (s, 1H, H-6'), 3.85-3.83 (dd, J = 9.9 Hz, 2.2 Hz, 1H, H-
5'), 3.83–3.79 (m, 1H, H-3''), 3.79 (t, J = 3.7 Hz, 1H, H-4'), 3.78-3.74 (m, 2H, H-4'), 3.67-3.65 
(dd, J = 4.4 Hz, 12.5 Hz, 2H, 6''-CH2), 3.62-3.58 (m, 1H, H-5''), 3.52-3.47 (m, 3H, H-4, H-5, H-
3), 3.47–3.45 (d, J = 3.7 Hz, 1H, H-2''), 3.42 (d, J = 4.4 Hz, 1H, H-1), 3.41-3.36 (t, 1H, H-4''), 
3.24 (t, J = 9.2 Hz, 1H, H-6), 3.22-3.18 (dt, J = 12.8 Hz, 4.0 Hz, 1H, H-2'), 2.54 (dd, J = 2.6 Hz, 
8.1 Hz, 1H, H-7'), 2.42 (s, 3H, NCH3), 2.25-2.21 (dt, J =4.0 Hz, 12.8 Hz, 1H, H-2ax), 2.18-2.14 
(dt, J =4.4 Hz, 11.4 Hz, 1H, H-3'eq), 2.00 (m, 1H, H-3'ax), 1.40 (m, 1H, H-2eq); 13C NMR (151 
MHz, CD3OD): δ 97.6 (s, C-1′), 95.8 (s, C-8′), 94.5 (s, C-1′′), 79.2 (s, C-4), 76.6, 76.5 (s, C-6), 
72.4 (s, C-3′′), 71.5 (s, CH), 71.1 (s, CH), 70.6 (s, C-5′), 66.4 (s, C-4′), 65.5 (s, C-6′′), 62.5 (s, C-
7′), 62.0 (s, C-4′′), 60.9 (s, C-4), 60.3 (s, CH), 59.7 (s, CH), 56.4 (s, C-2′), 32.2 (s, NCH3), 31.8 
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(s, C-2), 27.9 (s, C-3′′); ESI-HRMS: m/z calcd. for C21H34N13O11 [M+H]+ 644.2501, found: 
644.2501. 
 70: Rf= 0.49 (30% ammonical MeOH in EtOAc); [α]D25= + 170.8 (c=6.6, MeOH); 1H 
NMR (600 MHz, CD3OD): δ 5.59 (d, J = 3.3 Hz, 1H, H-1'), 5.30 (d, J = 3.7 Hz, 1H, H-1''), 5.05 
(d, J = 8.4 Hz, 1H, H-8'), 4.20 (br s, 1H, H-6'), 3.87 (dd, J = 9.9 Hz, 2.2 Hz, 1H, H-5'), 3.85–3.70 
(m, 4H, H-6, H-4', 6''-CH2), 3.58 (dt, J = 10.3 Hz, 2.9 Hz, 1H, H-3''), 3.52-3.49 (m, 2H, H-4", H-
2"), 3.49-3.43 (m, 3H, H-3, H-5, H-7'), 3.40 (dt, J = 4.4 Hz, 9.5 Hz, 1H, H-1), 3.29 (m, 1H, H-4), 
3.27-3.20 (m, 2H, H-5", H-2'), 2.24 (dt, J = 4.4 Hz, 12.8 Hz, 1H, H-2eq), 2.18 (dt, J = 4.4 Hz, 
11.0 Hz, 1H, H-3'eq), 2.17 (m, 1H, H-3'ax), 1.42 (m, 1H, H-2eq); 13C NMR (151 MHz, CD3OD): 
δ 97.58 (s, C-1′), 94.91 (s, C-1'′), 94.18 (s, C-8'), 79.26 (s, C-7"), 76.56 (s, C-2"), 76.49 (s, C-4), 
72.34 (s, C-4'), 71.43 (2s, C-3", C-4"),  69.80 (s, C-5'), 68.02 (s, C-6'), 66.55 (s, C-6), 63.43 (s, 
C-5), 61.71, 60.68 (s, 6"-CH2), 60.31 (s, C-3), 59.70 (s, C-1), 56.35 (s, C-2'), 31.80 (s, C-2), 
27.88 (s, C-3'); ESI-HRMS: m/z calcd. for C20H29N15O11 Na [M+Na]
 + 678.2069, found: 
678.2059. 
 1,3,2′,4′′-Tetraazido-7′-N-benzyloxycarbonyl-apramycin (71): Sodium carbonate (3.1 
g, 29.0 mmol) was added to a cold solution of 69 (3.76 g, 5.8 mmol) in 75% methanol in H2O 
(75.0 mL). Benzyl chloroformate (3.0 g, 17.5 mmol) was added drop wise to the reaction mixture 
at 0 ºC over 5 min, after which the reaction mixture was stirred at room temperature for 3 h. The 
solvent was evaporated under reduced pressure at room temperature and the residue was dried 
under reduced pressure for 1 h and then purified by column chromatography on silica gel (eluent: 
gradient of 2% to 4% to 6% to 8% to 10% MeOH in ethyl acetate) to give 71 (4.3 g, 93%) as a 
white solid. Rf= 0.5 (20% ammonical MeOH in EtOAc); mp: 116-119 oC; [α]D25= +79 (c=0.8, 
MeOH); The 1H-NMR spectrum showed the presence of two rotamers in a 4:3 ratio. 1H NMR 
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(600 MHz, CD3OD): δ 7.42–7.25 (m, 5H, ArHs), 5.60 (d, J = 3.3 Hz, 1H, H-1', major isomer), 
5.54 (d, J =2.9 Hz,1H, H-1', minor isomer), 5.31 (d, J =8.8 Hz, 1H, H-8', major isomer), 5.28 (d, 
J =8.8 Hz, H-8', minor isomer), 5.24 (2br s, 1H, H-1", 2 isomers), 5.17–5.06 (m, 2H, CH2Ph), 
4.19 (2br s, 1H, H-7'), 4.11 (m, 1H, H-5'), 3.94-3.83 (m, 2H, H-4', H-6'), 3.70-3.58 (m, 3H, 6"-
CH2, H-3"), 3.52-3.35 (m, 7H, H-3, H-4, H-4", H-5", H-5, H-6, H-2"), 3.25-3.16 (m, 2H, H-2', 
H-1), 3.12–3.03 (2br s, 3H, NCH3), 2.29–2.14 (m, 2H, H-2ax, H-3'eq), 2.10–1.99 (m, 1H, H-
3'ax), 1.45–1.35 (m, 1H, H-2eq); 13C NMR (CD3OD, 151 MHz): δ 157.71, 156.77 (2 s, C=O), 
136.55, 136.42 (2 s arom.), 127.27, 127.43, 127.66, 127.69, 128.17, 128.20 (s, arom.), 97.73, 
97.49, 97.42, 96.43, 95.06, 93.96 (s, C-1', C-1", C-8'), 79.23, 79.05, 76.60, 76.54, 76.49, 72.48, 
72.33, 71.62, 71.46, 70.39, 70.36, 69.91, 67.40, 67.19 (CH2-Cbz); 66.53, 66.49, 61.82, 61.72, 
60.79 (C-6"), 60.35, 60.31, 60.03, 59.65, 56.40 (C-2'), 31.82, 31.45 (s, NCH3, C-3'), 28.00, 27.9 
(C-2); ESI-HRMS: m/z calcd. for C29H39N13O13Na [M+Na]
+ 800.2688, found: 800.2690.  
 1,3,2′,4′′-Tetraazido-6′,7′-oxazolidino-apramycin (72): Sodium hydride (433 mg, 60% 
in paraffin oil, 18 mmol) was added to an ice-cooled solution of 71 (4.2 g, 5.4 mmol) in dry 
DMF (15.0 mL) and stirred under Ar for 4 h during which the temperature was raised to room 
temperature. After completion, the reaction mixture was re-cooled to 0 oC and the pH adjusted to 
the neutral with 2 M HCl in ether. The solvent was evaporated under reduced pressure and the 
residue was purified by silica gel column chromatography eluting with 5% ammonical methanol 
in dichloromethane to give 72 (3.14 g, 87%) as an off-white solid. Rf= 0.65 (5%  ammonical 
MeOH in EtOAc); mp: 146-148 oC; [α]D26 = +121.1 (c=0.7, MeOH); 1H NMR (600 MHz, 
CD3OD): δ 5.33 (d, J = 3.3 Hz, 1H, H-1'), 5.28 (d, J = 3.7 Hz, 1H, H-1''), 5.11 (d, J = 2.6 Hz, 
1H, H-8'), 4.94 (dd, J = 3.3 Hz, 10.6 Hz, 1H, H-5'), 4.87 (dd, J = 3.3 Hz, 8.8 Hz, 1H, H-6'), 4.02 
(dd, J = 2.6 Hz, 8.8 Hz, 1H, H-7'), 3.80 (t, J = 9.6 Hz, 1H, H-3''), 3.75 (dd, J = 12.1 Hz, J = 2.9 
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Hz, 1H, H-4'), 3.76-3.63 (dd, J = 5.1 Hz, 12.1 Hz, 2H, 6''-CH2), 3.59 (d, J = 4.4 Hz, 1H, H-3), 
3.54 (dd, J = 3.7 Hz, 9.5 Hz, 1H, H-2''), 3.50-3.45 (m, 1H, H-5''), 3.46-3.31 (m, 4H, H-5, H-4, H-
1, H-4"), 3.29 (t, J = 9.5 Hz, 1H, H-6), 3.23 (m, 1H, H-2'), 2.88 (s, 3H, NCH3), 2.30 (m, 1H, H-
2eq), 2.23 (m, 2H, H-3'ax,eq), 1.48 (q, J = 12.5 Hz, 1H, H-2ax); 13C NMR (151 MHz, CD3OD): 
δ 158.47 (s, C=O), δ 98.69 (s, C-1′), 94.62 (s, C-8′), 91.60 (s, C-1′′), 81.14 (s, C-4), 76.32 (s, C-
6), 72.52 (s, C-3′′), 71.87 (CH), 71.31 (CH), 70.68 (s, C-5′), 65.53 (s, C-4′), 65.13 (s, C-6′′), 
62.27 (s, C-7′), 61.16 (s, C-4′′), 60.34 (s, C-4), 60.06, 59.75, 58.49, 56.72 (s, C-2′), 31.29 (s, 
NCH3), 29.60 (s, C-2), 28.63 (s, C-3′′); ESI-HRMS: m/z calcd. for C22H31N13O12 Na [M+Na]+ 
692.2113, found: 692.2108. 
 1,3,2′,4′′-Tetraazido-5,6,2′′,3′′,6′′-penta-O-benzyl-6′,7′-oxazolidino-apramycin (73): 
To a stirred solution of compound 72 (3.15 g, 4.7 mmol) in DMF (65.0 mL) under Ar was added 
NaH (1.88 g, 60% in paraffin oil, 78.0 mmol) at 0 ºC. After stirring for 0.5 h at the same 
temperature benzyl bromide (12.0 g, 70.6 mmol) was added drop wise at 0 ºC and the resulting 
reaction mixture was stirred for 6 h at room temperature. On completion, the solvent was 
evaporated under reduced pressure at room temperature and the crude product was dissolved in 
EtOAc and washed sequentially with water and brine, dried, and concentrated under reduced 
pressure. Silica gel column chromatography of the residue eluting with EtOAc/toluene (2:8) gave 
73 (4.8 g, 92%) as an off-white solid. Rf= 0.55 (20% EtOAc in toluene); mp: 152-154 oC; [α]D26= 
+100.2 (c=1.0, CH2Cl2); 
1H NMR (600 MHz, CDCl3): δ 7.42-7.20 (m, 25H arom.), 5.50 (d, J = 
3.7 Hz, 1H, H-1'), 5.38 (d, J = 3.7 Hz, 1H, H-1''), 5.01-4.93 (m, 3H, 1 CH2Ph and H-8'), 4.87-
4.80, 4.79-4.66, 4.64-4.43 (m, 10H, 4 CH2Ph, H-6', H-5'), 4.83 (br s, 1H, H-7'), 3.85–3.77 (m, 
1H, H-4''), 3.72 (dt, J = 4.4 Hz, 11.0 Hz, 1H, H-4'), 3.67-3.55 (m, 5H, H-5", H-2'', H-4, 6"-CH2), 
3.50-3.42 (m, 2H, H-5, H-3"), 3.35 (t, J = 9.5 Hz, 1H, H-6), 3.30 (dt, J = 4.4 Hz, 12.1 Hz, 1H, H-
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1), 3.15 (dt, J = 4.0 Hz, 12.8 Hz, 1H, H-2'), 3.01(dt, J = 4.7 Hz, 12.8 Hz, 1H, H-3), 2.81 (s, 3H, 
NCH3), 2.30 (m, 1H, H-3'ax), 2.21-2.09 (m, 2H, H-3'eq, H-2eq), 1.49-1.38 (q, J = 12.8 Hz, 1H, 
H-2ax,); 13C NMR (151 MHz, CDCl3): δ 157.04 (s, C=O), 137.88, 137.59, 137.39, 137.23 
(arom.), 128.52, 128.46, 128.39, 128.07, 127.99, 127.95, 127.91, 127.87, 127.60, 126.95 (arom.), 
97.89 (s, C-1′),  94.50 (s, C-8′),  93.50 (s, C-1"), 84.64 (s, C-6), 84.00 (s, C-5), 79.69 (s, C-2"), 
78.91 (s, C-3"), 78.28 (s, C-4), 75.81, 75.57, 74.94, 73.74, 73.07 (5s, 5PhCH2), 70.97, 70.80 (s, 
C-6′), 68.78 (s, 6"-CH2), 66.05 (s, C-5′), 65.52 (s, C-4′), 61.86, 60.06 (s, C-1), 60.05, 58.37 (s, C-
3), 55.93 (s, C-2′), 31.78 (s, C-2), 30.08 (s, NCH3), 29.34 (s, C-3′); ESI-HRMS: m/z calcd. for 
C57H61N13O12Na [M+Na]
+ 1142.4460, found: 1142.4459. 
 1,3,2′,4′′-Tetraazido-5,6,2′′,3′′,6′′-penta-O-benzylapramycin (74): A stirred solution of 
73 (4.8 g, 4.28 mmol) in 1,4-dioxane (77.0 mL) was treated with 3.0 M aqueous NaOH (40.0 
mL) and heated to 100 ºC for 13 h. The solvent was evaporated under reduced pressure and the 
residue taken up in ethyl acetate and washed with H2O. The combined organic layers were 
washed with brine and concentrated under reduced pressure at room temperature. The residue 
was purified by column chromatography over silica gel, eluting with EtOAc:dichloromethane 
(3:7) to give 74 (3.65 g, 78%) as an off-white solid. Rf= 0.2 (30% EtOAc in toluene); mp: 68-70 
oC; [α]D26= +140.8 (c=0.93, CH2Cl2); 1H NMR (600 MHz, CDCl3): δ 7.42-7.22 (m, 25H arom.), 
5.63 (d, J = 3.7 Hz, 1H, H-1'), 5.31 (d, J = 3.3 Hz, 1H, H-1''), 5.04-4.93 (m, 2H, H-6' and H-8'), 
4.90-4.75, 4.72-4.65, 4.63-4.58, 4.52-4.44 (m, 10H, 5 CH2Ph), 4.01 (d, J = 9.5 Hz, 1H, H-5'), 
3.85–3.78 (m, 2H, H-4', H-4''), 3.74-3.56 (m, 8H, H-2'', H-5", 6"-CH2, H-4, H-5, H-6, H-7'), 3.51 
(dt, J = 4.4 Hz, 9.5 Hz, 1H, H-3), 3.43-3.35 (m, 2H, H-1, H-3"), 3.16 (dt, J = 4.1 Hz, 13.2 Hz, 
1H, H-2'), 2.74 (s, 1H, NH), 2.42 (br s, 3H, NCH3), 2.33 (dt, J = 4.4 Hz, 13.2 Hz, 1H, H-2eq), 
2.26-2.13 (m, 2H, H-3'eq, H-3ax), 1.49 (q, J = 12.8 Hz, 1H, H-2ax,); 13C NMR (151 MHz, 
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CDCl3): δ 137.97, 137.83, 137.42, 137.26, (4s, arom.), 128.46, 128.44, 128.39, 128.37, 128.25, 
128.08, 128.00, 127.85, 127.79, 127.74, 127.62, 127.14 (arom.), 97.40 (s, C-1′), 94.0 (s, C-1"), 
84.69 (s, C-3"), 84.50 (s, C-2"), 79.71 (s, C-4′), 78.63 (CH), 75.89, 75.70, 75.06, 73.56, 72.75 
(5s, 5PhCH2), 70.47, 70.20 (s, C-5′),  68.60 (s, 6"- CH2), 66.44 (s, C-4"), 64.75, 62.78 (s, C-3"), 
61.39 (s, C-5"), 60.25 (s, C-1), 60.04, 59.41 (s, C-3), 56.23, 56.14 (s, C-2′), 33.08 (s, NCH3), 
32.23(s, C-2), 28.20 (s, C-3′). ESI-HRMS: m/z calcd. for C56H64N13O11 [M+H]+ 1094.4848, 
found: 1094.4813. 
 1,3,2′,4′′-Tetraazido-5,6,2′′,3′′,6′′-penta-O-benzyl-7′-N-benzylozycarbonyl-apramycin 
(75): Sodium carbonate (509 mg, 4.8 mmol) was added to a solution of 74 (1.05 g, 0.9 mmol) in 
methanol (30 mL) and cooled to 0 ºC. Benzyl chloroformate (0.5 g, 2.9 mmol) was added drop 
wise to the reaction mixture at 0 oC over 5 min, after which the reaction mixture was stirred at 
room temperature for 3 h. The solvent was evaporated under reduced pressure at room 
temperature and the residue was purified by column chromatography on silica gel eluting with 
EtOAc:hexanes (5 to 40%) to give 75 (1.05 g, 90%) as a white solid. Rf= 0.3 (30% EtOAc in 
hexanes); mp:116-119 oC; [α]D26= +126.4 (c=0.8, CH2Cl2); The 1H-NMR spectrum showed the 
presence of two rotamers in a 3:2 ratio. 1H NMR (600 MHz, CDCl3): δ 7.38-7.25 (m, 30H 
arom.), 5.56-5.45 (m, 2H, H-1', H-1''), 5.29 (d, J = 3.8 Hz, 1H, H-8'), 5.24-4.38 (m, 12H, 5 
CH2Ph, H-5', H-4), 4.27 (br s, 1H, H-7'), 4.09 (d, J = 3.8 Hz, 1H, H-4', minor isomer), 4.06 (d, J 
= 9.5 Hz, 1H, H-4' major isomer),  3.93 (t, J = 10.6 Hz, 1H, H-6'), 3.83-3.30 (m, 8H, H-6', H-1, 
H-3, H-5, 6"-CH2, H-3", H-4"), 3.16 (d, J = 3.3 Hz, 1H, H-2'), 3.03 (br s, 3H, NCH3), 2.33 (m, 
1H, H-2eq), 2.28-2.18 (m, 2H, H-3'eq, H-3'ax), 1.50 (m, 1H, H-2ax); 13C NMR (151 MHz, 
CDCl3): δ 158.8 (s, C=O), 138.03, 137.88, 138.67, 137.59, 137.26, 137.83, 137.42, 137.26, 
136.6 (arom.), 128.54, 128.47, 128.37, 128.31, 128.20, 128.05, 127.95, 127.90, 127.78, 127.75, 
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127.71, 127.64, 127.27, 127.21 (arom.), 97.49 (s, C-1′), 96.4 (s, C-1"), 84.74, 84.38, 79.46, 
78.74, 77.54, 75.88, 75.70, 75.63, 75.08, 73.54, 72.62 (5s, 5PhCH2), 70.44, 68.16, 67.42, 66.47, 
61.12, 60.22, 59.17, 56.22, 32.13 (s, NMe, C-2), 28.21(s, C-3′); ESI-HRMS: m/z calcd. for 
C64H73N14O13 [M+NH4]
+ 1245.5482, found: 1245.5428. 
 1,3,2′,4′′-Tetraazido-5,6,2′′,3′′,6′′-penta-O-benzyl-7′-N-benzyloxycarbonyl-6’-
apramycinone (76): A solution of 75 (200.0 mg, 0.16 mmol) in dry dichloromethane (2.0 mL) 
was treated with Dess–Martin periodinane (103.0 mg, 0.24 mmol, 0.3 M solution in 
dichloromethane) and stirred for 8 h under Ar at room temperature. The reaction mixture was 
quenched by addition of saturated aqueous NaHCO3, washed with brine, dried, and concentrated 
under reduced pressure. The crude product was charged on a silica gel column and eluted with 
EtOAc:hexanes (3:7) to afford the ketone 76 (178.0 mg, 90%) as a white foam. Rf= 0.65 (30% 
EtOAc and hexane); [α]D26= +100.8 (c=0.8, CH2Cl2); The 1H-NMR spectrum showed the 
presence of the two rotamers in 3:2 ration. 1H NMR (600 MHz, CDCl3): δ 7.50-7.14 (m, 30H 
arom.), 5.73 (d, J = 2.6 Hz, 1H, H-1', major isomer), 5.63 (br s, 1H, H-1', minor isomer), 5.28 (br 
s, 1H, H-1''), 5.12-4.32 (m, 12H, 5CH2Ph, H-8', H-6'), 3.88-3.56 (m, 5H, H-3", H-4", H-5, H-6, 
H-4), 3.55-3.32 (m, 6H, H-2", H-1, H-3, H-4, 6"-CH2), 3.13 (br s, 3H, NMe), 3.09 (m, 1H, H-2'), 
2.40 (m, 1H, H-3'eq), 2.34-2.29 (m, 2H, H-3'ax, H-2eq), 1.50 (q, J = 12.8 Hz, H-2ax); 13C NMR 
(151 MHz, CDCl3): δ 195.41 (br s, C=O), 155.85 (br s, C=O), 138.02-136.16 (arom.), 127.78-
126.70 (arom.), 96.90 (s, C-1′), 94.41 (br s, C-8′, C-1"), 84.59, 84.45, 79.72, 79.62, 75.92-66.8 
(5PhCH2, C-6, 6"-CH2), 61.16, 61.12, 60.27, 59.10, 55.76 (s, NMe), 55.56 (s, C-2'), 31.88 (s, C-
2), 28.60 (s, C-3'); ESI-HRMS: m/z calcd. for C64H71N14O13[M+NH4]
+ 1243.5325, found: 
1243.5292. 
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 1,3,2′,4′′-Tetraazido-5,6,2′′,3′′,6′′-penta-O-benzyl-7′-N-benzyloxycarbonyl-6′-epi-
apramycin (77): Ketone 76 (100.0 mg, 0.08 mmol) was stirred with NaBH4 (6.2 mg, 0.16 mmol) 
in methanol (4.0 mL) for 10 min. The reaction mixture was neutralized with 0.1 N HCl and 
concentrated under reduced pressure. The crude mixture of alcohols (5:1 ratio) was separated by 
silica gel column using 30% EtOAc in hexanes to give the title compound 77 (58.0 mg, 58%) as 
a white foam. Rf= 0.45 (30% EtOAc in hexanes); [α]D25= +130.1 (c=0.8, CH2Cl2); The 1H-NMR 
spectrum showed the presence of two rotamers in 3:2 ratio. 1H NMR (CDCl3, 600 MHz): δ 7.42–
7.18 (m, 30H arom.), 5.51 (d, J = 2.9 Hz, 1H, H-1'), 5.24 (br s, 1H, H-1''), 5.11-4.34 (m, H-8', 5 
CH2Ph), 3.85-3.30 (m, 6H, H-6', H-1, H-3, H-5, H-3", H-4"), 3.40 (m, 2H, 6''-CH2), 3.30-2.82 
(m, 3H, NCH3), 3.11 (m, 1H, H-2'), 2.36-2.22 (m, 2H, H-2ax, H-3'eq),1.54-1.25 (m, 2H, H-2eq, 
H-3'ax); 13C NMR (151 MHz, CDCl3): δ138.02, 137.60, 137.24, 136.21 (arom.), 128.46, 128.39, 
128.29, 128.07, 128.00, 127.80, 127.71, 127.10 (arom.), 96.87-95.0 (s, C-1′, C-8′, C-1"), 84.73, 
84.30, 79.71, 78.65, 78.00, 75.87, 75.67,74.99, 73.32, 72.28 (5s, 5PhCH2), 70.40, 70.20, 68.99, 
68.55, 67.90, 67.72, 61.03, 60.20, 59.55, 56.41, 32.33 (s, C-2), 28.17 (s, NCH3, C-3′); ESI-
HRMS: m/z calcd. for C64H73N13O13 [M+Na]
+ 1250.5035, found: 1250.4999. 
 1,3,2′,4′′-Tetraazido-5,6,2′′,3′′,6′′-penta-O-benzyl-6’α-methyl-6′,7′-oxazolidino-
apramycin (79): A stirred solution of 76 (100.0 mg, 0.081 mmol) in anhydrous diethyl ether 
(1.6 mL) under Ar was treated with freshly prepared methylmagnesium iodide (30.0 mg, 0.180 
mmol, 2 M solution) at -20 ºC. The resulting reaction mixture stirred for 10 min and quenched 
with 1 N aqueous NH4Cl. The organic layer was washed with 10% aqueous Na2S2O3 followed by 
brine, dried, and concentrated under reduced pressure. The residue was purified by silica gel 
chromatography eluting with 2% to 30% EtOAc in hexanes to give the tertiary alcohol 78 (51.0 
mg, 50%) as a thick oil. Rf = 0.32 (20% EtOAc in Hexanes); [α]D26= +140.8 (c=0.8, CH2Cl2); 
123 
 
 
 
ESI-HRMS: m/z calcd. for C65H75N14O13[M+NH4]
+ 1259.5638, found: 1259.5682. Compound 78 
(7.0 mg, 0.005 mmol) in anhydrous DMF (0.2 mL) was treated with NaH (1.0 mg, 0.041 mmol) 
and stirred for 2 h at room temperature. The reaction mixture was extracted into EtOAc (1.0 mL) 
and washed with brine and dried over Na2SO4 and concentrated. The residue was purified by 
chromatography over silica gel eluting with ethyl acetate/hexanes (20% to 60%) to afford 79 (4.0 
mg, 80%) as an oil. Rf = 0.48 (20% EtOAc in hexanes); [α]D26= +185 (c=0.5, CH2Cl2); 1H NMR 
(600 MHz, CDCl3): δ 7.44-7.22 (m, 25H arom.), 5.54 (d, J = 3.7 Hz, 1H, H-1'), 5.41 (d, J = 3.7 
Hz, 1H, H-1''), 5.04-4.99 (m, 3H, 1 CH2Ph, H-8'), 4.85-4.68 (m, 10H, 4 CH2Ph, H-5', H-6), 3.80 
(t, J = 9.5 Hz, 1H, H-4"), 3.70-3.65 (m, 2H, H-4', H-2"), 3.63-3.55 (m, 3H, 6"-CH2, H-3"), 3.50-
3.40 (m, 2H, H-7', H-5"), 3.34 (t, J = 9.5 Hz, 1H, H-4), 3.26 (dt, J = 4.0 Hz, 9.5 Hz, 1H, H-3), 
3.09 (dt, J = 4.0 Hz, 12.8 Hz, 1H, H-2'), 2.76 (m, 1H, H-1), 2.75 (s, 4H, H-5, NCH3), 2.28 (dt, J 
= 4.4 Hz, 11.0 Hz, 1H, H-3'eq), 2.13-2.04 (m, 2H, H-3'ax, H-2eq), 1.56 (s, 3H, CH3-6'), 1.38 (q, 
J = 12.8 Hz, H-2ax); 13C NMR (151 MHz, CDCl3): δ 156.49 (s, C=O), 137.96, 137.79, 137.37, 
137.17 (arom.), 128.49, 128.45, 128.41, 128.13, 128.04, 127.98, 127.95, 127.92, 127.87, 127.77, 
127.65, 127.06 (arom.), 97.47 (s, C-1′), 93.07 (s, C-8′), 92.92 (s, C-1"), 84.72 (s, C-4), 84.11 (s, 
C-7'), 79.83 (s, C-4"), 79.16 (s, C-4'), 78.17 (s, C-5), 75.87, 75.51, 74.89, 73.79, 72.95 (5s, 
5PhCH2), 70.73, 68.93 (s, C-5', 6"-CH2), 66.24 (s, C-5"), 65.98 (s, C-2"), 62.08 (s, C-3"), 60.12 
(s, C-3), 60.03, 57.75 (s, C-1), 55.86 (s, C-2'), 3.62 (s, C-2), 29.86 (s, NCH3), 29.25 (s, C-3'), 
23.84 (s, CH3-6'); ESI-HRMS: m/z calcd. for C58H63N13O12Na [M+Na]
+ 1156.4617, found: 
1156.4604. 
 1,3,2′,4′′-Tetraazido-5,6,2′′,3′′,6′′-penta-O-benzyl-7′-N-benzyloxycarbonyl-6′-O 
trifluoromethanesulfonyl-apramycin (80): To a stirred solution of 75 (600.0 mg, 0.49 mmol) 
in dry dichloromethane (5.0 mL) at room temperature was added diisopropylethylamine (152.0 
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mg, 1.18 mmol) in one portion. Triflic anhydride (304.0 mg, 1.078 mmol) was added to the 
reaction mixture at 0 ºC under Ar. The reaction mixture was stirred at 0 ºC for 1 h and was 
quenched with sat. NaHCO3 solution and washed with brine, dried, filtered, and concentrated 
under reduced pressure. The crude product was purified via silica gel chromatography eluting 
with 5% to 25% EtOAc in hexanes to give 80 (424.0 mg, 64%) as a yellow foam. Rf= 0.6 (30% 
EtOAc in hexane); [α]D26= +107.6 (c=0.7, CH2Cl2); The 1H-NMR spectrum showed the presence 
of two rotamers in a 5:3 ratio. 1H NMR (600 MHz, CDCl3): δ 7.40-7.26 (m, 30H arom.), 5.52-
5.32 (m, 3H, H-1', H-8', H-1"), 5.20-5.15, 5.04-4.27 (m, 12H, 5 CH2Ph, H-6', H-5'), 3.80 (m, 1H, 
H-4'), 3.76-3.62 (m, 2H, H-5, H-6), 3.60-3.48 (m, 3H, 6"- CH2, H-2"), 3.45-3.42 (m, 1H, H-1), 
3.32 (dt, J = 4.8 Hz, 10.3 Hz, 1H, H-3), 3.10 (dt, J = 4.0 Hz, 12.5 Hz, 1H, H-2'), 2.98 (s, 3H, 
NCH3,minor isomer), 2.95 (s, 3H, NCH3, major isomer), 2.26-2.18 (m, 2H, H-3'eq, H-2ex), 1.59-
1.42 (m, 2H, H-3'ax, H-2eq); 13C NMR (151 MHz, CDCl3): δ 156.3, 155.5 (s, C=O), 137.87, 
137.56, 137.29, 136.11 (arom.), 128.55-127.08 (arom.), 121-117.5 (q, J = 319.8 Hz, CF3), 97.58-
95.51 (C-1′, C-8', C-1"), 87.46, 84.71, 83.93, 79.34, 78.75, 78.31, 75.88, 75.75, 75.04, 73.60, 
73.15, 72.78 (5PhCH2, 6"-CH2, H-2", H-6') , 70.95, 68.12, 67.86, 66.91 (s, C-4'), 61.35, 60.24, 
58.95, 57.0 (s, C-5'), 55.76 (s, C-2'), 31.82 (s, NCH3), 29.68, 28.08 ( s, C-2, C-3');
 19F NMR (400 
MHz, CDCl3) δ -73.7; ESI-HRMS: m/z calcd. for C64H68N13O15F3SNa [M+Na]+ 1382.4529, 
found: 1382.4501. 
 1,3,2′,4′′-Tetraazido-5,6,2′′,3′′,6′′-penta-O-benzyl-7′-N-benzyloxycarbonyl-6’-deoxy-
6'α-iodo-apramycin (81): To a solution of 80 (220.0 mg, 0.162 mmol) in dry acetonitrile (3.0 
mL) was added NaI (122.0 mg, 0.81 mmol) in one portion. The resulting reaction mixture was 
stirred at room temperature for 6 h and then concentrated under reduced pressure. The residue 
was dissolved in dichloromethane (2.0 mL) and washed with water and brine, and dried, and 
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filtered. After concentration under reduced pressure the crude product was purified via silica gel 
chromatography eluting with 2% to 20% EtOAc in hexanes to give 81 (158.0 mg, 80%) as an off 
white foam. Rf = 0.52 (20% EtOAc in hexanes); [α]D26= +126.9 (c=1.3, CH2Cl2); The 1H-NMR 
spectrum showed the presence of two rotamers in a 3:1 ratio. 1H NMR (600 MHz, CDCl3): δ 
7.48-7.25 (m, 30H arom.), 5.70 (d, J =3.3 Hz, 1H, H-1'), 5.42 (d, J =8.1 Hz, 1H, H-8"), 5.24 (br 
s, 1H, H-1"), 5.2-4.4 (m, 14H, 5CH2Ph, H-3'', H-4, H-5', H-6), 4.11 (t, J =9.5 Hz, 1H, H-5), 3.96 
(t, J = 9.2 Hz, 1H, H-5'), 3.86 (m, 1H, H-6), 3.74 (m, 1H, H-6'), 3.6-3.4 (m, 4H, H-2", H-4', H-1, 
H-3), 3.39 (m, 1H, H-7'), 3.17 (br s, 3H-NCH3), 3.14 (dt, J =3.7 Hz, 12.5 Hz, 1H, H-2'), 2.38-
2.19 (m, 3H, H-3'eq, H-2ax,H-2eq), 1.55 (m, 1H, H-3'ax); 13C NMR (151 MHz, CDCl3): δ 
156.27, 154.98 (s, C=O), 137.98, 137.66, 137.40, 137.35, 136.13 (arom.), 128.92-127.38 
(arom.), 96.29 (s, C-1'), 95.00 (s, C-8"), 93.32 (s, C-1"), 84.81 (s, C-4'), 84.64 (s, C-1), 79.59 (s, 
C-6'), 78.63 (s, C-4'), 75.90-56.62 (5PhCH2, C-4, C-3"), 70.34 (s, C-7'), 67.93 (s, C-6"), 60.56 (s, 
6"-CH2), 56.62 (s, C-2'), 40.29 (s, CH3), 32.41 (s, C-3'), 27.96 (s, C-2); ESI-HRMS: m/z calcd. 
for C64H68N13O12I Na [M+Na]
+ 1360.4053, found: 1360.4049. 
 1,3,2′,4′′-Tetraazido-5,6,2′′,3′′,6′′-penta-O-benzyl-6′α-trifluoromethyl-7′-N 
benzyloxycarbonylapramycin (84) and 1,3,2′,4′′-Tetraazido-5,6,2′′,3′′,6′′-penta-O-benzyl-
6′β-trifluoromethyl7′-N-benzyloxycarbonylapramycin (85): To a stirred solution of 76 (120.0 
mg, 0.097 mmol) under Ar in THF (3.0 mL) was added TMSCF3 (280.0 mg, 1.97 mmol) 
followed by a catalytic amount of CsF (2.0 mg) in one portion at room temperature. The 
resulting reaction mixture was stirred for 1 h at room temperature and then concentrated to a 
afford gum. Purification by chromatography over silica gel eluting with EtOAc and hexanes 
(gradient of 2% to 20%) gave 84 (20.0 mg, 15%) as a white solid and 85 (60.0 mg, 50%) as a 
gum. 
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 84: Rf = 0.66 (30% EtOAc in hexanes); [α]D26= +112.9 (c=1.3, CH2Cl2); The 1H-NMR 
spectrum showed the presence of two rotamers in a 3:2 ratio. 1H NMR (600 MHz, CDCl3): δ 
7.39-7.23 (m, 30H arom.), 5.65 (d, J = 3.3 Hz, 1H, H-1', minor isomer), 5.65 (d, J = 3.3 Hz, 1H, 
H-1', major isomer), 5.22 (br s, 1H, H-1''), 5.20-4.35 (m, 13H, 5CH2Ph, H-8', H-3", H-4), 4.26 (t, 
J = 9.2 Hz, 1H, H-5'), 3.76 (t, J = 9.2 Hz, 1H, H-4''), 3.80-3.37 (m, 6H, 6"-CH2, H-1, H-3, H-2", 
H-3") 3.99 (dt, J = 4.0 Hz, 12.8 Hz, 1H, H-2'), 2.97 (s, 3H, NCH3, major isomer), 2.93 (s, 3H, 
NCH3, minor isomer), 2.40-2.18 (m, H-2 eq, H-3'eq, H-3'ax), 1.47 (m, 1H, H-2ax), 0.14 (s, 
OTMS); 13C NMR (151 MHz, CDCl3): δ 156.53 (s, C=O), 138.10, 138.04, 137.88, 137.76, 
137.56, 137.51, 137.30, 136.18 (arom.), 128.48-126.92 (arom.), 123.89 (q, J = 296.2 Hz, CF3), 
96.22-95.64 (m, C-1', C-1", C-8'), 84.84, 84.73 (s, C-6'), 79.62, 79.23 (s, C-4"), 78.74, 75.98, 
75.68, 75.61, 74.82, 73.61, 73.55, 72.69, 72.52, 70.50, 70.46, 68.86, 68.78 (s, C-5'), 68.52, 67.93, 
67.83, 67.03 (5PhCH2, 6"-CH2), 61.21, 61.14, 60.41, 60.30, 58.76, 57.34, 55.89, 55.81 (s, C-2'), 
32.09, 31.98, 31.89, 31.72 (s, C-2), 27.97 (s, C-3'), 2.35 (TMS); ESI-HRMS: m/z calcd. for 
C68H76N13O13F3SiNa [M+Na
+] 1390.5305, found: 1390.5298. 
 85: Rf = 0.7 (30% EtOAc in hexanes); [α]D26=+109.3 (c=3.3, CH2Cl2); The 1H-NMR 
spectrum showed the presence of two rotamers in 3:1 ratio. 1H NMR (600 MHz, CDCl3): δ 7.40-
7.22 (m, 30H arom.), 6.03 (d, J = 8.2 Hz, 1H, H-8'), 5.70 (d, J = 3.4 Hz, H-1'), 5.46 (d, J = 3.4 
Hz, H-1''), 5.23-4.38 (m, 14H, 5CH2Ph, H-3", H-4, 6''-CH2), 4.23 (d, J = 10.7 Hz, 1H, H-4'), 4.08 
(d, J = 10.7 Hz, 1H, H-5'), 3.83-3.46 (m, 4H, H-1, H-3, H-2", H-3"), 3.32 (d, J = 8.8 Hz, 1H, H-
7'), 3.18 (s, 3H, NCH3),  3.06 (m, 1H, H-2'), 2.37 (m, 1H, H-2eq), 2.28-2.08 (m, 2H, H-3'eq, 
3'ax), 1.41 (m, 1H, H-2ax), 0.31-0.08 (9H, OTMS); 13C NMR (151 MHz, CDCl3): δ 157.32, 
155.45 (s, C=O), 138.13, 137.87, 137.73, 137.22, 136.42 (arom.), 128.50, 128.47, 128.39, 
128.36, 128.27, 128.17, 128.13, 128.05, 128.01, 127.93, 127.87, 127.79, 127.67, 127.41, 127.37, 
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127.30, 127.22 (arom.), 126.22-121.55 (4s, J = 289.5 Hz, CF3), 96.58 (s, C-1'), 93.78 (s, C-1"), 
92.53 (s, C-8"), 85.07 (s, C-6'), 84.44, 84.35, 84.27, 79.50, 78.81, 77.52, 76.77, 75.97, 75.43, 
75.06, 74.85, 73.57, 73.47, 73.06, 72.18 (5PhCH2), 70.71, 70.19, 68.08, 67.81, 66.90, 61.12, 
60.48, 60.37, 60.19, 55.84, 42.21 (s, NCH3), 32.92, 32.67 (s, C-2), 28.31 (s, C-3'), 2.29 (TMS); 
ESI-HRMS: m/z calcd. for C68H76N13O13F3SiNa [M+Na]
 + 1390.5305, found: 1390.5290. 
 1,3,2′,4′′,6′-epi-Pentaazido-5,6,2′′,3′′,6′′-penta-O-benzyl-7′-N-benzyloxycarbonyl-6’-
deoxy- apramycin (88): To a solution of 80 (70.0 mg, 0.051 mmol) in dry DMF (1.2 mL) was 
added sodium azide (28.0 mg, 0.41 mmol) in one portion. The resulting reaction mixture was 
stirred at room temperature for 12 h after which the solvent was evaporated under reduced 
pressure. The residue was dissolved in dichloromethane (2.0 mL) and washed with water and 
brine, dried, filtered, and concentrated under reduced pressure. The crude product was purified 
via silica gel chromatography eluting with 2% to 20% EtOAc in hexanes to give 88 (36.0 mg, 
55%) as an off white foam. Rf = 0.45 (20% EtOAc in Hexanes); [α]D26= +125.7 (c=1.0, CH2Cl2); 
1H NMR (600 MHz, CDCl3): δ 7.40-7.17 (m, 30H arom.), 5.58-5.41 (m, 2H, H-1', H-8'), 5.20 (br 
s, 1H, H-1''), 5.18-4.54 (m, 13H, 5CH2Ph, H-3", H-4, H-6'), 4.03 (t, J = 9.2 Hz, 1H, H-5'), 3.75-
3.43 (m, 6H, H-1, H-3, H-4',H-2', 6"-CH2), 2.85 (br s, 1H, H-2"), 3.11 (m, 1H, H-2'), 3.08 (s, 3H, 
NCH3), 2.35 (m, 1H, H-2 eq), 2.24-2.19 (m, 2H, H-3'eq, H-3'ex), 1.59-1.54 (q, J = 12.8 Hz, 1H, 
H-2ax); 13C NMR (151 MHz, CDCl3): δ 156.2, 155.06 (s, C=O), 137.98, 137.94, 137.85, 
136.61,137.54 (arom.), 128.91-127.27 (arom.), 96.69 (s, C-1'), 95.10 (s, C-1"), 94.08 (s, C-8"), 
84.77, 84.43, 79.57 (d, 6"-CH2), 78.61, 77.72, 75.89, 75.66, 75.03, 73.55, 72.84, 71.92, 71.88 
(5PhCH2),70.53, 70.29, 69.80, 67.93, 67.10, 60.97, 60.39, 59.98, 59.22, 56.25 ( s, C-7'), 39.74 (s, 
NCH3), 32.12 (s, C-2), 28.11 (s, C-3'); ESI-HRMS: m/z calcd. for C64H68N16O12Na [M+Na]
+ 
1275.5100, found: 1275.5039. 
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 1,3,2′,4′′-Tetraazido-5,6,2′′,3′′,6′′-penta-O-benzyl-7′-N-benzyloxycarbonyl-6′-epi-O-
trifluoromethanesulfonyl-apramycin (89): To a solution of the 6'-epi alcohol 77 (210.0 mg, 
0.171 mmol) in dry dichloromethane was added pyridine (42.0 mg, 0.53 mmol) at room 
temperature. Triflic anhydride (116.0 mg, 0.414 mmol) was added at 0 ºC under Ar and the 
reaction mixture was stirred at 0 ºC for 3 h. The reaction mixture was quenched with saturated 
aqueous NaHCO3, and washed with brine, dried, filtered and concentrated under reduced 
pressure. The residue was purified via silica gel chromatography eluting with 4% to 30% EtOAc 
in hexanes to give 89 (195.0 mg, 84%) as a yellow foam. Rf= 0.6 (30% EtOAc in hexanes); 
[α]D26= +97.3 (c=1.2, CH2Cl2). The 1H-NMR spectrum showed the presence of two rotamers in a 
5:2 ratio. 1H NMR (600 MHz, CDCl3): δ 7.45-7.25 (m, 30H arom.), 5.87 (t, J = 9.2 Hz, 1H, H-
6'), 5.61-5.19 (m, 3H, H-1',H-8', H-1"), 5.10-4.49, 4.38-4.31 (m, 14H, 5 CH2Ph, H-4", H-5', H-6, 
H-5), 3.74-3.31 (m, 7H, H-4', H-1, H-3, 6"-CH2, H-2", H-3"), 3.26 (m, 1H, H-7'), 3.15 (m, 1H, 
H-2'), 3.06 (s, 3H, NCH3), 2.35-2.23 (m, 3H, H-2eq, H-2ex, H-3'eq), 1.53 (m, 1H, H-3'ax); 
13C 
NMR (151 MHz, CDCl3): δ 155.18 (s, C=O), 137.91, 137.88, 137.38, 137.26 (arom.), 128.82-
126.98 (arom.), 121.59-115.2 (q, J = 320.3 Hz, CF3), 97.92-95.53 (C-1′, C-8', C-1"), 87.45 (s, C-
6'), 84.41, 83.44, 79.71, 78.56, 75.90-67.58 (5PhCH2, 6"-CH2, H-2", H-6'), 66.54, 65.50, 61.91, 
60.46, 58.62, 55.90 (s, C-2'), 39.27 (s, NCH3), 31.77 (s, C-3'), 28.14 (s, C-2); 
19F NMR (400 
MHz, CDCl3) δ -75.0; ESI-HRMS: m/z calcd. for C65H68N13O15F3SNa [M+Na]+ 1382.4529, 
found: 1382.4512. 
 1,3,2′,4′′,6′-Pentaazido-5,6,2′′,3′′,6′′-penta-O-benzyl-7′-N-benzyloxycarbonyl-6’-
deoxy-apramycin (90): A solution of 89 (90.0 mg, 0.066 mmol) in dry DMF (1.2 mL) was 
treated with sodium azide (90.0 mg, 1.03 mmol) in one portion. The resulting reaction mixture 
was stirred at room temperature for 4 h before the solvent was evaporated under reduced 
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pressure. The residue was dissolved in dichloromethane (2.0 mL) and washed with water and 
brine, dried, filtered, and concentrated under reduced pressure. The residue was purified by silica 
gel chromatography eluting with 4% to 24% EtOAc in hexanes to give 90 (73.0 mg, 88%) as an 
off white foam. Rf = 0.65 (20% EtOAc in hexanes); [α]D26=+157.4 (c=1.5, CH2Cl2); The 1H-
NMR spectrum showed the presence of two rotamers in a 1:1 ratio. 1H NMR (600 MHz, CDCl3): 
δ 7.40-7.25 (m, 30H arom.), 5.49 (2 br s, 1H, H-1', 2 isomers), 5.27 (2 br s, 1H, H-1", 2 isomers), 
5.17 (m, 1H, H-8'), 5.2-4.4 (m, 14H, 5CH2Ph, H-6', H-4, H-5', H-6), 4.13 (br s, 1H, H-7'), 3.80 (t, 
J =9.2 Hz, H-3"), 3.74 (dt, J =4.4 Hz, 10.3 Hz, H-4'), 3.70-3.49 (m, 7H, H-3", H-4", H-2", H-5, 
H-3, 6"-CH2), 3.44 (t, J =9.2 Hz, 1H, H-1), 3.18 (dt, J =3.7 Hz, 12.5 Hz, H-2'), 3.02 (2 br s, 3H, 
NCH3, 2 isomers), 2.35 (m, 1H, H-2 eq), 2.23-2.17 (m, 2H, H-3'eq, H-3'ex), 1.55 (m, 1H, H-2 
eq); 13C NMR (151 MHz, CDCl3): δ 156.37, 156.06 (s, C=O), 138.05, 137.93, 137.69, 137.57, 
137.30, 136.41 (arom.), 128.53-127.27 (arom.), 97.74, 97.60 (s, C-1'), 96.17-95.65 (s, C-1", C-
8"), 84.80, 84.17 (s, C-1), 78.83, 78.17 (s, C-3"), 75.87, 75.68, 75.11 (s, C-2"), 73.60, 72.92, 
72.59, 70.66, 69.79, 68.53, 68.46, 67.20 (5PhCH2), 67.77, 67.57 (s, 6"-CH2), 63.67, 62.86 (s, C-
7'), 61.31, 60.25 (s, C-3), 59.07 (s, C-1), 56.00 (s, C-2'), 32.03 (s, C-2), 31.37 (s, NCH3), 28.22 
(s, C-3'); ESI-HRMS: m/z calcd. for C64H68N16O12Na [M+Na]
+ 1252.5100, found: 1252.5039. 
 1,3,2′,4′′-Tetraazido-5,6,2′′,3′′,6′′-penta-O-benzyl-7′-N-ethyl-apramycin (91): To a 
stirred solution of 74 (100.0 mg, 0.091 mmol) in anhydrous CH2Cl2 (4.0 mL) under Ar was 
added acetaldehyde (40.0 mg, 0.91 mmol) and MgSO4 (50.0 mg) at room temperature. The 
resulting reaction mixture was stirred for 1 h then filtered through Celite. Sodium 
cyanoborohydride (30.0 mg, 0.476 mmol) was added to the filtrate and the reaction mixture 
stirred for 2 h before it was washed with water, and brine, dried, and concentrated to afford a 
colorless oil that was purified by flash chromatography over silica gel (eluent: 5% to 25% of 
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EtOAc/hexanes) to give 91 (76.0 mg, 74%) as a gum. Rf = 0.55 (50% EtOAc in hexanes); 
[α]D26= +136.5 (c=2.0, dichloromethane); 1H NMR (600 MHz, CDCl3): δ 7.45-7.22 (m, 25H, 
arom.), 5.55 (d, J = 2.9 Hz, 1H, H-1'), 5.41 (d, J = 2.6 Hz, 1H, H-1''), 5.03 (d, J = 8.1 Hz, 1H, H-
8'), 5.03-4.46 (m, 10H, 5CH2Ph), 4.40 (br s, 1H, H-6'), 3.98 (d, J = 9.9 Hz, 1H, H-5'), 3.84 (m, 
1H, H-3"), 3.78 (dt, J = 3.7 Hz, 10.6 Hz, 1H, H-4'), 3.68 (m, 3H, H-4, 6"-CH2), 3.60 (m, 3H, H-
3", H-6, H-2"), 3.52 (dt, J = 4.0 Hz, 12.8 Hz, 1H, H-1), 3.42 (t, J = 9.5 Hz, 1H, H-5), 3.36 (dt, J 
= 4.0 Hz, 13.2 Hz, 1H, H-3), 3.12 (dt, J = 3.3 Hz, 12.8 Hz, 1H, H-2'), 2.80 (m, 3H, H-5", 7'-
NCH2), 2.52 (br s, 3H, NCH3), 2.34 (dt, J = 4.4 Hz, 13.2 Hz, 1H, H-2eq), 2.27-2.14 (m, 2H, H-
3'ax, H-3'eq), 1.50 (m, 1H, H-2ax), 1.08 (br s, 3H, NCH2CH3); 
13C NMR (151 MHz, CDCl3): δ 
138.06, 137.91, 137.73, 137.69 (arom.), 128.48, 128.43, 128.40, 128.37, 128.33, 128.24, 128.05, 
128.01, 127.93, 127.80, 127.78, 127.71, 127.67, 127.25, 127.11 (arom.), 97.57 (s, C-1′), 96.33 (s, 
C-8′), 94.59 (s, C-1"), 84.75 (s, C-5), 84.38 (s, C-6), 79.49, 78.79 (s, C-2"), 77.53 (s, C-4), 75.89, 
75.58, 75.09, 73.59, 72.52 (5s, 5CH2Ph), 70.83 (s, C-3"), 70.28 (s, C-5'), 69.22 (C-6'), 68.57 (s, 
6"-CH2), 66.08 (s, C-4'), 64.35, 61.44, 60.23 (s, C-1), 59.11 (s, C-3), 56.31 (s, C-2'), 50.20 (br s, 
7'-NCH2), 38.75 (s, NCH3), 32.08 (s, C-2), 28.30 (s, C-3'), 13.19 (br s, NCH2CH3); ESI-HRMS: 
m/z calcd. for C58H68N13O11 [M+H]
+ 1122.5161, found: 1122.5130. 
 1,3,2′,4′′-Tetraazido-5,6,2′′,3′′,6′′-penta-O-benzyl-7′-N-ethyl-apramycin N-Oxide 
(92): m-CPBA (12.0 mg, 0.069 mmol) was added to the stirred solution of 91 (66.0 mg, 0.058 
mmol) in CH2Cl2 (2 mL) and the reaction mixture was stirred for 1h at room temperature before 
it was washed with 1N aqueous NaOH, water, and brine. The dried organic layer was 
concentrated under vacuum to afford 92 (60.0 mg, 80%) as a white foam. Rf = 0.15 (60% EtOAc 
in hexanes). The 1H-NMR spectrum showed the presence of two diastereomers in a 1:1 ratio. 1H 
NMR (600 MHz, CDCl3): δ 7.45-7.15 (m, 25H, arom.), 5.82, 5.78 (d, J = 7.7 Hz, 1H, H-8'), 
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5.68, 5.66 (d, J = 3.3 Hz, 1H,  H-1'), 5.55, 5.53 (d, J = 3.7 Hz, 1H, H-1"), 5.03-4.42 (m, 11H, 5 
CH2Ph, H-6'), 3.98 (m, 1H, H-5), 3.89-3.48 (m, 8H, H-4', H-3", H-4, H-5, H-5', H-4", 6"-CH2), 
3.44-3.34 (m, 2H, H-1, H-3), 3.31, 3.24 (s, 3H, NCH3), 3.19-3.11 (m, 2H, H-2',H-7'), 2.32 (m, 
1H, H-3'eq), 2.25 (m, 1H, H-2eq), 2.11 (m, 1H, H-3'ax), 1.48 (m, 1H, H-2ax), 1.34-1.21 (m, 5H, 
NCH2CH3); 
13C NMR (151 MHz, CDCl3): δ 137.81-137.14 (arom.), 128.62-126.90 (arom.), 
97.53, 97.44 (s, C-1′), 93.34, 92.86 (s, C-8′), 92.72, 92.10 (s, C-1"), 84.63, 84.59, 84.44, 79.48, 
78.38, 75.89-70.93 (5CH2Ph), 70.73, 68.20, 67.04, 66.78, 66.56, 66.41, 60.20, 60.03, 59.66, 
55.92, 55.05, 53.43, 32.41, 32.27 (s, C-2), 29.68 (m, NCH2CH3), 28.00, 27.88 (s, C-3'); ESI-
HRMS: m/z calcd. for C58H68N13O12 [M+H]
+ 1138.5110, found: 1138.5092. 
 1,3,2′,4′′-Tetraazido-7′-N-demethyl-apramycin (94): To a stirred solution of 69 (110.0 
mg, 0.171 mmol) in methanol (10.0 mL) was added sodium methoxide (120.0 mg, 2.22 mmol), 
tris base (270.0 mg, 2.23 mmol) and then iodine (130.0 mg, 0.51 mmol) at 0 ºC. The resulting 
reaction mixture was stirred for 3 h at 0 ºC, then warmed to room temperature and stirred for 
12h. The solvent was evaporated under vacuum and the residue was purified by column 
chromatography on silica gel eluting with gradient of 2% to 20 % ammonical methanol in 
dichloromethane to give 94 (64.0 mg, 58%) as a thick gum. Rf = 0.2 (30% ammonical methanol 
in dichloromethane); [α]D26= +90.7 (c=0.8, MeOH); 1H NMR (600 MHz, CD3OD): δ 5.61 (d, J = 
3.3 Hz, 1H, H-1'), 5.34 (d, J = 4.0 Hz, 1H, H-1''), 5.09 (d, J = 8.4 Hz, 1H, H-8'), 4.59 (br s, 2H, 
7'-NH2), 4.26 (t, J = 2.2 Hz, 1H, H-6'), 3.92-3.85 (m, 3H, H-5', 6"-CH2), 3.79-3.64 (m, 4H,  H-5, 
H-4', H-2", H-3"), 3.57-3.44 (m, 4H, H-4", H-5", H-6, H-1), 3.44-3.37 (m, 2H, H-3'', H-3), 3.26-
3.21 (m, 1H, H-2'), 2.26-2.18 (m, 2H, H-3'eq, H-2eq), 2.05 (m, 1H, H-3'ax), 1.48 (m, 1H, H-
2ax); 13C NMR (151 MHz, CD3OD): δ 97.69 (s, C-1'), 94.57 (s, C-8'), 93.06 (s, C-1''), 79.34 (s, 
C-7') , 76.61, 76.45 (s, C-6'), 71.97, 71.52, 71.16 (s, C-2'), 69.81, 66.93, 66.09, 62.08, 61.08, 
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60.28, 59.65, 56.28, 53.77, 31.77 (s, C-2), 27.69 (s, C-3'); ESI-HRMS: m/z calcd. for 
C20H31N13O11 [M+H]
+ 630.2344, found: 630.2333. 
 1,3,2′,4′′-Tetraazido-7’-N-(2-benzyloxyethyl)-7′-N-demethyl-apramycin (95): To a 
stirred solution of 94 (60.0 mg, 0.09 mmol) and 4 Å molecular sieves (50.0 mg) in anhydrous 
MeOH (2.0 mL) under Ar were added benzyloxyacetaldehyde (17.0 mg, 0.11 mmol), NaBH3CN 
(60.0 mg, 0.95 mmol) and 2 drops of glacial acetic acid. The reaction mixture was stirred for 2 h 
at room temperature then was filtered through Celite, and concentrated to afford a gum, which 
was purified by chromatography over silica gel eluting with gradient of 3% to 20% ammonical 
methanol in dichloromethane to give 95 (45.0 mg, 63%) as an off-white foam. [α]D26= +57.2 
(c=0.4, MeOH); 1H NMR (600 MHz, CDCl3): δ 7.41-7.23 (m, 5H, arom.), 5.59 (d, J = 3.4 Hz, 
1H, H-1'), 5.27 (d, J = 3.4 Hz, 1H, H-1"), 4.91 (d, J = 8.0 Hz, 1H,  H-8'), 4.57-4.51 (m, 2H, 6"-
CH2), 4.17 (br s, 1H, H-6'), 3.84 (dd, J = 2.2 Hz, 9.9 Hz, 1H, H-7'), 3.82-3.67 (m, 4H, OCH2, H-
3", H-4'), 3.57 (t, J = 4.8 Hz, 1H, H-4"), 3.52-3.43 (m, 5H, H-1, H-2", H-4, H-6), 3.43-3.36 (m, 
2H, H-3, H-5"), 3.23 (t, J = 9.2 Hz, 1H, H-5), 3.20 (dt, J = 4.3 Hz, 12.8 Hz, 1H, H-2'), 2.93 (br s, 
2H, NCH2), 2.70 (br s, 1H, H-5'), 2.24 (m, J = 3.7 Hz, 1H, H-2eq), 2.15 (m, 1H, H-3'eq), 2.01 
(m, 1H, H-3'ax), 1.39 (m, 1H, H-2ax ); 13C NMR (151 MHz, CDCl3) δ 138.16 (s, arom.), 128.02, 
127.60, 127.32 (3s, arom.), 97.64 (s, C-1'), 95.93 (s, C-8'), 94.89 (s, C-1"), 79.20 (s, C-6"), 
76.60, 76.52, 72.85, 72.52, 71.46, 71.13, 70.43, 68.61, 66.41(s, NCH2), 61.92, 60.80, 60.70, 
60.31, 59.77, 56.42, 46.32(s, C-4'), 31.84 (s, C-2), 27.96 (s, C-3'); ESI-HRMS: m/z calcd. for 
C29H41N13O12Na [M+Na]
+ 786.2896, found: 786.2872. 
 1,3,2',7'-Tetra-N-benzyloxycarbonyl-5,6-O-cyclohexylidene-epiaprosamine (99): To 
a stirred solution of 98101 (80.0 mg, 0.077 mmol) under Ar in anhydrous DCM (2.0 mL) was 
added Dess–Martin periodinane (98.0 mg, 0.23 mmol) and stirred for 8h under Ar at room 
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temperature. The reaction mixture was quenched by addition of saturated aqueous NaHCO3, 
washed with brine, dried over Na2SO4, and concentrated under reduced pressure to crude ketone. 
To a solution of this ketone in anhydrous MeOH (2.0 mL) under Ar was added NaBH4 (5.8 mg, 
3.89 mmol) and stirred for 10 min at room temperature. The reaction mixture concentrated under 
reduced pressure and crude dissolved in DCM (2.0 mL) was washed with water followed by 
brine. Then, the solvent was evaporated under reduced pressure and the crude mixture of 
alcohols (2:1 ratio) was separated by silica gel column using 30% EtOAc in hexanes to give the 
title compound 99 (40.0 mg, 41%) as a white foam. [α]D25= +27.3 (c=1.2, CH2Cl2); The 1H 
NMR spectrum showed the presence of two rotamers in 2:1 ratio.  1H NMR (CDCl3, 600 MHz): δ 
7.30 (m, Ar-H), 6.18 (m, 2H, H-8'), 5.54 (d, J = 9.1 Hz, 2H, H-1'), 5.20-5.08 (m, 2H), 5.08-5.02 
(m, 6H), 4.99 (m, 2H), 4.29 (s, 1H), 4.17-4.07 (m, 1H), 3.93-3.82 (m, 2H), 3.80 (s, 1H), 3.74 (m, 
1H), 3.62 (d, J = 10.1 Hz, 1H), 3.53 (s, 1H), 3.45 (m, 1H), 3.32 (br s, 1H), 2.96 (s, 5H), 2.92 (s, 
3H), 2.40 (s, 1H), 2.15 (m, 1H), 2.10 (s, 1H), 2.03 (br s, 3H), 1.96 (s, 5H), 1.72 (m, 1H), 1.52 (d, 
J = 7.3 Hz, 1H), 1.24 (q, J = 7.3 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 169.22, 156.89, 
155.88, 155.67, 136.49, 136.28, 136.19, 128.52, 128.49, 128.46, 128.39, 128.15, 127.67, 113.07, 
97.68, 89.37, 80.05, 77.25, 77.04, 76.83, 70.66, 70.37, 67.39, 66.89, 66.76, 51.68, 49.44, 36.25, 
35.98, 35.61, 30.17, 24.75, 23.46, 20.89; ESI-HRMS: m/z calcd. for C55H64N4O16Na [M+Na]
+ 
1059.4215, found: 1059.4199. 
 General procedure for the Staudinger reduction of azides to amines: A stirred 
solution of substrate (0.06 mmol, 1 eq) in THF (5.0 mL) was treated with 0.1 M aqueous NaOH 
(0.3 mL, 0.03 mmol, 5 eq) and 1 M trimethylphosphine in THF (0.5 mL, 0.6 mmol, 10 eq) at 
room temperature. The reaction mixture was stirred for 2 h at 55 °C, and then cooled to room 
temperature, and neutralized with 1 M aqueous AcOH to pH 7 before concentration. The 
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resulting slurry was subjected to silica gel chromatography, eluting first with EtOAc (100 mL), 
followed by 20% of ammonical methanol in EtOAc (250 mL) to give the product. 
 General procedure for hydrogenolysis: The substrate (0.01 mmol) was dissolved in a 
mixture of methanol (1.0 mL), deionized water H2O (1.0 mL), and glacial AcOH (10 eq). A 
catalytic amount of Pd(OH)2 on carbon (20 wt. %) was added and the reaction mixture was 
stirred at room temperature under 1 atm of hydrogen (balloon) for 12-15 h. After completion, the 
reaction mixture was filtered through Celite® and the filtrate was neutralized by the addition of 
Amberlite-IRA400 to pH 7 and filtered. The filtrate was evaporated under reduced pressure, and 
the residue was purified by silica gel column chromatography eluting with MeOH:H2O:NH4OH 
(1:0.4:0.4). The product containing fractions were evaporated and dissolved in 0.002 M aqueous 
AcOH (2.0 mL) and then charged to a Sephadex column (CM Sephadex C-25, 5.0 g). The 
Sephadex column was eluted with deionized water H2O (50.0 mL), 0.5% aqueous NH4OH (40.0 
mL), and 1.5% NH4OH (40.0 mL). The product-containing fractions were combined and 
evaporated to give the product in the form of the free base, which was taken up in H2O (2.0 mL) 
and treated with glacial acetic acid (10 eq). The resulting solution was frozen in a dry ice acetone 
bath, and then lyophilized to give the product in the form of the acetate salt.  
 6'-epi-Aprosamine (19): A solution of compound 99 (40.0 mg, 0.04 mmol) in acetic 
acid/water (0.7 mL, 2:1) was heated at 60 ºC for 15 min. The mixture was diluted with EtOAc 
(2.0 mL) and washed with sat NaHCO3 followed by brine. Then, the solvent was evaporated 
under reduced pressure and subjected to next reaction without further purification. The crude was 
dissolved in MeOH (1.0 mL) and sodium methoxide added at room temperature.  The reaction 
mixture was stirred for 30 min and concentrated under reduced pressure. Then, reaction mixture 
dissolved in EtOAc (2.0 mL) and washed with 0.1N HCl, water, and followed by brine. The 
135 
 
 
 
volatiles were evaporated at 30 ºC in vacuo and the residue was dried under vacuum and was 
subjected to the hydrogenolysis using general procedure to give 19 (23.0 mg, 90%) as a white 
foam. [α]D26= +28.5 (c=0.13, H2O); The 1H NMR spectrum showed the presence of two 
anomers (8') in 5:1 ratio. 1H NMR (600 MHz, D2O) δ 5.31 (t, J = 2.9 Hz, 1H, 1'-H), 5.27 (m, 2H, 
8'-H, 1'-H), 4.88 (d, J = 8.1 Hz, 1H), 3.83 (m, 1H), 3.78 (d, J = 6.9 Hz, 1H), 3.63 (t, J = 9.6 Hz, 
1H), 3.50 (t, J = 11.7 Hz, 1H), 3.49-3.39 (m, 1H), 3.37-3.25 (m, 2H),  3.13-3.04 (br s, 1H), 2.60 
(s, 1H), 2.57 (s, 3H), 2.25 (d, J = 12.5 Hz, 1H), 2.03(m, 1H), 1.74 (d, J = 12.8 Hz, 1H), 1.69 (s, 
12H); 13C NMR (151 MHz, D2O) δ 181.14, 96.12, 92.11, 88.10, 81.37, 74.53, 72.36, 72.20, 
66.26, 63.73, 61.19, 49.55, 48.77, 48.26, 30.83, 28.53, 27.23, 23.09; ESI-HRMS: m/z calcd. for 
C15H30N4O7Na [M+Na]
+ 401.2012, found: 401.2026. 
 6'-Deoxyapramycin Pentaacetate Salt (107): Compound 82 (90.0 mg, 90%) was 
obtained in the form of a yellow thick gum by Staudinger reaction of 81 (95.0 mg) after silica gel 
chromatography (eluent: 20% ammonical methanol in EtOAc). [α]D26 =+38.0 (c=2.5, MeOH); 
ESI-HRMS: m/z calcd. for C64H78N5O12[M+H]
+ 1234.4614, found: 1234.4611. This compound 
was taken forward to the next step without further characterization. To a solution of 82 (90.0 mg, 
0.072 mmol) in toluene (3.0 mL) under Ar was added tris(trimethylsilyl)silane (0.1 g, 0.403 
mmol) followed by azoisobutyronitrile (13.6 mg, 0.08 mmol) at room temperature. The resulting 
reaction mixture was stirred at 65 ºC for 3 h giving a mixture of the deiodinated product and its 
partially debenzylated congeners as determined by mass spectrometry. The solvent was 
evaporated under reduced pressure and the residue filtered on silica gel (eluent: 20% ammonical 
methanol in EtOAc) to give a mixture of 83 and partially debenzylated 83 (62.0 mg). This 
mixture (55.0 mg) was subjected to the standard hydrogenolysis protocol to give 107 (8.0 mg, 
55%) as an off white foam after Sephadex chromatography. [α]D26= +62.0 (c 0.3, H2O); 1H NMR 
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(600 MHz, D2O): δ 5.47 (d, J = 3.7 Hz, 1H, H-1'), 5.38 (d, J = 3.3 Hz, 1H, H-1"), 4.88 (d, J = 8.4 
Hz, 1H, H-8'), 3.82-3.59 (m, 6H, H-3", H-5", H-4, H-5', 6"-CH2), 3.57-3.49 (m, 2H, H-2', H-2"), 
3.45 (t, J = 9.2 Hz, 1H, H-5), 3.42-3.34 (m, 2H, H-4', H-6), 3.26 (t, J = 9.5 Hz, 1H, H-3), 3.20 
(m, 1H, H-7'), 3.10 (m, 2H, H-1, H-4"), 2.58 (s, 3H, NMe), 2.43 (m, 1H, H-6'eq), 2.30 (m, 1H, 
H-2eq), 2.22 (m, 1H, H-3'eq), 1.80 (s, 15H, 5CH3COOH), 1.89 (m, 1H, H-3'ax), 1.62-1.60 (m, 
2H, H-2ax, H-6ax); 13C NMR (151 MHz, D2O): δ 178.76 (CO), 95.57 (s, C-8′), 95.52 (s, C-1'), 
94.46 (s, C-1"), 78.49 (s, C-5'), 75.07 (s, C-5), 72.52 (s, C-4'), 72.24 (s, C-6), 70.23 (s, C-3'), 
69.55, 67.00 (s, C-4),  60.33 (s, C-6"), 56.01 (s, C-7'), 52.11 (s, C-4"), 49.71 (s, C-1), 48.47 (s, C-
3), 48.06 (s, C-2"), 30.20 (s, NMe), 28.41 (s, C-6'), 28.18 (s, C-2), 27.05 (s, C-3'), 21.73 (s, 
CH3COOH); ESI-HRMS: m/z calcd. for C21H41N5O10[M+H]
+ 524.2932, found: 524.2909. 
 6'-epi-Apramycin Pentaacetate Salt (108): Compound 100 (30.0 mg, 85%) was 
obtained in the form of a white thick gum by Staudinger reaction of 77 (40.0 mg) after silica gel 
chromatography (eluent: 20% ammonical methanol in EtOAc). [α]D26=+49.0 (c=0.8, MeOH); 
ESI-HRMS: m/z calcd. for C64H78N5O13[M+H]
+ 1124.5596, found: 1124.5450. This compound 
was taken forward to the next step without further characterization. Compound 107 (10.3 mg, 
60%) was obtained in the form of a white foam by hydrogenolysis of 100 (27.0 mg) after 
Sephadex chromatography. [α]D26=+51.0 (c=0.5, H2O); 1H NMR (600 MHz, D2O): δ 5.38–5.35 
(m, 2H, H-1', H-1"), 4.98 (d, J = 8.4 Hz, 1H, H-8'), 3.86 (t, J = 9.2 Hz, 1H, H-6'), 3.83 (m, 1H, 
H-5"), 3.75–3.63 (m, 4H, H-3", H-4'', 6"-CH2), 3.61 (t, J = 9.2 Hz, 1H, H-5'), 3.58 (m, 1H, H-
2"), 3.55 (t, J = 4.4 Hz, 1H, H-2'), 3.50 (t, J = 9.5 Hz, 1H, H-5), 3.42 (m, 2H, H-4', H-4), 3.32 
(dt, J = 4.4 Hz, 12.1 Hz, 1H, H-3). 3.15 (dt, J = 4.4 Hz, 11.4, 1H, H-1), 3.10 (t, J = 10.3 Hz, 1H, 
H-6), 3.04 (t, J = 8.8 Hz, 1H, H-7'), 2.62 (s, 3H, NCH3), 2.30 (dt, J = 4.0 Hz, 12.8 Hz, 1H,  H-
2eq), 2.27-2.22 (m, 1H, H-3'eq), 1.87 (m, 1H, H-3'ax), 1.78 (s, 15 H, 5 CH3COOH), 1.69-1.58 
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(m, 1H, H-2ax); 13C NMR (151 MHz, D2O): δ 180.49 (s, CO), 96.11 (s, C-1′), 95.02 (s, C-1′), 
94.37 (s, C-1"), 81.32 (s, C-4'), 74.58 (s, C-5'), 72.36, 70.19, 70.02, 68.66, 68.26, 67.2 (s, C-6'), 
66.93, 61.54 (s, C-7'), 60.22 (s, 6"-CH2), 51.92, 49.55 (s, C-3), 48.79 (s, C-1), 48.08 (s, C-2'), 
30.78 (s, NMe), 28.2 (s, C-2), 27.15 (s, C-3'), 22.72 (CH3COOH); ESI-HRMS: m/z calcd. for 
C21H42N5O11 [M+H]
+ 540.2881, found: 540.2892. 
 6'α-Methylapramycin Pentaacetate Salt (109): Compound 78 (45.0 mg) was subjected 
to the Staudinger reaction using water instead of 0.1 N NaOH as solvent to give 101 (30.0 mg, 
70%) in the form of a thick gum after silica gel chromatography (eluent: 20% ammonical 
methanol in EtOAc). [α]D26=+79 (c 0.8, MeOH); ESI-HRMS: m/z calcd. for C65H80N5O13[M+H]+ 
1138.5753, found: 1138.5741. This compound was taken forward to the next step without further 
characterization. Compound 109 (12.0 mg, 75%) was obtained in the form of a white foam by 
hydrogenolysis of 101 (40 mg) after Sephadex chromatography. [α]D26=+66.0.0 (c=0.5, H2O); 1H 
NMR (600 MHz, D2O): δ 5.55 (d, J = 2.8 Hz, 1H, H-1'), 5.40 (d, J = 3.1 Hz, 1H, H-1"), 5.11 (d, 
J = 8.2 Hz, 1H, H-8'), 3.85 (m, 1H, H-5"), 3.73 (m, 1H, H-4'), 3.70-3.62 (m, 4H, H-4", H-4, 6"-
CH2), 3.57 (m, 2H, H-5', H-2"), 3.50 (m, 2H, H-2', H-6), 3.41 (t, J = 9.8 Hz, 1H, H-5), 3.27 (dt, J 
= 3.6 Hz, 11.3 Hz, 1H, H-1), 3.20-3.10 (m, 2H, H-3, H-3"), 3.02 (d, J = 8.2 Hz, 1H, H-7'), 2.77 
(s, 3H, NCH3), 2.29 (dt, J = 3.6 Hz, 12.5 Hz, 1H, H-2eq), 2.23 (dt, J = 3.6 Hz, 11.3 Hz, 1H, H-
3'eq), 1.86 (m, 1H, H-3'ax), 1.78 (s, 15H, 5CH3COOH), 1.67 (m, 1H, H-2ax), 1.37 (s, 3H, 6'-
CH3); 
13C NMR (151 MHz, D2O): δ 180.86 (s, CO), 95.84 (s, C-1′), 95.09 (s, C-1"), 95.04 (s, C-
8'), 80.43 (s, C-4"), 75.13 (s, C-2'), 72.55 (s, C-5), 70.84 (s, C-6'), 70.31 (s, C-5"), 70.01, 68.77 
(s, C-5'), 66.63, 65.30 (s, C-7'), 60.31(s, 6"-CH2), 52.01 (s, C-3"), 49.79 (s, C-3), 48.63 (s, C-1), 
48.09 (s, C-6), 34.94 (s, NCH3), 29.01 (s, C-2), 26.85 (s, C-3'), 22.93 (CH3COOH), 20.52 (s, 6'-
CH3); ESI-HRMS: m/z calcd. for C22H44N5O11 [M+H]
+ 554.3037, found: 554.3054. 
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 6'α-Trifluoromethylapramycin Pentaacetate Salt (110): To a solution of compound 84 
(100.0 mg, 0.073mmol) in THF (2.0 mL) was added TBAF (38.0 mg, 0.15 mmol, 1M THF 
solution) at room temperature. The resulting reaction mixture was stirred for 1 h and then 
concentrated to afford a thick gum, which was purified by chromatography over silica gel 
(eluent: gradient of 4% to 30% EtOAc in hexanes) to give 86 (64.0 mg, 80%) as an off-white 
foam. This compound was taken forward to the next step without further characterization. 
Compound 86 (50.0 mg, 0.038 mmol) was subjected to the Staudinger reaction conditions to 
afford a 6′,7′-oxazolidinone in the form of a white thick gum from after silica gel 
chromatography (eluent: 20% ammonical methanol in EtOAc). This compound was taken up in 3 
N NaOH (1.0 mL) and 1,4-dioxane (2.0 mL) and heated to 100 ºC for 6 h. After cooling to room 
temperature the reaction mixture was neutralized with glacial acetic acid followed by 
concentration to afford a thick mass that was purified by chromatography over silica gel (eluent: 
20% ammonical methanol in EtOAc) to give the compound 102 (40.0 mg, 90%) as a gum. 
[α]D26=+143 (c 0.7, MeOH); ESI-HRMS: m/z calcd. for C65H77F3N5O13[M+H]+ 1192.5470, 
found: 1192.5458. Compound 102 was taken forward to the next step without further 
characterization. Compound 110 (21.0 mg, 60%) was obtained in the form of a white foam by 
hydrogenolysis of 102 (50.0 mg) after Sephadex chromatography. [α]D26=+77.0 (c=1.1, H2O); 1H 
NMR (600 MHz, D2O): δ 5.50 (d, J = 3.7 Hz, 1H, H-1'), 5.30 (d, J = 3.7 Hz, 1H, H-1"), 4.99 (d, 
J = 6.6 Hz, 1H, H-8'), 4.29 (d, J = 9.9 Hz, 1H, H-5'),  3.84 (dt, J = 4.0 Hz, 10.3 Hz, 1H, H-4''), 
3.75 (dd, J = 4.0 Hz, 11.4 Hz, 1H, H-4'), 3.71 (dd, J = 3.7 Hz, 12.5 Hz, 1H, H-3"), 3.68-3.60 (m, 
3H, 6"-CH2, H-4), 3.55 (dd, J = 3.7 Hz, 9.5 Hz, 1H, H-2"), 3.49 (dt, J = 4.0 Hz, 12.8 Hz, 1H, H-
2'), 3.45 (t, J = 8.8 Hz, 1H, H-5), 3.39 (t, J = 9.9 Hz, 1H, H-6), 3.25 (dt, J = 4.0 Hz, 12.8 Hz, 1H, 
H-3), 3.17-3.08 (m, 3H, H-5", H-7', H-1), 2.54 (s, 3H, NCH3),  2.30-2.19 (m, 2H, H-2eq, H-
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3'eq), 1.90 (q, J = 11.7 Hz, 1H, H-2ax), 1.76 (s, 15H, CH3COOH), 1.67 (q, J = 12.8 Hz, H-3'ax); 
13C NMR (151 MHz, D2O): δ 180.58 (s, CO), 127.40, 125.58, 123.67, 121.71 (q, J = 288.4 Hz, 
CF3), 96.08 (s, C-1′), 95.71 (s, C-8'), 94.93 (s, C-1"), 80.95 (s, C-4), 75.11 (s, C-5), 72.30 (s, C-
6), 70.42 (s, C-2''), 69.63, 68.93 (s, C-5"), 68.24 (s, C-5'), 65.33 (s, C-3"), 63.68, 60.70 (s, C-7'), 
60.31 (s, 6"-CH2), 52.11, 49.78 (s, C-1), 48.68 (s, C-3), 47.81 (s, C-2'), 35.08 (s, NCH3), 28.78 
(s, C-2), 27.05 (s, C-3'), 22.79 (s, CH3COOH); 
19F NMR (400 MHz, CDCl3) δ -75.6; ESI-
HRMS: m/z calcd. for C22H41F3N5O11 [M+H]
+ 608.2755, found: 608.2741.  
 6'-epi-6'β-Trifluoromethylapramycin Pentaacetate Salt (111): To a solution of 
compound 85 (60.0 mg, 0.043 mmol) in THF (2.0 mL) was added TBAF (23.0 mg, 0.087 mmol, 
1M THF solution) at room temperature. The resulting reaction mixture was stirred for 1 h and 
concentrated to afford thick mass, which was purified by chromatography over silica gel (eluent: 
gradient of 4% to 30% EtOAc in hexanes) to give 87 (55.0 mg, 80%) as an off-white solid. This 
compound was taken forward to the next step without further characterization. Compound 103 
(45.0 mg, 80%) was obtained in the form of a white thick gum by Staudinger reaction of 87 (50.0 
mg) after silica gel chromatography (eluent: 20% ammonical methanol in EtOAc). [α]D26=+153 
(c 0.8, MeOH); ESI-HRMS: m/z calcd. for C65H77F3N5O13[M+H]
+ 1192.5470, found: 1192.5446. 
Compound 103 was taken forward to the next step without further characterization. Compound 
111 (20.6 mg, 72%) was obtained in the form of a white foam by hydrogenolysis of 103 (45.0 
mg) after Sephadex chromatography. [α]D26=+74.0 (c=1.1, H2O); 1H NMR (600 MHz, D2O): δ 
5.38 (d, J = 3.7 Hz, 1H, H-1'), 5.33 (d, J = 3.7 Hz, 1H, H-1"), 4.99 (d, J = 8.8 Hz, 1H, H-8'), 3.93 
(d, J = 10.3 Hz, 1H, H-5'),  3.83 (m, 2H, H-5", H-4'), 3.74 (t, J = 9.5 Hz, 1H, H-4), 3.72- 3.60 
(m, 3H, 6"-CH2, H-4"), 3.58-3.53 (m, 2H, H-2', H-2"), 3.47 (t, J = 9.2 Hz, 1H, H-5), 3.41 (m, 
1H, H-6), 3.34 (dt, J = 4.0 Hz, 10.3 Hz, 1H, H-3), 3.17-3.08 (m, 2H, H-3", H-1), 2.92 (d, J = 8.1 
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Hz, 1H, H-7'), 2.51 (s, 3H, NCH3), 2.33 (dt, J = 4.0 Hz, 12.8 Hz, 1H, H-2eq), 2.24 (m, 1H, H-
3'eq), 1.79 (m, 1H, H-3'ax), 1.77 (s, 15H, 5CH3COOH), 1.67 (q, J = 12.5 Hz, 1H, H-2ax); 
13C 
NMR (151 MHz, D2O): δ 180.80 (s, CO), 125.58 (q, J = 290.0 Hz, CF3), 96.38 (s, C-1′), 95.81 
(s, C-8'), 94.86 (s, C-1"), 81.88 (s, C-3''), 74.65 (s, C-6', C-5), 72.49 (s, C-6), 70.45 (s, C-2'), 
69.80 (s, C-4'), 69.12 (s, C-4"), 67.19 (s, C-7'), 66.35 (s, C-5"), 60.32 (s, 6"-CH2), 52.09 (s, C-1), 
49.73, 48.74 (s, C-3), 47.76 (s, C-2"), 37.15 (s, NCH3), 28.96 (s, C-2), 28.24 (s, C-3'), 22.92 (s, 
CH3COOH); 
19F NMR (400 MHz, CDCl3) δ -66.2; ESI-HRMS: m/z calcd. for C22H41F3N5O11 
[M+H]+ 608.2755, found: 608.2746. 
 6'-epi-Amino-6'-deoxy-apramycin Hexaaacetate Salt (112): Compound 104 (30.0 mg, 
85%) was obtained in the form of a white thick mass by Staudinger reaction of 88 (40.0 mg) 
after silica gel chromatography (eluent: 20% ammonical methanol in EtOAc). [α]D26=+40 (c 0.7, 
MeOH); ESI-HRMS: m/z calcd. for C64H79N6O12[M+H]
+ 1123.5756, found: 1123.5747. Without 
further characterization 104 (30.0 mg) was subjected to the hydrogenolysis protocol to yield 112 
(12.0 mg, 60%) in the form of a white foam after Sephadex chromatography. [α]D26=+19.0 
(c=1.2, H2O); 
1H NMR (600 MHz, D2O): δ 5.58 (br s, 1H, H-1'), 5.32 (d, J = 3.7 Hz, 1H, H-1"), 
4.92 (d, J = 8.1 Hz, 1H, H-8'), 3.85 (m, 1H, H-4"), 3.75-3.64 (m, 4H, H-3", H-6, 6"-CH2) 3.60–
3.48 (m, 4H, H-2", H-5, H-4', H-2'), 3.45–3.36 (m, 2H, H-5", H-4), 3.23 (t, J = 9.5 Hz, 1H, H-1), 
3.20-3.08 (m, 2H, H-6', H-3), 2.72 (t, J = 9.2 Hz, 1H, H-7'), 2.41 (s, 3H, NCH3), 2.27 (m, 1H, H-
2eq), 2.21 (m, 1H, H-3'eq), 1.92-1.86 (m, 1H, H-3'ax), 1.79 (s, 15H, 5CH3COOH), 1.65-1.58 (q, 
J = 12.8 Hz, 1H, H-2ax); 13C NMR (151 MHz, D2O): δ 181(s, CO), 96.56 (s, C-8′), 95.03 (s, C-
1"), 94.66 (s, C-1'), 79.06 (s, C-6), 75.13 (s, C-4'), 72.68 (s, C-4), 70.61, 70.36, 69.74 (s, C-4"), 
69.29 (s, C-3"), 68.92, 60.64 (s, C-7'), 60.32 (s, 6"-CH2), 60.03, 52.08 (s, C-3), 51.61 (s, C-6"), 
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48.53 (s, C-1), 48.05 (s, C-2'), 31.03 (s, NCH3), 29.14 (s, C-2), 26.86 (s, C-3'), 22.95 
(CH3COOH); ESI-HRMS: m/z calcd. for C21H42N6O10 [M+H]
+ 539.3041, found: 539.3030.  
 6'-Amino-6'-deoxyapramycin Hexaacetate Salt (113): Compound 105 (44.0 mg, 76%) 
was obtained in the form of a thick mass form by Staudinger reaction of 90 (65.0 mg) after silica 
gel chromatography (eluent: 20% ammonical methanol in EtOAc). [α]D26=+41 (c 0.8, MeOH); 
ESI-HRMS: m/z calcd. for C64H79N6O12[M+H]
+ 1123.5756, found 1123.5709. Without further 
characterization 105 (40.0 mg) was subjected to the standard hydrogenolysis protocol to give 113 
(12.0 mg, 75%) in the form of a white foam after Sephadex chromatography. [α]D26=+73.0 
(c=0.6, H2O); 
1H NMR (600 MHz, D2O): δ 5.50 (d, J = 3.7 Hz, H-1'), 5.32 (d, J = 3.7 Hz, 1H, H-
1"), 4.95 (d, J = 8.8 Hz, 1H, H-8'), 3.82-3.68 (m, 6H, H-4", H-5, H-4', H-6', 6"-CH2), 3.65 (dd, J 
= 4.7 Hz, 12.5 Hz, 1H, H-5'), 3.62-3.55 (m, 2H, H-3", H-5"), 3.52-3.45 (m, 2H, H-2', H-6), 3.39 
(t, J = 9.9 Hz, 1H, H-4), 3.19 (dt, J = 3.7 Hz, 9.9 Hz, 1H, H-1), 3.13 (dt, J = 4.4 Hz, 12.5 Hz, 1H, 
H-3), 3.07-3.01 (m, 2H, H-7', H-2"), 2.49 (s, 3H, NCH3), 2.27-2.19 (m, 2H, H-3'eq, H-2eq ), 1.89 
(m, 1H, H-3'ax), 1.77 (s, 18H, 6CH3COOH), 1.60 (q, J = 12.5 Hz, 1H, H-2ax); 
13C NMR (151 
MHz, D2O): δ 180.8 (s, CO), 95.72 (s, C-1′), 94.40 (s, C-1"), 93.22 (s, C-8'), 80.11 (s, C-3"), 
75.10 (s, C-6), 72.75 (s, C-4), 70.22 (s, C-6'), 69.88, 68.83, 68.70 (s, C-5), 65.94 (s, C-4"), 60.33 
(s, 6"-CH2), 59.66 (s, C-2"), 52.03 (s, C-7'), 49.85 (s, C-3), 48.41 (s, C-1), 47.93 (s, C-2'), 46.62, 
30.98 (s, NCH3), 29.41 (s, C-2), 27.11 (s, C-3'); ESI-HRMS: m/z calcd. for C21H42N6O10 [M+H]
+ 
539.3041, found: 539.3045. 
 7'-N-Ethyl 7'-N-demethylapramycin Pentaacetate Salt (114): The N-oxide 92 (40.0 
mg, 0.035 mmol) was dissolved in methanol (2.0 mL) and cooled in an ice-water bath followed 
by addition of a solution of FeSO4.7H2O (20.0 mg, 0.071 mmol) in methanol (0.5 mL). This 
mixture was stirred at 0 ºC for 6 h then basified to ~pH 10 with NH4OH solution before an 1 M 
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aqueous EDTA (2 mL) was added. The reaction mixture was extracted with CH2Cl2, dried over 
Na2SO4, filtered and the solvent evaporated to afford a colorless thick mass that was purified by 
chromatography over silica gel (eluent: 40% EtOAc in hexanes) to yield compound 93 (14.0 mg, 
40%). Without further characterization 93 (14.0 mg) was subjected to the Staudinger reaction to 
give 106 (9.0 mg, 71%) in the form of a thick mass after silica gel chromatography (eluent: 20% 
ammonical methanol in EtOAc). [α]D26=+95 (c 0.6, MeOH); ESI-HRMS: m/z calcd. for 
C57H73N5O11[M+H]
+ 1004.5385, found: 1004.5370. Without further characterization 106 (40.0 
mg) was subjected to the hydrogenolysis protocol to give 114 (2.0 mg, 40%) in the form of a 
white foam after Sephadex chromatography. [α]D26=+47.0 (c=0.1, H2O); 1H NMR (600 MHz, 
D2O): δ 5.45 (d, J = 3.3 Hz, 1H, H-1'), 5.34 (d, J = 3.7 Hz, 1H, H-1"), 5.06 (d, J = 8.4 Hz, 1H, H-
8'), 3.77 (dt, J = 4.0 Hz, 10.6 Hz, 1H, H-4'), 3.75-3.60 (m, 6H, H-4", H-5", H-6, H-5', 6"-CH2), 
3.55 (dd, J = 4.0 Hz, 9.9 Hz, 1H, H-2"), 3.53 (t, J = 9.5 Hz, 1H, H-5), 3.49-3.42 (m, 2H, H-2', H-
3"), 3.34 (t, J = 9.9 Hz, 1H, H-4), 3.24 (dd, J = 2.2 Hz, 8.1 Hz, 1H, H-7'), 3.14-3.06 (m, 2H, 
NCH2), 3.01 (t, J = 9.2 Hz, 1H, H-3), 2.95 (m, 1H, H-1), 1.86 (m, 2H, H-3'eq, H-2eq ), 1.53 (m, 
1H, H-3'ax), 1.75 (s, 15H, 6CH3COOH), 1.53 (m, 1H,  H-2ax), 1.13 (t, J = 9.9 Hz, 3H, 
NCH2CH3); 
13C NMR (151 MHz, D2O): δ 180.87 (s, CO), 95.83 (s, C-1′), 94.55 (s, C-8'), 93.33 
(s, C-1"), 75.19 (s, C-2'), 72.94 (s, C-4), 70.40 (s, C-3"), 70.27, 69.59, 69.27, 66.10 (s, C-4'), 
63.42 (s, C-6'), 60.34 (s, 6"-CH2), 58.08 (s, C-7'), 50.00 (s, C-3), 48.48, 48.06 (s, C-1), 40.23 (s, 
NCH2), 34.21, 30.12 (s, C-2), 27.11 (s, C-3'), 23.10 (s, CH3COOH), 22.94, 10.64 (s, CH3); ESI-
HRMS: m/z calcd. for C22H43N5O11 [M+H]
+ 554.3037, found: 554.3018.  
 7'-N-Demethylapramycin Pentaacetate Salt (115): Compound 70 (45.0 mg) was 
subjected to the Staudinger reaction using 0.1 N NaOH to give 115 (30.0 mg, 90%) in the form 
of a thick mass after silica gel chromatography (eluent: 20% ammonical methanol in EtOAc). 
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[α]D26=+66.0 (c=1.3, H2O); 1H NMR (600 MHz, D2O): δ 5.52 (d, J = 3.7 Hz, 1H, H-1'), 5.31 (d, 
J = 3.7 Hz, 1H, H-1''), 5.01 (d, J = 8.4 Hz, 1H, H-8'), 4.24 (br s, 1H, H-6'), 3.85-3.72 (m, 3H, H-
4', H-3", H-4"), 3.72-3.61 (m, 4H, H-5', H-6, 6"-CH2), 3.54 (dd, J = 3.7 Hz, 9.5 Hz, 1H, H-2"), 
3.48 (m, 2H, H-5, H-2'), 3.39 (t, J = 9.9 Hz, 1H, H-4), 3.30 (dt, J = 4.0 Hz, 10.6 Hz, 1H, H-3), 
3.24 (dd, J = 2.9 Hz, 8.8 Hz, 1H, H-7'), 3.17-3.08 (m, 2H, H-1, H-5"), 2.30 (dt, J = 4.0 Hz, 12.5 
Hz, 1H, H-2 eq), 2.20 (m, 1H,  H-3'eq), 1.88 (m, 1H, H-3'ax), 1.75 (s, 15H, CH3COOH), 1.67 
(m, 1H, H-2ax); 13C NMR (151 MHz, D2O): δ 180.94 (s, CO), 95.67 (s, C-1′), 94.53 (s, C-1'′), 
93.53 (s, C-8'), 79.26 (s, C-7'), 75.09 (s, C-2"), 72.62 (s, C-4), 70.32, 69.61, 69.47, 68.54, 66.10 
(s, C-6'), 65.86, 60.36 (s, 6"-CH2), 53.16 (s, C-5), 52.15 (s, C-3), 49.79 (s, C-1), 48.45 (s, C-3"), 
47.99, 28.86 (s, C-2), 27.00 (s, C-3'), 23.01 (s, CH3COOH); ESI-HRMS: m/z calcd. for 
C20H40N5O11 [M+H]
 + 526.2724, found: 526.2715. 
 7'-N-(2-Hydroxyethyl)-7'-N-demethyl-apramycin Pentaacetate Salt (117): Compound 
116 (22.0 mg, 65%) was obtained in the form of a white thick mass by Staudinger reaction of 95 
(40.0 mg) after silica gel chromatography (eluent: 20% ammonical methanol in EtOAc). 
[α]D26=+132 (c=0.7, MeOH); ESI-HRMS: m/z calcd. for C29H50N5O12 [M+H]+ 660.3456, found: 
660.3451. Without further characterization 116 (27.0 mg) was subjected to the hydrogenolysis 
protocol to give 117 (14.6 mg, 75%) in the form of a white foam after Sephadex 
chromatography. [α]D26=+83.0 (c=1.0, MeOH); 1H NMR (600 MHz, D2O): δ 5.52 (d, J = 3.3 Hz, 
1H, H-1'), 5.33 (d, J = 4.0 Hz, 1H, H-1"), 5.04 (d, J = 8.4 Hz, 1H, H-8'), 4.35 (br s, 1H, H-6'), 
3.86 (dt, J = 3.7 Hz, 10.6 Hz, 1H, H-5"), 3.78 (dt, J = 4.4 Hz, 11.0 Hz, 1H, H-4'), 3.81-3.60 (m, 
6H, H-3", H-4", H-4, H-5', 6"-CH2), 3.55 (dd, J = 3.7 Hz, 9.5 Hz, 1H, H-2"), 3.49 (m, 1H, H-5), 
3.48 (t, J = 9.5 Hz, 1H, H-2'), 3.38 (t, J = 9.9 Hz, 2H, CH2OH), 3.29 (dt, J = 3.7 Hz, 9.2 Hz, 1H, 
H-1), 3.17-3.05 (m, 4H, H-7', NCH2, H-3),  2.98 (m, 1H, H-6), 2.28 (dt, J = 4.0 Hz, 8.4 Hz, 1H, 
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H-2eq), 2.19 (m, 1H, H-3'eq), 1.86 (m, 1H, H-3'ax), 1.76 (s, 15H, 5CH3COOH), 1.64 (m, 1H, H-
2ax); 13C NMR (151 MHz, D2O): δ 180.69 (s, CO), 95.66 (s, C-1′), 94.59 (s, C-1''), 94.15 (s, C-
8'), 79.25 (s, C-6''), 75.09 (C-2'), 72.63 (s, CH2OH), 70.32 (s, C-2"), 69.58 (s, C-5'), 68.71, 65.98 
(s, NCH2), 64.06 (s, C-6'), 60.28 (s, C-1), 60.03, 58.87 (s, C-7'), 57.70, 52.04 (s, C-7'), 49.77, 
48.43 (s, C-3"), 47.99, 46.80 (s, C-4'), 28.90 (s, C-2), 26.97 (s, C-3'), 22.35 (s, CH3COOH); ESI-
HRMS: m/z calcd. for C22H44N5O11[M+H]
+ 570.2986, found: 570.2967. 
Chapter 3: 
 6'-Allyl-1,3,2’,2’’’,6’’’-pentadeamino-1,3,2’,2’’’,6’’’-pentaazido-6,3',3'',5'',3''',4'''-
hexa-O-benzyl-paromomycin (162R &162S): To a stirred solution of 160 (1.0 g, 0.77 mmol) 
under Ar in anhydrous DCM (20.0 mL) was added bis(acetoxy)iodobenzene (300.0 mg, 0.93 
mmol) followed by a catalytic amount of TEMPO (12.0 mg, 0.08 mmol) in one portion at room 
temperature. The resulting reaction mixture was stirred for 12 h at room temperature and was 
quenched with sat. Na2S2O3 solution, washed with sat. NaHCO3, brine, dried over Na2SO4, and 
concentrated under reduced pressure to give crude aldehyde 161. To a solution of this aldehyde 
in anhydrous DCM (10.0 mL) under Ar was added allyltributyltin (1.29 g, 3.89 mmol) followed 
by boron trifluoride ethyl etherate (133.0 mg, 0.04 mmol) at 0 oC. The resulting reaction mixture 
was stirred at 0 oC for 2 h before it was quenched with sat. NaHCO3. The comibined extracts 
were washed with brine, dried over Na2SO4, filtered, and concentrated to a afford gum. The 
crude product was purified via silica gel column chromatography (eluent: 2%-30% EtOAc in 
hexane) to give 162R (295 mg, 30%, over 2 steps) and 162S (293 mg, 28%, over 2 steps), as a 
yellow foam.  
 Compound 162R: [α]D26= +82.5 (c=0.20, CH2Cl2); 1H NMR (600 MHz, Chloroform-d): 
δ 7.46-7.18 (m, 30H, Ar-H), 6.21 (d, J = 3.6 Hz, 1H, H-1'), 5.97 (m, 1H, 8'-CH), 5.74 (d, J = 5.7 
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Hz, 1H, H-1''), 5.29-5.21 (m, 2H, H-9'CH2), 5.03 (d, J = 10.6 Hz, 1H, CH2Ph), 4.96 (d, J = 1.9 
Hz, 1H, H-1'''), 4.92 (d, J = 11.1 Hz, 1H, CH2Ph), 4.84 (d, J = 11.2 Hz, 1H, CH2Ph), 4.77 (d, J = 
10.6 Hz, 1H, CH2Ph), 4.67 (d, J = 12.0 Hz, 1H, CH2Ph), 4.62 (d, J = 11.8 Hz, 1H, CH2Ph), 4.60-
4.42 (m, 4H, CH2Ph), 4.39-4.33 (m, 3H, H-3'', H-4'', CH2Ph), 4.30 (d, J = 12.1 Hz, 1H, CH2Ph), 
4.05-3.94 (m, 3H, H-2'', H-5, H-3'), 3.90-3.75 (m, 5H, H-5', H-3''', H-6', H-5''CH2,OH), 3.71 (dd, 
J = 13.0, 8.6 Hz, 1H, H-6'''CH2), 3.65 (t, J = 9.4 Hz, 1H, H-4), 3.62 (dd, J = 2.2, 1.8 Hz, 1H, H-
5'' CH2), 3.52 (t, J = 9.0 Hz, 1H, H-4'), 3.50-3.42 (m, 2H, H-1, H-3), 3.41 (br s, 1H, H-2'''), 3.32 
(t, J = 9.3 Hz, 1H, H-6), 3.27 (br s, 1H, H-5'''), 3.17 (t, J = 2.3 Hz, 1H, H-4'''), 2.95 (dd, J = 10.3, 
3.7 Hz, 1H, H-2'), 2.92 (dd, J = 13.0, 3.8 Hz, 1H, H-6'''CH2), 2.77 (br s, 1H, OH), 2.61 (dt, J = 
15.0, 4.0 Hz, 1H, H-7'CH2), 2.33 (dt, J = 15.1, 8.0 Hz, 1H, H-7'CH2), 2.24 (dt, J = 13.2, 4.6 Hz, 
1H, H-2CH2), 1.41 (q, J = 12.7 Hz, 1H, H-2CH2); 
13C NMR (151 MHz, Chloroform-d): δ 
138.31, 138.23, 137.97, 137.57, 137.04, 136.98 (Ar-C), 134.62 (C-8'), 128.72, 128.57, 128.56, 
128.46, 128.40, 128.38, 128.34, 128.32, 128.24, 128.21, 127.95, 127.87, 127.80, 127.55, 127.50, 
127.24 (arom.), 118.48 (C-9'), 106.18 (C-1''), 98.67 (C-1'''), 95.60 (C-1'), 84.36 (C-6), 82.48 (C-
2''), 82.21(C-5), 81.92 (C-4''), 79.24 (C-3'), 75.55 (C-3''), 75.10 (C- CH2Ph, C-4), 75.03 (C-
CH2Ph), 74.51 (C-CH2Ph), 74.49 (C-4'), 73.59 (C-6'), 73.26 (C-CH2Ph), 73.22 (C-5'), 72.92 (C-
3'''), 72.42 (C-4'''), 71.85 (C-CH2Ph), 71.76 (C-CH2Ph), 71.55 (C-5'''), 70.33 (C-5''), 62.39 (C-2'), 
60.41 (C-1), 60.33 (C-3), 57.29 (C-2'''), 51.18 (C-6'''), 37.74 (C-7'), 32.67 (C-2); ESI-HRMS: m/z 
calcd. for C68H75N15O14Na [M+Na]
+ 1348.5516, found: 1348.5491. 
 Compound 162S: [α]D26= +58.8 (c=0.27, CH2Cl2); 1H NMR (600 MHz, Chloroform-d) δ 
7.42-7.13 (m, 30H, Ar-H), 6.19 (d, J = 3.6 Hz, 1H, H-1'), 5.91 (m, 1H, H-8'), 5.72 (d, J = 5.9 Hz, 
1H, H-1''), 5.21-5.11 (m, 2H, H-9'), 5.01 (d, J = 10.5 Hz, 1H, CH2Ph), 4.96-4.90 (m, 2H, H-1''', 
CH2Ph), 4.73 (d, J = 10.5 Hz, 1H, CH2Ph), 4.70 (d, J = 11.4 Hz, 1H, CH2Ph), 4.62 (m, 2H, 
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CH2Ph), 4.54-4.39 (m, 4H, CH2Ph), 4.33 (m, 3H, CH2Ph, H-3'', H-4''), 4.26 (d, J = 12.0 Hz, 1H, 
CH2Ph), 4.01 (dd, J = 5.9, 4.8 Hz, 1H, H-2''), 3.97 (t, J = 8.9 Hz, 1H, H-5), 3.92-3.83 (m, 3H, H-
3', H-6', H-5''CH2), 3.81 (m, 1H, H-5'''), 3.79-3.75 (m, 2H, H-5', H-3'''), 3.67 (dd, J = 13.0, 8.7 
Hz, 1H, H-6'''CH2), 3.62-3.55 (m, 2H, H-4, H-5''CH2), 3.52 (t, J = 9.4 Hz, 1H, H-4'), 3.45 (m, 
2H, H-1, H-3), 3.38 (t, J = 2.3 Hz, 1H, H-2'''), 3.29 (t, J = 9.4 Hz, 1H, H-6), 3.13 (d, J = 2.4 Hz, 
1H, H-4'''), 2.88 (dd, J = 13.0, 3.8 Hz, 1H, H-6'''CH2), 2.83 (dd, J = 10.3, 3.6 Hz, 1H, H-2'), 2.43-
2.34 (m, 1H, H-7'CH2), 2.34-2.26 (m, 1H, H-7'CH2), 2.23 (dt, J = 13.2, 4.6 Hz, 1H, H-2CH2), 
1.35 (q, J = 12.8 Hz, 1H, H-2CH2); 
13C NMR (151 MHz, Chloroform-d) δ 138.26, 138.12, 
137.89, 137.53, 136.98, 136.92 (arom.), 135.07 (C-8'), 128.67, 128.63, 128.51, 128.41, 128.37, 
128.33, 128.27, 128.20, 128.11, 128.03, 127.81, 127.80, 127.68, 127.58, 127.51, 127.02 (arom.), 
117.48 (C-9'), 106.10 (C-1''), 98.69 (C-1'''), 95.93 (C-1'), 84.42 (C-6), 82.48 (C-2''), 82.20 (C-4''), 
81.93 (C-5), 79.68 (C-3'), 75.51 (C-3'''), 75.13 (C-CH2Ph), 74.93 (C-CH2Ph), 74.81 (C-4), 74.45 
(C-5'''), 73.12 (2C-CH2Ph), 72.86 (C-4'''), 72.58 (C-3'''), 72.37 (C-5'), 71.71 (C-CH2Ph), 71.47 
(C-CH2Ph), 70.21 (C-5''CH2), 70.04 (C-4'), 68.73 (C-6'), 62.48 (C-2'), 60.40 (C-1), 60.33 (C-3), 
57.25 (C-2'''), 51.14 (C-6''), 38.48 (C-7'), 32.70 (C-2); ESI-HRMS: m/z calcd. for 
C68H75N15O14Na [M+Na]
+ 1348.5516, found: 1348.5509. 
 6'-Allyl-1,3,2’,2’’’,6’’’-pentaazido-6,3',3'',5'',3''',4'''-hexa-O-benzyl-4’,6’-O-
benzylideneparomomycin (163): To a stirred solution of 162R (15.0 mg, 0.011 mmol) under Ar 
in anhydrous acetonitrile (0.5 mL) was added benzaldehyde dimethyl acetal (5.2 mg, 0.033 
mmol) followed by a catalytic amount of CSA (0.30 mg, 0.001 mmol) in one portion at room 
temperature. The resulting reaction mixture was stirred for 2 h at room temperature before it was 
quenched with TEA and concentrated under reduced pressure. The crude product was purified 
via silica gel chromatography eluting with 5% to 15% EtOAc in hexanes to give 163 (10.5 mg, 
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66%) as a yellow foam. [α]D26= +65.0 (c=0.48, CH2Cl2); 1H NMR (600 MHz, Chloroform-d) δ 
7.61-6.98 (m, 30H, Ar-H), 6.21 (d, J = 3.8 Hz, 1H, H-1'), 6.03 (m, 1H, H-8'), 5.67 (d, J = 5.7 Hz, 
1H, H-1''), 5.56 (s, 1H, Benzylidene), 5.18 (m, 1H, H-9'CH2), 4.97 (d, J = 10.6 Hz, 1H, CH2Ph), 
4.94-4.87 (m, 2H, H-1''', CH2Ph), 4.76 (d, J = 11.2 Hz, 1H, CH2Ph), 4.73 (d, J = 10.6 Hz, 1H, 
CH2Ph), 4.62 (d, J = 12.1 Hz, 1H, CH2Ph), 4.57 (d, J = 11.8 Hz, 1H, CH2Ph), 4.51 (d, J = 11.9 
Hz, 1H, CH2Ph), 4.49-4.39 (m, 3H, CH2Ph), 4.35-4.2 (m, 3H, H-3'', H-4'', CH2Ph), 4.25 (d, J = 
12.1 Hz, 1H, CH2Ph), 4.09 (t, J = 9.6 Hz, 1H, H-3'), 4.01-3.91 (m, 2H, H-2'', H-5), 3.82-3.75 (m, 
3H, H-3''', H-4''', H-5''CH2), 3.72 (d, J = 9.3 Hz, 1H, H-5'), 3.74-3.66 (m, 3H, H-6', H-5''', H-
6'''CH2), 3.65 (t, J = 9.1 Hz, 1H, H-4), 3.57 (dd, J = 10.5, 2.9 Hz, 1H, H-5''CH2), 3.49-3.40 (m, 
3H, H-1, H-3, H-4'), 3.35 (t, J = 2.4 Hz, 1H, H-4'''), 3.28 (t, J = 9.3 Hz, 1H, H-6), 3.12 (d, J = 2.4 
Hz, 1H, H-2'''), 3.04 (dd, J = 10.1, 3.8 Hz, 1H, H-2'), 2.87 (dd, J = 13.0, 3.8 Hz, 1H, 6'''CH2), 
2.67 (m, 1H, H-7'CH2), 2.42 (dt, J = 14.8, 7.4 Hz, 1H, H-7'CH2), 2.23 (dt, J = 13.2, 4.6 Hz, 1H, 
H-2CH2), 1.37 (q, J = 12.7 Hz, 1H, H-2CH2);
 13C NMR (151 MHz, Chloroform-d) δ 138.27, 
138.06, 137.87, 137.59, 137.54, 136.98, 136.92, 134.30 (C-8'CH2), 128.75, 128.66, 128.49, 
128.40, 128.34, 128.31, 128.27, 128.18, 128.13, 127.80, 127.78, 127.72, 127.68, 127.50, 127.42, 
127.23, 126.07 (arom.), 117.16 (C-9'CH2), 106.13 (C-1''), 100.81 (C-Benzylidene), 98.60 (C-1'''), 
96.06 (C-1'), 84.31 (C-6), 82.37 (C-3''), 82.11 (C-5), 81.79 (C-2''), 81.73 (C-4'), 78.92 (C-6'), 
75.97 (C-3'), 75.47 (C-4''), 75.10 (C-CH2Ph), 75.04 (C-4), 74.93 (C-5'''), 74.4 (C-CH2Ph), 73.21 
(C-CH2Ph), 73.10 (C-CH2Ph), 72.87 (C-3'''), 72.36 (C-CH2Ph), 71.71 (C-CH2Ph), 71.50 (C-2'''), 
70.29 (C-5''), 67.05 (C-5'), 62.75 (C-2'), 60.35 (C-1), 59.99 (C-3), 57.24 (C-4'''), 51.11 (C-6'''), 
35.98 (C-6'''), 32.55 (C-7'CH2), 29.69 (C-2CH2); ESI-HRMS: m/z calcd. for C68H74N15O14BrNa 
[M+Na]+ 1436.5829, found: 1436.5852. 
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 4-O-(2'-Azido-3',6'-di-O-benzyl-9'-bromo-4',8'-anhydro-2',7',9'-trideoxy-D-erythro-
α-D-gluco-nonapyranosyl)-5-O-[3''-O-(2''',6'''-diazido-3''',4'''-di-O-benzyl-2''',6'''-dideoxy-
β-L-idopyranosyl)-2'',5''-di-O-benzyl-β-D-ribofuranosyl]-1,3-diazido-6-O-benzyl-2-
deoxystreptamine (164): A stirred solution of 162R (480.0 mg, 0.36 mmol) in anhydrous 
acetonitrile (5.0 mL) was treated with N-bromosuccinamide (66.4 mg, 0.37 mmol) at 0 ºC. The 
resulting reaction mixture was stirred at 0 ºC for 12 h. The resulted compound was extracted into 
ethyl acetate (10.0 mL) and was washed with brine (5.0 mL). The organic layer was concentrated 
to afford a yellow oil that was purified by chromatography on silica gel (EtOAc/Hexanes 3% to 
30%) to afford 164 (196 mg, 38%), 165 (100 mg, 25%), and 166 (102 mg, 20%), as a white 
foam. [α]D26= +73.0 (c=0.46, CH2Cl2); 1H NMR (600 MHz, Chloroform-d) δ 7.54-7.11 (m, 30H, 
Ar-H), 6.17 (d, J = 3.7 Hz, 1H, H-1'), 5.74 (d, J = 5.7 Hz, 1H, H-1''), 5.07 (d, J = 11.1 Hz, 1H, 
CH2Ph), 5.03 (d, J = 10.5 Hz, 1H, CH2Ph), 4.95 (d, J = 1.9 Hz, 1H, H-1'''), 4.80 (d, J = 11.1 Hz, 
1H, CH2Ph), 4.75 (d, J = 10.6 Hz, 1H, CH2Ph), 4.65 (d, J = 12.1 Hz, 1H, CH2Ph), 4.63 (d, J = 
11.8 Hz, 1H, CH2Ph), 4.53- 4.49 (m, 3H, CH2Ph), 4.43 (d, J = 12.0 Hz, 1H, CH2Ph), 4.39 (m, 
1H, H-4''), 4.37 (m, 1H, H-3''), 4.34 (m, 1H, CH2Ph), 4.28 (d, J = 12.1 Hz, 1H, CH2Ph), 4.14 (q, 
J = 2.7 Hz, 1H, H-6'), 4.06 (t, J = 5.2 Hz, 1H, H-2''), 4.04-3.95 (m, 3H, H-8', H-3', H-5), 3.88 
(dd, J = 10.4, 2.2 Hz, 1H, H-5''), 3.86-3.81 (m, 2H, H-5', H-5'''), 3.80 (t, J = 2.9 Hz, 1H, H-3'''), 
3.72 (dd, J = 13.0, 8.7 Hz, 1H, H-6'''CH2), 3.66-3.56 (m, 3H, H-4', H-5'', H-4), 3.46-3.41 (m, 2H, 
H-1, H-3), 3.39 (m, 1H, H-2'''), 3.38-3.35 (m, 2H, H-9'CH2), 3.32 (t, J = 9.4 Hz, 1H, H-6), 3.15 
(t, J = 2.3 Hz, 1H, H-4'''), 2.96 (dd, J = 10.2, 3.8 Hz, 1H, H-2'), 2.88 (dd, J = 13.0, 3.6 Hz, 1H, 
H-6'''CH2), 2.24 (dq, J = 13.1, 4.4 Hz, 1H, H-2CH2), 2.02 (dt, J = 14.0, 2.8 Hz, 1H, H-7'CH2), 
1.62 (ddd, J = 14.2, 11.4, 2.7 Hz, 1H, H-7'CH2), 1.41 (q, J = 12.7 Hz, 1H, H-2CH2); 
13C NMR 
(151 MHz, Chloroform-d) δ 138.37, 137.92, 137.00, 128.71, 128.55, 128.45, 128.38, 128.37, 
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128.32, 128.31, 128.30, 128.24, 127.86, 127.84, 127.77, 127.70, 127.64, 127.60, 127.53, 127.03 
(arom.), 106.21 (C-1''), 98.68 (C-1'''), 96.50 (C-1'), 84.28 (C-6), 82.66 (C-2''), 82.30 (C-4''), 
81.95 (C-5), 76.39 (C-3'), 75.65 (C-3''), 75.57 (C-4'), 75.06 (C-CH2Ph), 74.93 (2C, C-4, C-
CH2Ph), 74.88 (C-CH2Ph), 74.51 (C-5'''), 73.23 (C-3'''), 73.14 (C-CH2Ph), 72.85 (C-CH2Ph), 
72.40 (C-CH2Ph), 71.71 (C-8'), 71.49 (C-4'''), 70.35 (C-5''), 69.15 (C-5'), 65.08 (C-6'), 62.51 (C-
2'), 60.28 (C-1), 60.05 (C-3), 57.29 (C-2'''), 51.20 (C-6'''CH2), 35.81 (C-7'CH2), 34.91 (C-9'CH2), 
32.45 (C-2CH2); ESI-HRMS: m/z calcd. for C68H74N15O14BrNa [M+Na]
+ 1428.4600, found: 
1428.4596. 
 4-O-(2'-Azido-3'-O-benzyl-9'-bromo-5',8'-anhydro-2',7',9'-trideoxy-D-erythro-α-D-
glucononafuranosyl)-5-O-[3''-O-(2''',6'''-diazido-2''',6'''-dideoxy-3''',4'''-di-O-benzyl-β-L-
idopyranosyl)-2'',5''-di-O-benzyl-β-D-ribofuranosyl]-1,3-diazido-6-O-benzyl-2-
deoxystreptamine (165): [α]D26= +60.2 (c=0.42, Dichloromethane); 1H NMR (600 MHz, 
Chloroform-d) δ 7.48-6.97 (m, 30H, arom.), 5.91 (d, J = 4.6 Hz, 1H, H-1'), 5.32 (d, J = 3.7 Hz, 
1H, H-1''), 4.83 (d, J = 1.9 Hz, 1H, H-1'''), 4.81 (s, 2H, CH2Ph), 4.63 (d, J = 12.1 Hz, 1H, 
CH2Ph), 4.59 (d, J = 11.7 Hz, 1H, CH2Ph), 4.54 (d, J = 11.7 Hz, 1H, CH2Ph), 4.48 (d, J = 11.9 
Hz, 1H, CH2Ph), 4.42 (m, 1H, CH2Ph), 4.40 (m, 1H, CH2Ph), 4.38 (m, 3H, CH2Ph, H-6'), 4.36-
4.32 (m, 2H, CH2Ph, H-3''), 4.30-4.23 (m, 3H, H-4' H-4'', H-8'), 4.17 (d, J = 11.7 Hz, 1H, 
CH2Ph), 4.12-4.09 (m, 1H, H-3'), 4.09-4.07 (m, 1H, H-2'), 4.00 (dd, J = 8.9, 3.5 Hz, 1H, H-5'), 
3.86-3.80 (m, 2H, H-2'', H-5'''), 3.77 (t, J = 3.0 Hz, 1H, H-3'''), 3.73 (dd, J = 10.8, 2.2 Hz, 1H, H-
5''CH2Ph), 3.67-3.64 (m, 1H, H-6'''CH2), 3.64-3.59 (m, 1H, H-5), 3.58 (dd, J = 10.8, 4.4 Hz, 1H, 
H-5''CH2Ph), 3.52-3.44 (m, 3H, H-4, H-9'CH2),  3.41 (m, 1H, H-2'''), 3.40-3.32 (m, 2H, H-1, H-
3), 3.20 (t, J = 9.5 Hz, 1H, H-6), 3.17 (d, J = 2.4 Hz, 1H, H-4'''), 2.95 (dd, J = 13.0, 4.0 Hz, 1H, 
H-6'''CH2), 2.88 (s, 1H, OH), 2.31-2.24 (m, 1H, H-7' CH2), 2.21 (dt, J = 13.3, 4.5 Hz, 1H, H-
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2CH2), 2.05 (m, 1H, H-7'CH2), 1.35 (q, J = 12.8 Hz, 1H, H-2 CH2); 
13C NMR (151 MHz, 
Chloroform-d) δ 128.67, 128.52, 128.43, 128.35, 128.33, 128.29, 128.24, 128.22, 127.85, 
127.70, 127.66, 127.54, 127.47 (Ar-C.), 107.76 (C-1''), 102.97 (C-1), 98.27 (C-1'''), 83.54 (C-5), 
83.48 (C-6), 82.10 (C-3'), 81.65 (C-2''), 81.04 (C-4''), 80.37 (C-5'), 79.24 (C-8'), 79.12 (C-4), 
78.14 (C-4'), 75.33 (C-CH2Ph), 74.70 (C-3''), 74.35 (C-5'''), 72.96 (C-3'''), 72.91 (C-CH2Ph), 
72.86 (C-6'), 72.71(C-CH2Ph), 72.50 (C-CH2Ph), 72.47 (C-CH2Ph), 71.79 (C-CH2Ph), 71.55 (C-
4'''), 70.14 (C-5''CH2), 65.76 (C-2'), 60.47 (C-1), 59.67 (C-3), 57.48 (C-2'''), 51.13 (C-6'''CH2), 
37.75 (C-7'CH2), 35.73 (C-9'CH2), 32.42 (C-2CH2); ESI-HRMS: m/z calcd. for 
C68H74N15O14BrNa [M+Na]
+ 1428.4600, found: 1428.4559. 
 4-O-(2'-Azido-3'-O-benzyl-9'-bromo-5',8'-anhydro-2',7',9'-trideoxy-L-threo-α-D-
gluco-nonafuranosyl)-5-O-[3''-O-(2''',6'''-diazido-2''',6'''-dideoxy-3''',4'''-di-O-benzyl-β-L-
idopyranosyl)-2'',5''-di-O-benzyl-β-D-ribofuranosyl]-1,3-diazido-6-O-benzyl-2-
deoxystreptamine (166): [α]D26= +63.7 (c=0.40, Dichloromethane); 1H NMR (600 MHz, 
Chloroform-d) δ 7.56-7.06 (m, 30H, arom.), 5.98 (d, J = 4.5 Hz, 1H, H-1'), 5.44 (d, J = 4.3 Hz, 
1H, H-1''), 4.93-4.86 (m, 2H, H-1''', CH2Ph), 4.82 (d, J = 10.8 Hz, 1H, CH2Ph), 4.66 (d, J = 12.0 
Hz, 1H, CH2Ph), 4.61-4.55 (m, 2H, CH2Ph), 4.51 (m, 2H, CH2Ph), 4.47-4.43 (m, 2H, CH2Ph), 
4.42-4.34 (m, 4H, H-4', H-3'', CH2Ph, H-8'), 4.34-4.27 (m, 5H, H-6', H-4'', CH2Ph), 4.19 (t, J = 
4.4 Hz, 1H, H-3'), 4.01 (dd, J = 6.1, 3.3 Hz, 1H, H-5'), 3.92-3.88 (m, 2H, H-2'', H-2'), 3.86 (m, 
1H, H-5'''), 3.81 (m, 2H, H-3''', H-5''CH2), 3.74-3.66 (m, 2H, H-4, H-6'''CH2), 3.64 (dd, J = 7.4, 
3.4 Hz, 1H, H-5''CH2),  3.62 (m, 1H, H-5), 3.45 (m, 2H, H-2''', H-9'CH2), 3.43-3.36 (m, 2H, H-3, 
H-9'CH2), 3.31 (ddd, J = 12.7, 9.7, 4.5 Hz, 1H, H-1), 3.25 (t, J = 9.5 Hz, 1H, H-6), 3.19 (d, J = 
2.3 Hz, 1H, H-4'''), 2.96 (dd, J = 13.0, 3.9 Hz, 1H, H-6'''CH2), 2.18 (dt, J = 13.3, 4.6 Hz, 1H, H-
2CH2), 2.04 (ddd, J = 13.2, 6.3, 3.2 Hz, 1H, H-7'CH2), 1.93 (m, 1H, H-7'CH2), 1.36 (q, J = 12.8 
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Hz, 1H, H-2CH2); 
13C NMR (151 MHz, Chloroform-d) δ 128.72, 128.57, 128.47, 128.39, 
128.38, 128.36, 128.35, 128.26, 128.09, 127.99, 127.89, 127.77, 127.75, 127.66, 127.63, 127.56, 
127.30 (Ar-C), 107.35 (C-1''), 102.59 (C-1'), 98.43 (C-1'''), 85.03 (C-5'), 83.68 (C-6), 83.24 (C-
4'''), 81.89 (C-6'), 81.72 (C-3'), 79.29 (C-2''), 78.56 (C-4), 77.64 (C-5), 75.33 (C-CH2Ph), 74.97 
(C-8'), 74.42 (C-3''), 73.12 (C-5'''), 73.02 (C-CH2Ph), 72.89 (C-CH2Ph), 72.71(C-CH2Ph), 72.50 
(C-CH2Ph), 71.80 (C-CH2Ph), 71.55 (C-3'''), 70.26 (C-5''CH2), 66.16 (C-2'), 60.52 (C-3), 59.44 
(C-1), 57.48 (C-2'''), 51.17 (C-6'''CH2), 38.76 (C-7'), 35.29 (C-9'CH2), 32.35 (C-2CH2); ESI-
HRMS: m/z calcd. for C68H74N15O14BrNa [M+Na]
+ 1428.4600, found: 1428.4602. 
 4-O-(2'-Azido-3',6'-di-O-benzyl-9'-bromo-4',8'-anhydro-2',7',9'-trideoxy-D-threo-α-
D-gluco-nonapyranosyl)-5-O-[3''-O-(2''',6'''-diazido-3''',4'''-di-O-benzyl-2''',6'''-dideoxy-β-
L-idopyranosyl)-2'',5''-di-O-benzyl-β-D-ribofuranosyl]-1,3-diazido-6-O-benzyl-2-
deoxystreptamine (170): A solution of 164 (150.0 mg, 0.11 mmol) in dry dichloromethane (5.0 
mL) was treated with Dess–Martin periodinane (90.6 mg, 0.21 mmol) and Sodium bicarbonate 
(18.0 mg, 0.21 mmol), stirred for 9 h under Ar at room temperature. The reaction mixture was 
washed with water followed by brine, dried, and concentrated under reduced pressure. The crude 
mixture (ketone) (115 mg, 0.08 mmol) was stirred with NaBH4 (6.2 mg, 0.16 mmol) in methanol 
(4.0 mL) for 30 min. The reaction mixture was neutralized with acetic acid and concentrated 
under reduced pressure. The crude diastereomer (3:1 ratio) was separated by silica gel column 
using 30% EtOAc in hexanes to give the title compound 170 (66 mg, 58%) as a white foam. 
[α]D26= +67.9 (c=0.19, CH2Cl2); 1H NMR (600 MHz, Chloroform-d) δ 7.56-6.98 (m, 30H), 6.13 
(d, J = 3.9 Hz, 1H, H-1'), 5.65 (d, J = 5.2 Hz, 1H, H-1''), 5.02 (d, J = 11.0 Hz, 1H, CH2Ph), 4.96 
(d, J = 10.7 Hz, 1H, CH2Ph), 4.88 (d, J = 1.9 Hz, 1H, H-1'''), 4.75 (m, 2H, CH2Ph), 4.63 (d, J = 
12.1 Hz, 1H, CH2Ph), 4.55 (d, J = 11.7 Hz, 1H, CH2Ph), 4.52 (d, J = 11.9 Hz, 1H, CH2Ph), 4.46 
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(d, J = 11.9 Hz, 1H, CH2Ph), 4.42 (m, 2H, CH2Ph), 4.36-4.31 (m, 3H, H-3'', H-4'', CH2Ph), 4.26 
(d, J = 12.1 Hz, 1H, CH2Ph), 4.01-3.97 (m, 2H, H-2'', H-3'), 3.96- 3.91 (m, 1H, H-5'), 3.84-3.75 
(m, 3H, H-5''', H-3''', H-5''CH2), 3.72-3.62 (m,5H, H-4', H-4, H- 6'''CH2, H-6', H-8'), 3.59 (dd, J = 
10.5, 2.9 Hz, 1H, H-5''CH2), 3.52-3.35 (m, 5H, H-1, H-3, H-9'CH2, H-2'''), 3.31 (t, J = 9.2 Hz, 
1H, H-5), 3.13 (t, J = 2.3 Hz, 1H, H-4'''), 3.09-3.02 (m, 2H, H-2', H-6), 2.89 (dd, J = 13.0, 3.8 
Hz, 1H, H-6'''CH2), 2.33-2.15 (m, 2H, H-7'CH2, H-2CH2), 1.53-1.38 (m, 2H, H-7'CH2, H-2CH2); 
13C NMR (151 MHz, Chloroform-d) δ 128.68, 128.52, 128.43, 128.34, 128.31, 128.30, 128.28, 
128.21, 127.84, 127.79, 127.72, 127.68, 127.46, 127.28 (Ar-C), 106.35 (C-1''), 98.55 (C-1'''), 
95.83 (C-1'), 83.94 (C-5), 82.25 (C-2''), 81.98 (C-5'), 79.94 (C-6), 76.41 (C-3'), 75.52 (C-3''), 
75.37 (C-4, C-4''), 74.95 (2C, C-CH2Ph), 72.59 (C-6'), 74.41 (2C, C-5''',C-8'), 73.17 (C-CH2Ph), 
73.07 (C-CH2Ph), 72.86 (C-3'''), 72.41 (C-CH2Ph), 71.72 (C-CH2Ph), 71.49 (C-4'''), 70.30 (C-
5''CH2), 69.67 (C-4'), 62.66 (C-2'), 60.23 (C-1), 59.98 (C-3), 57.30 (C-2'''), 51.13 (C-6'''CH2), 
37.21 (C-7'CH2), 34.07 (C-9'CH2), 32.31 (C-2CH2); ESI-HRMS: m/z calcd. for 
C68H74N15O14BrNa [M+Na]
+ 1428.4600, found: 1428.4626. 
 4-O-(2',6'-Diazido-3',6'-di-O-benzyl-9'-bromo-4',8'-anhydro-2',6',7',9'-tetradeoxy-D-
threo-α-D-gluco-nonapyranosyl)-5-O-[3''-O-(2''',6'''-diazido-3''',4'''-di-O-benzyl-2''',6'''-
dideoxy-β-L-idopyranosyl)-2'',5''-di-O-benzyl-β-D-ribofuranosyl]-1,3-diazido-6-O-benzyl-
2-deoxystreptamine (169): To a stirred solution of 164 (90.0 mg, 0.06 mmol) in dry 
dichloromethane (1.0 mL) at room temperature was added dry pyridine (21.7 mg, 0.27 mmol) in 
one portion. Triflic anhydride (40 mg, 0.14 mmol) was added to the reaction mixture at 0 ºC 
under Ar. The reaction mixture was stirred at 0 ºC for 1 h and was quenched with sat. NaHCO3 
solution. The reaction mixture was washed with brine, dried over Na2SO4, filtered, and 
concentrated under reduced pressure. The crude product was stirred with sodium azide (20.0 mg, 
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0.30 mmol) in dry DMF (0.5 mL) at room temperature. The resulting reaction mixture was 
stirred at room temperature for 6 h after which the solvent was evaporated under reduced 
pressure. The residue was dissolved in dichloromethane (2 mL) and washed with water, brine, 
dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was 
purified via silica gel chromatography (eluent: 2% to 20% EtOAc in hexanes) to give 169 (45.0 
mg, 49%) as a colorless oil. [α]D26= +51.0 (c=0.6, CH2Cl2); 1H NMR (600 MHz, Chloroform-d) 
δ 7.65-6.99 (m, 30H, Ar-H), 6.23 (d, J = 3.8 Hz, 1H, H-1'), 5.69 (d, J = 5.8 Hz, 1H, H-1''), 4.97 
(d, J = 11.1 Hz, 1H, CH2Ph), 4.95 (m, 2H, CH2Ph, H-1'''), 4.74 (d, J = 11.0 Hz, 1H, CH2Ph), 4.71 
(d, J = 10.7 Hz, 1H, CH2Ph), 4.63 (d, J = 7.4 Hz, 1H, CH2Ph), 4.61 (d, J = 7.1 Hz, 1H, CH2Ph), 
4.49 (m, 2H, CH2Ph), 4.46 (d, J = 9.1 Hz, 1H, CH2Ph), 4.42 (d, J = 11.5 Hz, 1H, CH2Ph), 4.32 
(d, J = 12.0 Hz, 1H, CH2Ph), 4.28 (m, 2H, H-3'', H-4'), 4.24 (d, J = 12.1 Hz, 1H, CH2Ph), 4.00-
3.91 (m, 3H, H-2'', H-3', H-5), 3.83-3.77 (m, 3H, H-3''', H-4'', H-5''CH2), 3.76 (t, J = 2.9 Hz, 1H, 
H-5'''), 3.70 (t, J = 9.54 Hz, 1H, H-6), 3.67 (m, 1H, H-6'''CH2), 3.63 (m, 1H, H-8'), 3.56 (dd, J = 
10.4, 3.0 Hz, 1H, H-5''CH2), 3.46 (m, 3H, H-1, H-3, H-5'), 3.40-3.32 (m, 3H, H-2''', H-9'CH2), 
3.31 (t, J = 9.54 Hz 1H, H-6), 3.11 (t, J = 2.3 Hz, 1H, H-4'''), 3.03-2.94 (m, 2H, H-2', H-6'), 2.84 
(dd, J = 13.0, 3.8 Hz, 1H, H-6'''CH2), 2.25 (dt, J = 13.2, 4.6 Hz, 1H, H-2CH2), 2.15 (m, 1H, H-
7'CH2), 1.44 (q, J = 12.84 Hz 1H, H-2CH2), 1.41 (q, J = 12.10 Hz, 1H, H-7'CH2); 
13C NMR (151 
MHz, Chloroform-d) δ 138.32, 138.09, 137.92, 137.64, 136.99, 136.93, 128.67, 128.49, 128.42, 
128.34, 128.32, 128.29, 128.25, 128.18, 127.81, 127.74, 127.70, 127.69, 127.43, 127.33, 127.17 
(Ar-C), 106.09 (C-1''), 98.57 (C-1'''), 95.64 (C-1'), 84.39 (C-6), 82.62 (C-2''), 82.11 (C-3''), 81.59 
(C-5), 80.65 (C-6'), 76.21 (C-3'), 75.55 (C-4'), 75.47 (C-8'), 75.04 (C-CH2Ph, C-4), 75.00 (C-
CH2Ph), 74.45 (C-4''), 73.33 (C-CH2Ph), 73.16 (C-CH2Ph), 72.80 (C-5'''), 72.33 (C-CH2Ph), 
71.66 (C-CH2Ph), 71.41 (2C, C-4''', C-3'''), 70.32 (C-5''), 62.53 (C-2'), 60.36 (C-5'), 59.93 (C-1), 
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59.81 (C-3), 57.23 (C-2'''), 51.08 (C-6'''), 35.09 (C-7'), 33.48 (C-9'), 32.46 (C-2); ESI-HRMS: 
m/z calcd. for C68H73N18O13BrNa [M+Na]
+ 1451.4686, found: 1451.4667. 
 4-O-(2',6'-Diazido-3',6'-di-O-benzyl-9'-bromo-4',8'-anhydro-2',6',7',9'-tetradeoxy-D-
erythro-α-D-gluco-nonapyranosyl)-5-O-[3''-O-(2''',6'''-diazido-3''',4'''-di-O-benzyl-2''',6'''-
dideoxy-β-L-idopyranosyl)-2'',5''-di-O-benzyl-β-D-ribofuranosyl]-1,3-diazido-6-O-benzyl-
2-deoxystreptamine (172): To a stirred solution of 170 (70.0 mg, 0.05 mmol) in dry 
dichloromethane (1.5 mL) at room temperature was added dry pyridine (17.0 mg, 0.22 mmol) in 
one portion. Triflic anhydride (31.0 mg, 0.11 mmol) was added to the reaction mixture at 0 ºC 
under Ar. The reaction mixture was stirred at 0 ºC for 1 h and was quenched with sat. NaHCO3 
solution and washed with brine, dried, filtered, and concentrated under reduced pressure. The 
crude product was stirred with sodium azide (32.0 mg, 0.49 mmol) in dry DMF (0.7 mL) at room 
temperature. The resulting reaction mixture was stirred at room temperature for 4 h after which 
the solvent was evaporated under reduced pressure. The residue was dissolved in 
dichloromethane (3.0 mL) and washed with water, brine, dried over Na2SO4, filtered, and 
concentrated under reduced pressure. The crude product was purified via silica gel 
chromatography eluting with 2% to 30% EtOAc in hexanes to give 172 (61.0 mg, 67%) as an 
off-white foam. [α]D26= +132.1 (c=0.11, Dichloromethane); 1H NMR (600 MHz, Chloroform-d) 
δ 7.43-7.38 (m, 30H, Ar-C), 6.06 (d, J = 3.8 Hz, 1H, H-1'), 5.62 (d, J = 5.5 Hz, 1H, H-1''), 4.97 
(d, J = 11.2 Hz, 1H, CH2Ph), 4.94 (d, J = 10.7 Hz, 1H, CH2Ph), 4.84 (d, J = 1.9 Hz, 1H, H-1'''), 
4.74 (d, J = 11.2 Hz, 1H, CH2Ph), 4.70 (d, J = 10.7 Hz, 1H, CH2Ph), 4.60 (d, J = 12.0 Hz, 1H, 
CH2Ph), 4.57-4.51 (m, 2H, CH2Ph), 4.42 (d, 2H, CH2Ph), 4.39 (d, J = 11.9 Hz, 1H, CH2Ph), 4.30 
(d, J = 11.9 Hz, 1H, CH2Ph), 4.27-4.22 (m, 3H, H-3'', H-4'', CH2Ph), 4.11 (dd, J = 5.7, 2.2 Hz, 
1H, H-6'), 4.02 (dd, J = 10.0, 3.3 Hz, 1H, H-5'), 3.95-3.89 (m, 3H, H-2'', H-5, H-3'), 3.86 (m, 1H, 
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H-8'), 3.80-3.71 (m, 3H, H-5''CH2, H-5''', H-3'''), 3.68-3.57 (m, 3H, H-4', H-4, H-6'''CH2), 3.53 
(dd, J = 10.5, 3.5 Hz, 1H, H-5''CH2), 3.41 (m, 2H, H-1, H-3), 3.36-3.31 (m, 3H, H-2''', H-9'CH2), 
3.29 (t, J = 9.2 Hz, 1H, H-6), 3.10 (d, J = 2.4 Hz, 1H, H-4'''), 3.04 (dd, J = 10.2, 3.8 Hz, 1H, H-
2'), 2.88 (dd, J = 12.9, 4.1 Hz, 1H, H-6'''CH2), 2.24 (dt, J = 13.3, 4.6 Hz, 1H, H-2CH2), 1.98 (dt, 
J = 14.0, 2.7 Hz, 1H, H-7'CH2), 1.69 (ddd, J = 14.2, 11.3, 3.2 Hz, 1H, H-7'CH2), 1.41 (q, J = 
12.7 Hz, 1H, H-2CH2);
 13C NMR (151 MHz, Chloroform-d) δ 138.31, 138.20, 137.79, 137.64, 
137.01, 136.94, 128.67, 128.49, 128.40, 128.34, 128.32, 128.30, 128.27, 128.18, 127.83, 127.80, 
127.77, 127.59, 127.56, 127.54 (Ar-C), 106.02 (C-1''), 98.58 (C-1'''), 96.49 (C-1'), 83.97 (C-6), 
82.34 (C-4''), 82.08 (C-5), 81.39 (C-2''), 76.67 (C-3'), 76.38 (C-4'), 75.51 (C-4), 75.42 (C-3''), 
75.05 (C-CH2Ph), 74.85 (C-CH2Ph), 74.27 (C-5'''), 73.31 (C-CH2Ph), 73.23 (C-CH2Ph), 72.88 
(C-3'''), 72.38 (C-CH2Ph), 71.72 (C-CH2Ph), 71.47 (C-8'), 71.41 (C-4'''), 70.05 (C-5''CH2), 69.26 
(C-5'), 62.28 (C-2'), 60.21 (C-1), 59.89 (C-3), 57.63 (C-6'), 57.30 (C-2'''), 51.03 (C-6'''CH2), 
34.86 (C-7'CH2), 34.27 (C-9'CH2), 32.41 (C-2CH2); ESI-HRMS: m/z calcd. for 
C68H73N18O13BrNa [M+Na]
+ 1451.4686, found: 1451.4679. 
 General procedure A for hydrogenolysis. To a stirred solution of substrate (0.02 mmol) 
in a mixture of p-dioxane (0.5 mL), deionized water H2O (0.2 mL), and glacial AcOH (20 µL) 
was treated with Pd/C on carbon (20 wt. %, 100 % loading) and stirred for 48h at room 
temperature under 40 psi of hydrogen. After completion, the reaction mixture was filtered 
through Celite® and the filtrate was evaporated under reduced pressure to give crude product. 
The residue was dissolved in 0.002 M aqueous AcOH (2.0 mL) and then charged to a Sephadex 
column (CM Sephadex C-25, 5.0 g). The Sephadex column was eluted with deionized water H2O 
(50 mL), 0.5% aqueous NH4OH (40 mL), and 1.5% NH4OH (40 mL). The product-containing 
fractions were combined and evaporated to give the product in the form of the free base, which 
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was taken up in H2O (2 mL) and treated with glacial acetic acid (10 eq). The resulting solution 
was lyophilized to give the product in the form of the acetate salt.  
 4-O-(2'-Amino-4',8'-anhydro-2',7',9'-trideoxy-D-erythro-α-D-gluco-nonapyranosyl)-
5-O-[3-O-(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]-2-
deoxystreptamine.5AcOH (154): Following general procedure A, Compound 154 (12.7 mg, 
63%) was synthesized from 164, as a white foam. [α]D26= +25.7 (c=0.37, H2O);1H NMR (600 
MHz, D2O) δ 5.70 (d, J = 4.1 Hz, 1H, H-1'), 5.25 (d, J = 2.2 Hz, 1H, H-1''), 5.14 (d, J = 1.8 Hz, 
1H, H-1'''), 4.38 (dd, J = 7.0, 4.8 Hz, 1H, H-3''), 4.26 (dd, J = 4.9, 2.1 Hz, 1H, H-2''), 4.16 (dd, J 
= 6.9, 4.0 Hz, 1H, H-5'''), 4.07 (m, 3H, H-6', H-3''', H-4''), 3.87-3.80 (m, 3H, H-3', H-8', H-4), 
3.77 (dd, J = 12.5, 2.9 Hz, 1H, H-5''CH2), 3.71 (t, J = 8.1 Hz, 1H, H-6), 3.67 (br s, 1H, H-4'''), 
3.62 (dd, J = 12.4, 4.6 Hz, 1H, H-5''CH2), 3.58 (dd, J = 10.0, 2.8 Hz, 1H, H-5'), 3.54-3.45 (m, 
2H, H-4', H-5), 3.43 (br s, 1H, H-2'''), 3.28 (dd, J = 13.7, 6.8 Hz, 1H, H-6'''CH2), 3.25-3.10 (m, 
3H, H- H-6'''CH2, H-1, H-3), 2.22 (dt, J = 12.8, 4.3 Hz, 1H, H-2CH2), 1.76 (m, 1H, H-7'CH2), 
1.62-1.37 (m, 2H, H-2CH2, H-7'CH2), 1.05 (d, J = 6.2 Hz, 3H, H-9'CH3);
 13C NMR (151 MHz, 
Deuterium Oxide) δ 181.13 (C-CH3COOH), 110.01 (C-1''), 96.30 (C-1'), 95.28 (C-1'''), 84.84 (C-
6), 81.10 (C-3''), 77.93 (C-8'), 74.93 (C-3'''), 73.45 (C-2''), 73.37 (C-5), 72.80 (C-4''), 70.29 (C-
5'''), 70.21 (C-5'), 69.11 (H-4'), 67.62 (C-3'''), 67.30 (C-3'), 67.22 (C-4'''), 64.37 (C-6'), 59.85 (C-
5''CH2), 54.39 (C-2'), 50.81 (C-2'''), 50.03 (C-1), 48.64 (C-3), 40.34 (C-6'''CH2), 38.86 (C-
7'CH2), 29.60 (C-2CH2), 23.11 (C-CH3COOH), 19.81 (C-9'CH3); ESI-HRMS: m/z calcd. for 
C26H49N5O14Na [M+Na]
+ 678.3174, found: 678.3166. 
 4-O-(2'-Amino-4',8'-anhydro-2',7',9'-trideoxy-D-threo-α-D-gluco-nonapyranosyl)-5-
O-[3-O-(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]-2-
deoxystreptamine.5AcOH (155): Following general procedure A, Compound 155 (7.0 mg, 
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40%) was synthesized from 170, as a white foam. [α]D26= +30.5 (c=0.20, H2O); 1H NMR (600 
MHz, D2O) δ 5.53 (d, J = 4.1 Hz, 1H, H-1'), 5.20 (d, J = 2.6 Hz, 1H, H-1''), 5.11 (s, 1H, H-1'''), 
4.34 (t, J = 5.1 Hz, 1H, H-3''), 4.19 (br s, 1H, H-2''), 4.13 (t, J = 5.3 Hz, 1H, H-5'''), 4.03 (m, 2H, 
H-3''', H-4''), 3.79 (t, J = 9.9 Hz, 1H, H-3'), 3.77-3.68 (m, 4H, H-4, H-6, H-6', 5''CH2), 3.64 (d, J 
= 3.2 Hz, 1H, H-4'''), 3.62-3.54 (m, 2H, H-8', 5''CH2), 3.50 (t, J = 9.7 Hz, 1H, H-5), 3.40 (s, 1H, 
H-2'''), 3.37 (t, J = 9.4 Hz, 1H, H-5'), 3.31-3.22 (m, 3H, H-3, H-2', 6'''CH2), 3.21-3.15 (m, 2H, H-
1, 6'''CH2), 3.12 (t, J = 9.5 Hz, 1H, H-4'), 2.25 (d, J = 11.8 Hz, 1H, H-2CH2), 1.96 (dd, J = 12.1, 
3.3 Hz, 1H, H-7'CH2), 1.66-1.52 (m, 1H, H-2CH2), 1.25 (q, J = 11.9 Hz, 1H, H-7'CH2), 1.06 (d, 
J = 6.2 Hz, 3H, 9'-CH3). 13C NMR (151 MHz, D2O) δ 180.92 (C-CH3COOH), 109.70 (C-1''), 
96.65 (C-1'), 95.34 (C-1'''), 84.05 (C-6), 81.21 (C-4''), 79.17 (C-4), 77.20 (C-4'), 75.00 (C-3''), 
73.50 (C-5'), 73.29 (C-8'), 73.00 (C-2''), 72.47 (C-5), 70.11 (C-5'''), 68.30 (C-6'), 67.56 (C-4'''), 
67.18 (2C-3', 3'''), 60.02 (C-5''CH2), 54.34 (C-2'), 50.74 (C-2'''), 49.69 (C-3), 48.91 (C-1), 40.30 
(C-6'''CH2), 40.16 (C-7'CH2), 28.91 (C-2), 22.94 (C-CH3COOH), 19.80 (C-9'CH3); ESI-
HRMS: m/z calcd. for C26H50N5O14 [M+H]+ 656.3354, found: 656.3371. 
 4-O-(2',6'-Diamino-4',8'-anhydro-2',6',7',9'-tetradeoxy-D-threo-α-D-gluco-
nonapyranosyl)-5-O-(β-paramobiosyl)-2-deoxystreptamine.6AcOH (157): Following general 
procedure A, Compound 157 (6.2 mg, 40%) was obtained from 169, as a white foam. [α]D26= 
+33.8 (c=0.13, H2O); 
1H NMR (600 MHz, D2O) δ 5.87 (d, J = 4.0 Hz, 1H, H-1'), 5.25 (d, J = 2.6 
Hz, 1H, H-1''), 5.11 (s, 1H, H-1'''), 4.31 (t, J = 5.7 Hz, 1H, H-3''), 4.20 (dd, J = 5.0, 2.6 Hz, 1H, 
H-2''), 4.12 (d, J = 5.5 Hz, 1H, H-5'''), 4.04 (br s, 2H, H-3''', H-4''), 3.90 (t, J = 10.1 Hz, 1H, H-
3'), 3.73 (m, 3H, H-6, H-4, H-5''CH2), 3.64 (br s, 1H, H-8'), 3.61-3.53 (m, 2H, H-5', H-5''CH2), 
3.47 (t, J = 8.8 Hz, 1H, H-5), 3.40 (m, 2H, H-2''', H-6'), 3.27 (dd, J = 11.0, 4.0 Hz, 1H, H-2'), 
3.25-3.21 (m, 1H, H-6'''CH2), 3.21-3.09 (m, 5H, H-4''', H-1, H-3, H-4', H-6'''CH2), 2.19 (dt, J = 
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12.6, 4.3 Hz, 1H, H-2CH2), 2.10-2.00 (m, 1H, H-7'CH2), 1.74 (s, 18H, CH3COOH), 1.57 (q, J = 
12.6 Hz 1H, H-2CH2), 1.42 (q, J = 12.2 Hz, 1H, H-7'CH2), 1.08 (q, J = 6.1 Hz 3H, H-9'CH2).
 13C 
NMR (151 MHz, D2O) δ 180.81 (C-CH3COOH), 109.97 (C-1''), 95.40 (2C-1',1''), 84.92 (C-6), 
81.44 (C-4''), 77.99 (C-4'), 76.72 (C-3''), 74.96 (C-4), 73.47 (C-2''), 72.92 (C-4'), 72.74 (C-5), 
70.06 (C-5'''), 69.91 (C-5'), 67.53 (C-3'''), 67.20 (C-8'), 65.95 (C-3'), 60.02 (C-5''), 54.11 (C-2'), 
50.72 (C-2'''), 50.36 (C-6'), 49.94 (C-1), 48.44 (C-3), 40.29 (C-6'''CH2), 35.83 (C-7'CH2), 26.36 
(C-2CH2) 22.87 (C-CH3COOH), 19.60 (C-9'CH3); ESI-HRMS: m/z calcd. for C26H51N6O13 
[M+H]+ 655.3514, found: 655.3505. 
 4-O-(2',6'-Diamino-4',8'-anhydro-2',6',7',9'-tetradeoxy-D-erythro-α-D-gluco-
nonapyranosyl)-5-O-(β-paramobiosyl)-2-deoxystreptamine.6AcOH (156): To a Compound 
172 (20.0 mg, 0.014 mmol) in a mixture of p-dioxane (0.5 mL), deionized water H2O (0.2 mL), 
and 0.1 N NaOH (0.1 mL) was treated with Pd/C on carbon (20 mg, 20 wt. %) and stirred for 8h 
at room temperature under 40 psi of hydrogen. Added 10% AcOH (0.2 mL) and stirred for 20h at 
room temperature under 40 psi of hydrogen. After completion, the reaction mixture was filtered 
through Celite®, evaporated under reduced pressure, and the residue was dissolved in AcOH (1 
mL) and then charged to a Sephadex column. The Sephadex column was eluted with deionized 
water H2O (50 mL), 0.5% aqueous NH4OH (40 mL), and 1.5% NH4OH (40 mL) to give the 156 
(8.5 mg, 60%) as a white form. [α]D26= +41.8 (c=0.17, H2O); 1H NMR (600 MHz, D2O) δ 5.74 
(d, J = 4.2 Hz, 1H, H-1'), 5.24 (d, J = 2.7 Hz, 1H, H-1''), 5.13 (d, J = 1.8 Hz, 1H, H-1'''), 4.33 
(dd, J = 6.4, 5.0 Hz, 1H, H-3''), 4.21 (dd, J = 5.0, 2.7 Hz, 1H, H-2''), 4.14 (td, J = 4.4, 2.0 Hz, 1H, 
H-5'''), 4.06 (br s, 2H, H-4'', H-3'''), 3.91-3.83 (m, 2H, H-3', H-5'), 3.81-3.70 (m, 5H, H-6', H-6, 
H-4, H-8', 5''CH2), 3.66 (br s, 1H, H-4'''), 3.59 (dd, J = 12.4, 4.8 Hz, 1H, H-5''CH2), 3.50 (t, J = 
9.2 Hz, 1H, H-5), 3.42 (br s, 1H, H-2'''), 3.39 (t, J = 9.4 Hz, 1H, H-4') 3.32-3.18 (m, 4H, H-2', H-
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1, H-6'''CH2), 3.18-3.11 (m, 1H, H-3), 2.25 (dt, J = 12.8, 4.4 Hz, 1H, H-2CH2), 1.92 (dt, J = 15.8, 
2.4 Hz, 1H, H-7'CH2), 1.82-1.76 (m, 1H, H-7'CH2), 1.76 (s, 18H, CH3COOH), 1.59 (q, J = 12.6 
Hz, 1H, H-2CH2), 1.07 (d, J = 6.1 Hz, 3H, H-9'CH2);
 13C NMR (151 MHz, D2O) δ 180.56 (C-
CH3COOH), 109.88 (C-1''), 96.29 (C-1'), 95.48 (C-1'''), 84.70 (C-6), 81.55 (C-4''), 77.44 (C-4), 
75.32 (C-3''), 73.73 (C-4'), 73.56 (C-2''), 72.63 (C-5), 70.08 (C-5'''), 68.69 (C-8'), 67.55 (C-4'''), 
67.26 (C-3'''), 66.88 (C-3'), 66.63 (C-5'), 59.97 (C-5''CH2), 54.02 (C-2'), 50.77 (C-2'''), 49.87 (C-
1), 48.37 (C-3), 46.93 (C-6'), 40.34 (C-6'''CH2), 34.26 (C-7'CH2), 29.17 (C-2CH2), 22.79 (C-
CH3COOH), 19.63 (C-9'CH3); ESI-HRMS: m/z calcd. for C26H51N6O13 [M+H]
+ 655.3514, 
found: 655.3508. 
 4-O-(2-Amino-5,8-anhydro-2,7,9-trideoxy-D-erythro-α-D-glucononafuranosyl)-5-O-
[3-O-(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]-2-
deoxystreptamine.5AcOH (173): Following general procedure A, Compound 173 (34.0 mg, 
56%) was obtained from 165 (50.0 mg, 0.035 mmol), as a white foam. [α]D26= +63.7 (c=0.40, 
Dichloromethane); 1H NMR (600 MHz, D2O) δ 5.66 (d, J = 5.1 Hz, 1H, H-1'), 5.10 (d, J = 1.8 
Hz, 1H, H-1'''), 5.05 (d, J = 2.5 Hz, 1H, H-1''), 4.46 (t, J = 4.7 Hz, 1H, H-3'), 4.30 (t, J = 5.7 Hz, 
1H, H-3''), 4.28-4.23 (m, 1H, H-6'), 4.17 (dd, J = 5.1, 2.5 Hz, 1H, H-6'), 4.14-4.02 (m, 4H, H-4', 
H-5''', H-8', H-3'''), 4.00 (td, J = 6.0, 3.1 Hz, 1H, H-4''), 3.78 (m, 2H, H-2', H-5'), 3.76-3.68 (m, 
2H, H-4, H-5''CH2), 3.62 (br s, 1H, H-4'''), 3.58-3.51 (m, 2H, H-5, H-5''CH2), 3.46 (t, J = 9.8 Hz, 
1H, H-6), 3.39 (br s, 1H, H-2'''), 3.31-3.20 (m, 2H, H-3, H-6'''CH2), 3.19-3.09 (m, 2H, H-1, H-
6'''CH2), 2.28 (dt, J = 12.7, 4.4 Hz, 1H, H-2CH2), 1.82 (dd, J = 13.1, 4.5 Hz, 1H, H-7'CH2), 1.73 
(s, 16H, AcOH), 1.64 (q, J = 13.5 Hz, 1H, H-2CH2), 1.60-1.52 (m, 1H, H-7'CH2), 1.06 (d, J = 
6.0 Hz, 3H, H-9'CH3). 
13C NMR (151 MHz, D2O) δ 180.79 (C-CH3COOH), 110.54 (C-1''), 
101.18 (C-1'), 95.33 (C-1'''), 84.65 (C-5), 84.07 (C-5'), 81.29 (C-4''), 79.43 (C-4'), 78.58 (C-4), 
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75.67 (C-3''), 75.40 (C-8'), 73.44 (C-6'), 73.09 (C-2''), 72.24 (C-3'), 71.81 (C-6'), 70.14, 67.55 
(C-5'''), 67.13 (C-4'''), 61.15 (C-5''CH2), 58.41 (C-2'), 50.73 (C-2'''), 49.61 (C-1), 48.30 (C-3), 
41.42 (C-7'), 40.27 (C-6'''CH2), 27.95 (C-2CH2), 22.86 (CH3COOH), 19.43 (C-9'CH3); ESI-
HRMS: m/z calcd. for C68H74N15O14Na [M+Na]
+ 1428.4600, found: 1428.4602. 
 4-O-(2-Amino-5,8-anhydro-2,7,9-trideoxy-L-threo-β-D-gluco-nonafuranosyl)-5-O-
[3-O-(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]-2-
deoxystreptamine.5AcOH (174): Following general procedure A, Compound 174 (14.0 mg, 
70%) was synthesized from 166 (30 mg, 0.021 mmol), as a white foam. [α]D26= +60.2 (c=0.42, 
Dichloromethane); 1H NMR (600 MHz, D2O) δ 5.62 (d, J = 5.1 Hz, 1H, H-1'), 5.08 (br s, 1H, H-
1'''), 5.04 (d, J = 2.5 Hz, 1H, H-1''), 4.44 (t, J = 5.0 Hz, 1H, H-3'), 4.33-4.24 (m, 2H, H-6', H-3''), 
4.16 (dd, J = 5.1, 2.5 Hz, 1H, H-2''), 4.14-4.00 (m, 4H, H-4', H-8', H-3''', H-5'''), 3.99 (td, J = 6.3, 
3.3 Hz, 1H, H-4''), 3.70 (t, J = 5.8 Hz, 1H, H-5'), 3.75 (t, J = 4.8 Hz, 1H, H-2'), 3.73-3.66 (m, 2H, 
H-4, H-5''CH2), 3.61 (d, J = 3.3 Hz, 1H, H-4'''), 3.56-3.48 (m, 2H, H-5, H-5''CH2), 3.43 (t, J = 9.9 
Hz, 1H, H-6), 3.37 (s, 1H, H-2''), 3.22 (m, 2H, H-1, H-6'''CH2), 3.15 (dd, J = 13.7, 3.7 Hz, 1H, 
H-6'''CH2), 3.13-3.06 (m, 1H, H-3), 2.31-2.19 (m, 2H, H-7'CH2, H-2CH2), 1.70 (s, 16H, 
AcOH),1.65-1.53 (m, 1H, H-2 CH2), 1.43 (m, 1H, H-7'CH2), 1.07 (d, J = 6.2 Hz, 3H, H-9'), 
13C 
NMR (151 MHz, D2O) δ 181.00 (C-CH3COOH), 110.51 (C-1''), 101.14 (C-1'), 95.31 (C-1'''), 
84.66 (C-5), 81.72 (C-5'), 81.22 (C-4''), 79.09 (C-4'), 78.67 (C-4), 75.60 (C-3''), 75.37 (C-8'), 
73.25 (C-6'), 73.07 (C-2'''), 72.25 (C-3'), 71.87 (C-6), 70.11 (C-5'''), 67.54 (C-4'''), 67.12 (C-3'''), 
61.11 (C-5''), 58.21 (C-2'), 50.71 (C-2''), 49.63 (C-3), 48.27 (C-1), 41.04 (C-7'CH2), 40.26 (C-
6'''CH2), 28.09 (C-2), 23.00 (CH3COOH), 20.31 (C-9'CH3); ESI-HRMS: m/z calcd. for 
C68H74N15O14 [M+Na]
+ 1428.4600, found: 1428.4559. 
Chapter 4: 
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 General Coupling Protocol: A solution of donor (0.15 mmol), acceptor (0.18 mmol), 
and activated 4 Å acid-washed powdered molecular sieves (300 mg, 2.0 g/mmol) in anhydrous 
CH2Cl2:MeCN (2:1, 2 mL) was stirred for 0.5 h under Ar, and then cooled to -78 
oC followed by 
addition of NIS (42.0 mg, 0.18 mmol) and TfOH (2 μL, 0.02 mmol). The reaction mixture was 
stirred at -78 oC for 5 h and then quenched with DIPEA (7 μL). The mixture was diluted with 
CH2Cl2, filtered through Celite, washed with 20% aqueous Na2S2O3 solution, dried over Na2SO4, 
and concentrated under reduced pressure. The residue was purified by column chromatography 
on silica gel eluting with EtOAc: hexanes systems to afford the desired coupled products. 
 Acid washed molecular sieves: 4 Å molecular sieves (30 g) were soaked in 2 N HCl (80 
mL) for 12 h. The mixture was concentrated under reduced pressure, and then slurried with water 
(100.0 mL). The slurry was filtered and washed with water (200.0 mL). The resulting solid was 
dried at 254 oC for 24 h to give acid-washed molecular sieves (28.0 g), which were directly used 
for glycosylation. 
 General Protocol for Amide Formation from Isothiocyanates208,209: To the required 9-
fluorenylmethyl (Fm) thioester (0.03 mmol) at room temperature was added a piperidine (0.21 
mmol) in DMF (500 μL). The reaction mixture was stirred for 15 min, then diluted with CHCl3 
(3.0 mL). The resulting solution was washed with 1N HCl aq. (3.0 mL) and brine (3.0 mL), dried 
over Na2SO4, and concentrated in vacuo. The residue was dried under high vacuum, and 
dissolved in dry CH2Cl2 (0.5 mL) before addition of the isothiocyanate (0.02 mmol). The 
reaction mixture was stirred for 36 h at room temperature before the volatiles were removed in 
vacuo. The residue was purified by column chromatography on silica gel eluting with EtOAc: 
hexanes systems to afford the corresponding amides. 
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 Methyl (1-Adamantanyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-isothiocyanato-2-thio-
D-glycero-β-D-galacto-non-2-ulopyranosid)onate (218): To a stirred solution of 213 (1.5 g, 2.8 
mmol) in MeOH (8.0 mL) was added 2M HCl in diethyl ether (8.0 mL) at 0 oC. The resulting 
solution was stirred at room temperature for 3.5 h, and then concentrated under reduced pressure. 
Without further purification the residue was dissolved in MeCN (8.0 mL) and H2O (16.0 mL), 
and NaHCO3 (2.3 g, 27 mmol) added. To the vigorously stirred mixture at room temperature was 
slowly added O-phenyl chlorothionoformate (0.8 g, 4.8 mmol) in MeCN (8.0 mL) through a 
dropping funnel, after which stirring was continued for 1.0 h at room temperature. The resulting 
mixture was extracted with EtOAc (100 mL x 3), and the combined extracts were washed with 
brine and then dried over Na2SO4 and concentrated. The crude was treated with acetic anhydride 
(15.0 mL) and pyridine (12.0 mL), stirred at room temperature for 6 h, and concentrated under 
reduced pressure. The residue was purified by column chromatography on silica gel eluting with 
EtOAc/DCM (1/5) to give the desired isothiocyanate 218 (1.0 g, 59%) as a off-white compound 
with spectral data consistent with those reported in the literature.180  
 Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-isothiocyanato-D-glycero-α-D-
galacto-2-nonulopyranosyl)onate]-(2→6)-2,3,4-tri-O-benzyl-β-D-galactopyranoside (224): 
Compound 224 was prepared according to general glycosylation procedure using donor 218 
(50.0 mg, 0.08 mmol) and acceptor 219 (43.0 mg, 0.09 mmol) in CH2Cl2/CH3CN (1.2 mL, 2:1) 
at -78 oC. After chromatographic purification (gradient elution of EtOAc /Hexanes 2% to 20%) 
compound 224 (57.0 mg, 80%) was obtained as a white foam. []20D = -10.3 (c =1, CHCl3); 1H 
NMR (600 MHz, CDCl3) : 7.35-7.22 (m, 15H), 5.45 (d, J = 9.2 Hz, 1H), 5.33 (m, 1H), 4.94 (d, 
J = 11.7 Hz, 1H), 4.92-4.89 (m, 1H), 4.87 (d, J = 11.0 Hz, 1H), 4.75-4.68 (m, 3H), 4.62 (d, J = 
11.7 Hz, 1H), 4.28-4.26 (m, 2H), 4.15 (dd, J = 12.8, 4.4 Hz, 1H), 4.01 (d, J = 10.6 Hz, 1H), 3.88-
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3.85 (m, 1H), 3.82 (d, J = 2.6 Hz, 1H), 3.77 (t, J = 9.5 Hz, 1H), 3.63 (s, 3H), 3.58 (t, J = 10.3 Hz, 
1H), 3.55 (s, 3H), 3.52-3.48 (m, 3H), 2.67 (dd, J =13.2, 4.8 Hz, 1H), 2.15 (s, 3H), 2.12 (s, 3H), 
2.11 (s, 3H), 2.05 (s, 3H), 1.75 (t, J = 12.5 Hz, 1H); 13C NMR (151 MHz, CDCl3) : 170.7, 
169.6, 169.5, 169.4, 167.2 (3JC-H = 6.7 Hz), 140.2, 138.8, 138.5, 128.3, 128.2, 128.1, 128.0, 
127.6, 127.5, 127.4, 127.3, 104.9, 98.5, 81.9, 79.5, 75.1, 74.2, 73.4, 72.9, 72.6, 71.8, 69.7, 67.9, 
67.6, 63.0, 61.7, 57.0, 56.3, 52.9, 37.2, 20.9, 20.8, 20.7, 20.6; ESIHRMS calcd for 
C47H55O17NSNa ([M + Na]
+) 960.3088, found 960.3089. 
 Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-isothiocyanato-D-glycero-α-D-
galacto-2-nonulopyranosyl)onate]-(2→3)-2,4-di-O-benzyl-β-D-galactopyranoside (225): 
Compound 225 was prepared according to general glycosylation procedure using donor 218 
(30.0 mg, 0.05 mmol) and acceptor 220 (21.0 mg, 0.06 mmol) in CH2Cl2/CH3CN (0.6 mL, 2:1) 
at -78 oC. After chromatographic purification (gradient elution of EtOAc /Hexanes 2% to 20%), 
compound 225 (30.0 mg, 79%) was obtained as a white foam. []20D = -11.9 (c = 1.1, CHCl3); 
1H NMR (600 MHz, CDCl3) : 7.35-7.27 (m, 10H), 5.43 (d, J = 8.8 Hz, 1H), 5.38 (m, 1H), 4.91 
(m, 1H), 4.79 (d, J = 11.7 Hz, 1H), 4.64 (d, J = 11.7 Hz, 1H), 4.58-4.56 (m, 1H), 4.32 (d, J = 7.7 
Hz, 1H), 4.25 (dd, J = 2.2, 12.8 Hz, 1H), 4.04 (dd, J = 9.2, 4.7 Hz, 1H), 4.02 (d, J = 4.0 Hz, 1H), 
3.97 (dd, J = 10.6, 1.5 Hz, 1H), 3.80 (s, 3H), 3.78 (d, J = 5.9 Hz, 1H), 3.75-3.71 (m, 2H), 3.59 (t, 
J = 5.9 Hz, 1H), 3.55 (m, 4H), 3.51-3.48 (m, 2H), 2.65 (dd, J = 13.2, 4.8 Hz, 1H), 2.11 (s, 3H), 
2.07 (s, 3H), 2.05 (s, 3H), 1.93 (s, 3H), 1.78 (t, J = 12.5 Hz, 1H); 13C NMR (151 MHz, CDCl3) : 
170.6, 169.8, 169.3, 169.2, 167.9 (3JC-H = 7.5 Hz), 140.3, 138.9, 138.0, 128.36, 128.1, 127.7, 
127.4, 104.6, 97.7, 77.3, 75.8, 74.8, 73.5, 72.6, 71.9, 69.7, 69.2, 68.2, 67.9, 67.6, 61.8, 56.9, 56.2, 
53.2, 36.3, 29.5, 20.8, 20.7, 20.3; ESIHRMS calcd for C40H49O17NSNa ([M + Na]
+) 870.2618, 
found 870.2619. 
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 Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-isothiocyanato-D-glycero-α-D-
galacto-2-nonulopyranosyl)onate]-(2→3)-2,4,6-tri-O-benzyl-β-D-galactopyranoside (226): 
Compound 226 was prepared according to general glycosylation procedure using donor 218 
(300.0 mg, 0.5 mmol) and acceptor 221 (260.0 mg, 0.6 mmol) in CH2Cl2/CH3CN (6 mL, 2:1) at -
78 ºC. After chromatographic purification (gradient elution of EtOAc /Hexanes 2% to 20%), 
compound 226 (380 mg, 87%) was obtained as a white foam. []20D = -23.0 (c =0.9, CHCl3); 1H 
NMR (600 MHz, CDCl3) : 7.35-7.22 (m, 15H), 5.43-5.39 (m, 2H), 4.95 (dt, J = 10.3, 4.7 Hz, 
1H), 4.84 (d, J = 11.7 Hz, 1H), 4.80 (d, J = 11.4 Hz, 1H), 4.64 (d, J = 11.4 Hz, 1H), 4.50 (d, J = 
11.7 Hz, 1H), 4.44 (d, J = 11.4 Hz, 1H), 4.38 (d, J = 11.7 Hz, 1H), 4.30-4.26 (m, 2H), 3.99 (dd, J 
= 12.8, 3.7 Hz, 1H), 3.93 (dd, J = 9.9, 2.9 Hz, 1H), 3.85 (d, J = 10.3 Hz, 1H), 3.74 (s, 3H), 3.68 
(d, J = 2.6 Hz, 1H), 3.67-3.57 (m, 3H), 3.54 (m, 4H), 3.50 (t, J = 10.3 Hz, 1H), 2.58 (dd, J = 4.8, 
13.6 Hz, 1H), 2.13 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H), 1.90 (s, 3H), 1.85 (t, J = 12.8 Hz, 1H); 13C 
NMR (151 MHz, CDCl3) : 170.6, 169.6, 169.3, 169.2, 167.5 (3JC-H = 7.0 Hz), 140.3, 139.0, 
138.7, 137.9, 128.4, 128.1, 128.0, 127.8, 127.7, 127.6, 127.4, 127.2, 104.9, 98.77, 77.5,76.3, 
76.2, 74.8, 73.5, 73.0, 71.6, 69.9, 68.4, 68.0, 67.5, 61.5, 57.0, 56.3, 53.0, 43.3, 35.5, 21.0, 20.8, 
20.7, 20.3; ESIHRMS calcd for C47H55O17NSNa ([M + Na]
+) 960.3088, found 960.3090.  
 Benzyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-isothiocyanato-α-D-glycero-D-
galacto-2-nonulopyranosyl)onate]-(2→3)-(4-O-acetyl-2,6-di-O-benzyl-β-D-
galactopyranosyl)-(2→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (227): Compound 227 was 
prepared according to general glycosylation procedure using donor 218 (30.0 mg, 0.05 mmol) 
and acceptor 222 (49.6 mg, 0.06 mmol) in CH2Cl2/CH3CN (0.6 mL, 2:1) at -78 
oC. The crude 
was dissolved in pyridine (1.0 mL) was treated with acetic anhydride (0.8 mL) then stirred 
overnight at room temperature. The reaction mixture was concentrated under reduced pressure. 
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After chromatographic purification (gradient elution of EtOAc /Hexanes 2% to 20%) compound 
227 (34.8 mg, 55%) was obtained as a white foam. []25D = -21.3 (c = 0.3, CH2Cl2); 1H NMR 
(600 MHz, CDCl3) : 7.38-7.14 (m, 30H; Ar-H), 5.58 (m, 1H), 5.44 (dd, J = 9.2, 1.8 Hz, 1H), 
5.06 (d, J = 3.3 Hz, 1H), 5.01 (td, J = 9.9, 4.4 Hz, 1H), 4.96-4.85 (m, 4H), 4.75-4.67 (m, 3H), 
4.62 (dd, J = 11.7, 2.7 Hz, 2H), 4.53 (d, J = 12.1 Hz, 1H), 4.43 (m, 2H), 4.36 (d, J = 11.7 Hz, 
1H), 4.31 (dd, J = 9.9, 3.6 Hz, 1H), 4.26 (dd, J = 12.8, 2.2 Hz, 1H), 4.20 (d, J = 12.1 Hz, 1H), 
4.07 (dd, J = 12.4, 4.0 Hz, 1H), 3.97 (t, J = 9.5 Hz, 1H), 3.84 (s, 3H), 3.77 (t, J = 9.9 Hz, 1H), 
3.71 (dd, J = 10.2, 1.8 Hz, 1H), 3.65 (dd, J = 11.0, 5.1 Hz, 1H), 3.60 (t, J = 6.9 Hz, 1H),  3.52 
(m, 2H), 3.43 (m, 2H), 3.29 (m, 3H), 2.67 (dd, J = 12.8, 4.7 Hz, 1H),  2.10 (s, 3H), 2.09 (s, 3H), 
2.01 (s, 3H), 1.98 (s, 3H), 1.73 (s, 3H), 1.64 (t, J = 12.4 Hz, 1H); 13C NMR (151 MHz, CDCl3) : 
170.6, 169.7, 169.6, 169.2, 169.1, 167.2 (3JC-H = 6.5 Hz), 140.1, 139.2, 139.1, 138.6, 138.5, 
138.0, 137.4, 128.3, 128.2, 128.2, 128.1, 128.0, 127.9, 127.8, 127.8, 127.6, 127.6, 127.5, 127.4, 
127.3, 127.2, 127.2, 127.1, 127.1, 102.3, 102.0, 97.3, 82.7, 81.8, 79.1, 76.3, 75.0, 74.9, 74.7, 
74.0, 73.2, 72.9, 71.5, 70.8, 70.0, 68.7, 68.6, 67.7, 67.5, 67.4, 61.7, 60.0, 56.2, 53.2, 36.8, 21.1, 
20.8, 20.7, 20.6, 20.1; ESIHRMS calcd for C75H83O23NSNa ([M + Na]
+) 1420.4983, found 
1420.4974. 
 Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-isothiocyanato-α-D-glycero-D-
galacto-2-nonulopyranosyl)onate]-α(2→9)-[(5-acetamido-2,4,7-tri-O-benzoyl-3,5-dideoxy-2-
α-D-glycero-D-galacto-2-nonulopyranose)onate] (228): Compound 228 was prepared 
according to general glycosylation procedure using donor 218 (30.0 mg, 0.05 mmol) and 
acceptor 223 (49.6 mg, 0.06 mmol) in CH2Cl2/CH3CN (0.6 mL, 2:1) at -68 
oC. After 
chromatographic purification (gradient elution of EtOAc /Hexanes 2% to 20%) compound 228 
(35 mg, 58%) was obtained as a white foam. []20D = -10.6 (c = 0.5, CH2Cl2); 1H NMR (600 
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MHz, CDCl3) : 8.10 (dd, J = 7.7, 3.7 Hz, 4H), 7.95 (d, J = 7.3 Hz, 2H), 7.63 (t, J = 7.3 Hz, 1H), 
7.57 (t, J = 7.3 Hz, 1H), 7.53-7.44 (m, 5H), 7.37 (t, J = 7.7 Hz, 2H), 5.73 (td, J = 10.6, 4.7 Hz, 
1H), 5.60 (d, J = 9.5 Hz, 1H), 5.39 (m, 2H), 5.16 (m, 1H), 4.82 (td, J = 9.9, 4.4 Hz, 1H), 4.57 
(dd, J = 10.6, 1.5 Hz, 1H), 4.26 (m, 2H), 4.10 (dd, J = 12.5, 2.2 Hz, 1H), 4.00 (dd, J = 10.6, 1.5 
Hz, 1H), 3.92 (dd, J = 12.8, 2.2 Hz, 1H), 3.83 (s, 3H), 3.68 (m, 4H), 3.46 (m, 2H), 2.88 (dd, J = 
13.2, 5.1 Hz, 1H), 2.49 (dd, J = 13.2, 4.7 Hz, 1H), 2.17 (t, J =11.4 Hz, 1H), 2.09 (s, 3H), 2.07 (s, 
3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.84 (s, 3H), 1.57 (t, J =12.8 Hz, 1H); 13C NMR (151 MHz, 
CDCl3) : 170.8, 170.1, 169.8, 169.5, 169.4, 169.3, 167.4 (3JC-H = 6.5 Hz), 166.3, 165.4, 164.6, 
139.9, 134.0, 133.4, 133.1, 130.0, 130.0, 129.8, 129.2, 128.7, 128.8, 128.8, 98.54, 97.8, 71.9, 
69.6, 69.5, 69.5, 68.3, 67.9, 67.8, 66.9, 61.7, 60.0, 56.2, 53.2, 52.9, 49.3, 37.1, 36.7, 29.6, 23.2, 
21.0, 20.8, 20.4; ESIHRMS calcd for C52H56O23N2SNa ([M + Na]
+) 1131.2860, found 
1131.2892. 
 Methyl (5-acetamido-2,4,6-tri-O-benzoyl-3,5-dideoxy-D-β-glycero-D-galacto-2-
nonulopyranose)onate (223): A stirred solution of methyl ester of N-acetylneuraminic acid210 
(1.5 g, 4.64 mmol) in anhydrous dimethylformamide (15.0 mL) was treated with 2,2-
dimethoxypropane (1.2 g, 11.5 mmol) and p-toluenesulfonic acid (15.0 mg) at room temperature. 
The resulting reaction mixture was stirred at 80 ºC for 2 h. The solvent was evaporated under 
reduced pressure, taken up in pyridine (14 mL) and treated at 0 ºC with benzoyl chloride (3.9 g, 
27.7 mmol). After stirring for 1 h at 0 ºC, the volatiles were removed under reduced pressure and 
the residue was dissolved in dichloromethane (10.0 mL) and was washed with 0.1 N HCl (10.0 
mL), saturated aqueous NaHCO3 (2 x 5.0 mL), and brine (5.0 mL). The organic layer was 
concentrated to afford a yellow form which was treated with TFA (2.3 mL, 80 %) at room 
temperature for 10 min. The resulted compound was extracted into dichloromethane (10 mL) and 
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was washed with saturated aqueous NaHCO3 (10.0 mL), water (10.0 mL) and brine (5.0 mL). 
The organic layer was concentrated to afford a yellow oil that was purified by chromatography 
on silica gel (EtOAc/Hexanes 5% to 80%) to afford 223211 (480.0 mg, 85%) as a white foam. 
[α]D26= -71 (c = 0.4, CH2Cl2); 1H NMR (600 MHz, CDCl3) : 8.10 (m, 4H), 7.95 (d, J = 7.3 Hz, 
2H), 7.59 (m, 2H), 7.53 (t, J = 7.3 Hz, 1H), 7.47 (m, 4H), 7.38 (t, J = 7.7 Hz, 2H), 5.64 (m, 2H), 
5.27 (d, J = 8.8 Hz, 1H), 4.48 (m, 2H), 4.09 (d, J = 7.7 Hz, 1H), 3.85 (s, 3H), 3.65 (m, 1H), 3.51 
(m, 1H), 2.91 (dd, J = 13.2, 4.4 Hz, 1H), 2.28 (t, J =11.7 Hz, 1H), 1.79 (s, 3H); 13C NMR (151 
MHz, CDCl3) : 170.1, 166.9, 166.7 (3JC-H = 0 Hz), 166.6, 164.9, 129.7, 129.4, 129.0, 128.7, 
128.5, 128.4, 98.0, 72.7, 69.4, 69.3, 69.2, 62.5, 53.3, 49.5, 37.0, 23.0; ESIHRMS calcd for 
C33H33O12N ([M + Na]
+) 658.1901, found 658.1888. 
 Methyl (5-isothiocyanato-4,7,8,9-tetra-O-acetyl-2-(dibutylphosphoryl)-3,5-dideoxy-
D-glycero-β-D-galacto-non-2-ulopyranoside)onate (231): A solution of thiosialoside donor 
(300.0 mg, 0.47 mmol), dibutyl phosphate (252.5 mg, 1.20 mmol), and activated 4 Å powdered 
molecular sieves (100.0 mg, 2.0 g/mmol) in anhydrous CH2Cl2 (11.0 mL) was stirred for 1 h 
under Ar and then cooled to 0 ºC followed by addition of NIS (154.8 mg mg, 0.69 mmol) and 
TfOH (12 μL, 0.14 mmol). The reaction mixture was stirred at 0 oC for 5 h and then quenched 
with DIPEA (70 μL, 0.47 mmol). The mixture was diluted with CH2Cl2 (5.0 mL), filtered 
through Celite, washed with 20% aqueous Na2S2O3 solution, dried over Na2SO4, and 
concentrated under reduced pressure. The residue was purified by column chromatography on 
silica gel eluting with EtOAc: toluene (gradient elution 5% to 40%) afforded desired compound 
(243 mg, 76%) in a 3:2 ratio, as a yellow oil. 
 α-isomer: [α]D26= −22.4 (c=1.45, CH2Cl2); 1H NMR (600 MHz, Chloroform-d) δ 5.44 
(dd, J = 9.2, 1.4 Hz, 1H), 5.23 (ddd, J = 9.1, 4.1, 2.4 Hz, 1H), 4.97 (ddd, J = 12.1, 9.9, 4.7 Hz, 
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1H), 4.29 (dd, J = 12.6, 2.4 Hz, 1H), 4.19 (dd, J = 10.6, 1.4 Hz, 1H), 4.15 (dd, J = 12.7, 4.1 Hz, 
1H), 4.09-4.03 (m, 1H), 4.03-3.96 (m, 3H), 3.80 (s, 3H), 3.63 (t, J = 10.3 Hz, 1H), 2.73 (dd, J = 
13.0, 4.8 Hz, 1H), 2.29 (t, J = 12.6 Hz, 1H), 2.12 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H), 2.03 (s, 3H), 
1.61 (m, 4H), 1.36 (m, 4H), 0.89 (td, J = 7.4, 5.4 Hz, 6H); 13C NMR (151 MHz, CH2Cl2) δ 
170.62, 169.53, 169.49, 169.43, 166.51 (3JC-H = 7.2 Hz), 140.66, 97.91, 97.86, 77.26, 77.05, 
76.83, 72.74, 70.02, 69.36, 68.95, 68.25, 68.04, 68.00, 67.90, 67.86, 67.22, 61.34, 56.82, 56.10, 
53.35, 36.81, 36.78, 32.06, 32.03, 32.01, 31.98, 20.92, 20.83, 20.71, 20.56, 18.57, 18.53, 13.54, 
13.51; 31P NMR (151 MHz, Chloroform-d) δ -6.96; ESI-HRMS: m/z calcd. for C27H42NO15 
PSNa [M+Na]+ 706.1911, found: 706.1893. 
 β-isomer: [α]D26= −45.8 (c=0.95, CH2Cl2); 1H NMR (600 MHz, Chloroform-d) δ 5.50 
(dd, J = 6.5, 1.8 Hz, 1H), 5.36 (ddd, J = 11.4, 9.9, 4.9 Hz, 1H), 5.23 (td, J = 6.1, 2.4 Hz, 1H), 
4.43 (dd, J = 12.5, 2.5 Hz, 1H), 4.29 (dd, J = 10.6, 1.8 Hz, 1H), 4.23 (dd, J = 12.6, 5.7 Hz, 1H), 
4.12-4.02 (m, 5H), 3.80 (s, 3H), 3.68 (t, J = 10.3 Hz, 1H), 2.72 (dd, J = 13.7, 4.9 Hz, 1H), 2.15 
(s, 3H), 2.10 (s, 3H), 2.08 (s, 3H), 2.03 (s, 3H), 1.90 (ddd, J = 14.1, 11.4, 3.2 Hz, 1H), 1.64 (m, 
4H), 1.38 (m, 4H), 0.92 (td, J = 7.4, 3.8 Hz, 6H); 13C NMR (151 MHz, Chloroform-d) δ 170.60, 
169.91, 169.44, 169.31, 165.63 (3JC-H = 0 Hz), 140.74, 98.90, 71.82, 69.80, 68.84, 68.49, 68.45, 
68.40, 68.27, 61.77, 56.31, 53.29, 36.64, 36.61, 32.11, 32.06, 29.67, 20.90, 20.87, 20.76, 20.63, 
18.58, 13.54; 31P NMR (151 MHz, Chloroform-d) δ −6.17; ESI-HRMS: m/z calcd. for 
C27H42NO15 PSNa [M+Na]
+ 706.1911, found: 706.1887. 
 General protocol for glycosylation with sialyl phosphate donor 231: A solution of 
donor 231 (0.05 mmol), acceptor (0.06 mmol), and activated 4 Å powdered molecular sieves 
(100 mg, 2.0 g/mmol) in anhydrous CH2Cl2 (1.0 mL) was stirred for 1 h under Ar, and then 
cooled to -78 oC followed by addition of TMSOTf (0.07 mmol). The reaction mixture was stirred 
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at -78 oC for 6-8 h and then quenched with TEA (0.05 mmol). The mixture was diluted with 
CH2Cl2, molecular sieves were filtered off and reaction mixture was washed with brine. The 
organic layer was dried over Na2SO4 and concentrated under reduced pressure to give crude 
reaction mixtures which were purified by chromatography over silica gel using EtOAc:hexanes 
systems to afford the desired coupled products. 
Competition reaction: 
 A solution of isothiocyanate donor 208 (42.0 mg, 0.06 mmol), N-acetyl-5-N,4-O-
oxazolidinone-protected adamantanyl thiosialoside donor 206173 (41.0 mg, 0.06 mmol), acceptor 
221 (30.4 mg, 0.06 mmol) and activated 4 Å acid-washed powdered molecular sieves (150.0 mg) 
in anhydrous CH2Cl2:MeCN (2:1, 0.5 mL) was stirred for 0.5 h under Ar, and then cooled to -78 
oC followed by addition of NIS (7.0 mg, 0.06 mmol) and TfOH (1.0 μL, 0.01 mmol). The 
reaction mixture was stirred at -78 oC for 5 h and then quenched with DIPEA (10.0 μL). The 
mixture was diluted with CH2Cl2, filtered through Celite, washed with 20% aqueous Na2S2O3 
solution, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel eluting with EtOAc: hexanes systems to afford the 
coupled products, 230 (31.0 mg, 51%)173 and compound 226 (2.0 mg, 3%) and the unreacted 
donors 218 (31.0 mg, 74%) and 206 (7.0 mg, 17%).  
 Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy--α-D-gluco-2-
nonulopyranosyl)onate]-(2→3)-2,4,6-tri-O-benzyl-β-D-galactopyranoside (236): To a 
solution of 226 (50.0 mg, 0.05 mmol) in anhydrous toluene (1.5 mL) under Ar was added 
tris(trimethylsilylsilane) (65.0 mg, 0.26 mmol) followed by azoisobutyronitrile (1.0 mg, 0.006 
mmol) at room temperature. The resulting reaction mixture was stirred at 85 ºC for 1 h. The 
solvent was evaporated under reduced pressure and the residue was purified by silica gel column 
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chromatography eluting with 30% EtOAc in hexanes to give the title compound 236 (36.0 mg, 
78%) as a yellow foam. [α]D25= -7.4 (c = 2.3, CH2Cl2); 1H NMR (600 MHz, CDCl3) : 7.39 (d, J 
= 6.9 Hz, 2H), 7.34-7.20 (m, 13H), 5.44 (m, 1H), 5.17 (dd, J = 8.4, 2.2 Hz, 1H), 4.91 (d, J = 11.7 
Hz, 1H), 4.82 (m, 2H), 4.71 (d, J = 11.3 Hz , 1H), 4.52 (d, J = 11.7 Hz, 1H), 4.48 (d, J = 11.3 
Hz, 1H), 4.41 (d, J = 11.7 Hz, 1H), 4.32 (d, J = 7.7 Hz, 1H), 4.29 (dd, J = 12.8, 2.5 Hz, 1H), 4.05 
(m, 2H), 3.94 (dt, J = 12.1, 1.8 Hz, 1H), 3.73 (d, J = 2.5 Hz, 1H), 3.68 (s, 3H), 3.67-3.57 (m, 
4H), 3.54 (s, 3H), 2.50 (dd, J = 11.7, 4.4 Hz, 1H), 2.10 (s, 3H), 2.02 (s, 3H), 1.97 (s, 3H), 1.92 (s, 
3H), 1.89 (m, 1H), 1.80 (t, J = 12.4 Hz, 1H), 1.24 (m, 1H); 13C NMR (151 MHz, CDCl3) : 
170.4, 169.9, 169.8, 169.6, 168.3, 139.2, 138.9, 138.1, 128.3, 128.0, 127.9, 127.8, 127.7, 127.2, 
127.0, 104.9, 99.5, 77.6, 76.6, 75.8, 74.8, 73.4, 73.2, 70.6, 69.4, 68.8, 68.4, 67.1, 61.7, 60.0, 57.0, 
52.6, 36.1, 32.0, 21.0, 20.9, 20.6, 20.4; ESIHRMS calcd for C46H56O17Na ([M + Na]
+) 903.3415, 
found 903.3432. 
 Methyl [methyl (4,7,8,9-tetra-O-acetyl-5-C-allyl-3,5-dideoxy-D-glycero-α-D-galacto-
2-nonulopyranosyl)onate]-(2→3)-4-O-acetyl-2,6-di-O-benzyl-β-D-galactopyranoside (238): 
Acetic anhydride (1.0 mL) added to a solution of 225 (60.0 mg, 0.07 mmol) in pyridine (1.5 mL) 
at 0 ºC and the resulting reaction mixture stirred for 4 h. The reaction mixture was concentrated 
under reduced pressure and was purified by chromatography to give a pentaacetate which was 
taken forward to the next step without further characterization. To a solution of this pentaacetate 
237 (62.0 mg) in anhydrous benzene (1.0 mL) under Ar was added allyltris(trimethylsilylsilane) 
(502.0 mg, 1.74 mmol) followed by azoisobutyronitrile (11.4 mg, 0.04 mmol) at room 
temperature. The resulting reaction mixture was stirred at 80 ºC for 12 h. The solvent was 
evaporated under reduced pressure and the residue was purified by silica gel column 
chromatography eluting with 30% EtOAc in hexanes to give the title compound 238 (27.0 mg, 
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45%) as yellow foam. [α]D25= -2.2 (c= 0.7, CH2Cl2); 1H  NMR (600 MHz, CDCl3) : 7.41 (d, J = 
7.7 Hz, 2H), 7.32-7.20 (m, 8H), 5.62 (m, 1H), 5.57 (m, 1H), 5.42 (d, J = 8.4 Hz, 1H), 5.05 (d, J = 
3.3 Hz, 1H), 5.02 (m, 2H), 4.86 (td, J = 11.4, 4.7 Hz, 1H), 4.80 (m, 2H), 4.52 (d, J = 11.7 Hz, 
1H), 4.45 (d, J = 12.1 Hz, 1H), 4.44 (d, J = 8.4 Hz, 1H), 4.38 (dd, J = 9.4, 2.9 Hz, 1H), 4.30 (dd, 
J = 12.4, 1.8 Hz, 1H), 4.10 (dd, J = 12.8, 4.0 Hz, 1H), 3.80 (m, 3H), 3.67 (d, J = 11.0 Hz, 1H), 
3.56 (s, 3H), 3.53-3.41 (m, 4H), 2.57 (dd, J = 12.1, 4.4 Hz, 1H), 2.22 (dd, J = 14.3, 3.6 Hz, 1H), 
2.10 (s, 3H), 2.08 (m, 1H), 2.03 (s, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 1.76 (s, 3H), 1.59 (t, J = 12.1 
Hz, 1H); 13C NMR (151 MHz, CDCl3) : 170.6, 170.0, 170.0, 169.8, 169.7, 168.2, 139.6, 138.0, 
133.2, 128.2, 127.9, 127.6, 127.5, 127.1, 126.9, 117.7, 104.5, 97.0, 78.1, 74.3, 73.4, 72.7, 72.0, 
72.0, 69.3, 69.2, 68.7, 68.5, 68.0, 62.1, 57.3, 52.7, 38.9, 37.6, 30.3, 21.2, 20.9, 20.8, 20.7, 20.3; 
ESIHRMS calcd for C44H56O18Na ([M + Na]
+) 895.3364, found 895.3358. 
 S-(9-Fluorenylmethyl) benzyloxythioacetate (242): To a ~2.0 M solution of 2-
(benzyloxy)acetic acid (60.0 mg, 0.36 mmol), 9-fluorenylmethylthiol209 (100.0 mg, 0.47 mmol) 
and DMAP (5.0 mg, 0.04 mmol) in CH2Cl2 (1.0 mL), was added a solution of DCC (82.0 mg, 
0.39 mmol) in CH2Cl2 (0.4 mL) at 0 ºC. The suspension was stirred for 1 h at 0 ºC and overnight 
at room temperature. The suspension was filtered to remove the resulting white solid which was 
washed with CH2Cl2 (2.0 mL) repeatedly. The filtrate was concentrated and purified by 
chromatography over silica gel to give the title thioester (242) as a colorless oil (128.0 mg, 98%). 
α]D26= +30.0 (c = 1.2, CH2Cl2); 1H NMR (600 MHz, CDCl3) : 7.76 (d, J = 7.7 Hz, 2H), 7.69 (d, 
J = 7.3 Hz, 2H), 7.42 (t, J = 7.3 Hz, 2H), 7.39-7.29 (m, 7H), 4.48 (s, 2H), 4.22 (t, J = 5.9 Hz, 
1H), 4.10 (s, 2H), 3.59 (d, J = 5.9 Hz, 2H); 13C NMR (151 MHz, CDCl3) : 199.7, 145.4, 141.2, 
136.8, 128.5, 128.1, 128.1, 127.7, 127.2, 124.7, 119.9, 74.7, 73.7, 46.7, 31.1; ESIHRMS calcd 
for C23H20O2SNa ([M + Na]
+) 383.1082, found 383.1073.  
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 Methyl [methyl (4,7,8,9-tri-O-acetyl-5-(benzyloxyacetamido)-3,5-dideoxy-D-glycero-
α-D-galacto-2-nonulopyranosyl)onate]-(2→3)-2,4,6-tri-O-benzyl-β-D-galactopyranoside 
(246): Compound 246 was prepared according to general protocol for amide formation using 
isothiocyanate 221 (0.03 g, 0.05 mmol) and Fm thioester 242 (49.6 mg, 0.06 mmol) in CH2Cl2 
(0.5 mL) at 40 oC. After chromatographic purification (gradient elution of EtOAc/Hexanes 4% to 
40%) compound 246 (20.0 mg, 55%) was obtained as a white foam. []20D = -5.3 (c = 0.3, 
CH2Cl2); 
1H NMR (600 MHz, CDCl3) : 7.40-7.19 (m, 20H), 6.31 (d, J = 10.3 Hz, 1H), 5.47 (m, 
1H), 5.29 (dd, J = 8.8, 2.2 Hz, 1H), 4.89 (dt, J = 11.7, 4.7 Hz, 1H), 4.86 (d, J = 11.7 Hz, 1H), 
4.82 (d, J = 12.1 Hz, 1H), 4.72 (d, J = 12.1 Hz, 1H), 4.58 (d, J = 11.7 Hz, 1H), 4.53 (d, J = 11.7 
Hz, 1H), 4.49 (d, J = 11.7 Hz, 2H), 4.42 (d, J = 11.7 Hz, 1H), 4.34 (d, J = 7.3 Hz, 1H), 4.28 (dd, 
J = 12.4, 2.5 Hz, 1H), 4.10 (m, 2H), 3.95 (dd, J = 12.4, 4.7 Hz, 1H), 3.92-3.81 (m, 4H), 3.70 (s, 
3H), 3.68-3.59 (m, 4H), 3.53 (s, 3H), 2.52 (dd, J = 13.1, 4.7 Hz, 1H), 2.12 (s, 3H), 2.05 (t, J = 
13.1, 1H), 1.98 (s, 3H), 1.95 (s, 3H), 1.92 (s, 3H); 13C NMR (151 MHz, CDCl3) : 170.4, 170.3, 
170.2, 169.8, 169.7, 168.2, 139.1, 138.1, 136.7, 128.8-126.9, 104.8, 98.8, 77.6, 76.3, 76.2, 74.8, 
74.6, 73.5, 73.4, 73.0, 72.1, 69.1, 68.6, 68.5, 67.0, 62.0, 57.1, 52.8, 48.4, 36.7, 29.6, 21.1, 20.7, 
20.7, 20.6; ESIHRMS calcd for C55H65NO19Na ([M + Na]
+)  1066.4049, found 1066.4042. 
 Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-(L-methioninamido)-α-D-
glycero-D-galacto-2-nonulopyranosyl)onate]-(2→3)-2,4,6-tri-O-benzyl-β-D-
galactopyranoside (247): Compound 247 was prepared according to general amide formation 
procedure using isothiocyanate 221 (30.0 mg, 0.02 mmol) and 9-fluorenylmethyl thioester of N-
tert-Butoxycarbonyl-L-methionine 245209 (12.0 mg, 0.06 mmol) in CH2Cl2 (0.5 mL) at 40 
ºC. 
After chromatographic purification (gradient elution of EtOAc /Hexanes 10% to 90%) 
compound 247 (18 mg, 50%) was obtained as a white foam. []25D = -13.8 (c = 0.5, CH2Cl2); 1H 
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NMR (600 MHz, CDCl3) : 7.38 (d, J = 7.3 Hz, 2H), 7.34-7.19 (m, 15H), 6.10 (d, J = 9.5 Hz, 
1H), 5.46 (m, 1H), 5.17 (d, J = 8.4 Hz, 1H), 5.06 (d, J = 5.8 Hz, 1H), 4.90-4.84 (m, 2H), 4.82 (d, 
J = 11.7 Hz, 1H), 4.71 (d, J = 11.7 Hz, 1H), 4.48 (d, J = 11.7 Hz, 2H), 4.42 (d, J = 11.7 Hz, 1H), 
4.34 (d, J = 7.3 Hz, 1H), 4.22 (d, J = 12.1 Hz, 1H), 4.14 (q, J = 7.3 Hz, 1H), 4.08 (dd, J = 9.9, 
2.5 Hz, 1H), 4.04-3.94 (m, 2H), 3.90 (d, J = 7.3 Hz, 1H), 3.73 (d, J = 11.3 Hz, 1H), 3.72 (s, 3H), 
3.70-3.63 (m, 2H), 3.64-3.58 (m, 3H), 3.53 (s, 3H),  2.53 (dd, J = 13.2, 4.7 Hz, 1H), 2.10 (s, 6H), 
2.03 (t, J = 8.4 Hz, 1H), 2.00 (s, 3H), 1.96 (s, 3H), 1.90 (s, 3H), 1.80 (m, 1H), 1.47 (s, 9H); 13C 
NMR (151 MHz, CDCl3) : 171.7, 170.4, 170.2, 169.9, 169.6, 168.1, 156.1, 139.2, 138.1, 128.3, 
128.0, 127.9, 127.7, 127.6, 127.6, 127.6, 127.1, 127.0, 104.9, 98.5, 80.5, 77.63, 76.3, 76.2, 74.8, 
74.6, 73.4, 73.0, 72.1, 68.8, 68.6, 68.4, 67.2, 62.1, 60.0, 57.0, 52.7, 53.6, 48.8, 36.5, 30.1, 29.6, 
28.3, 21.0, 20.8, 20.7, 20.6, 15.0; ESIHRMS calcd for C56H74O20N2SNa ([M + Na]
+) 1149.4453, 
found 1149.4462. 
 Methyl [methyl (4,7,8,9-tetra-O-acetyl-5-(benzyloxyacetamido)-3,5-dideoxy-α-D-
glycero-D-galacto-2-nonulopyranosyl)onate]-α(2→9)-[5-acetamido-8-O-acetyl-2,4,7-tri-O-
benzoyl-3-deoxy-2-α-D-glycero-D-galacto-nonulopyranosel)onate] (249): Acetic anhydride 
(0.8 mL) added to a solution of compound 228 (24.0 g, 0.02 mmol) in pyridine (1.0 mL) at 0 ºC 
and the resulting reaction mixture stirred for 4 h. The reaction mixture was concentrated under 
reduced pressure and was purified by chromatography to give a pentaacetate which was taken 
forward to the next step without further characterization. Compound 249 was prepared according 
to general amide formation procedure using isothiocyanate 248 (24.0 mg) and Fm thioester 242 
(12.0 mg, 0.06 mmol) in CH2Cl2 (0.5 mL) at 40 
ºC. After chromatographic purification (gradient 
elution of EtOAc/Hexanes 10% to 90%), compound 249 (12.0 mg, 46%) was obtained as a white 
foam. []25D = -13.3 (c = 0.6, CH2Cl2); 1H NMR (600 MHz, CDCl3) : 8.15 (d, J = 7.7 Hz, 2H), 
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8.13 (d, J = 7.7 Hz, 2H), 7.95 (d, J = 7.7 Hz, 2H), 7.62 (t, J = 7.3 Hz, 1H), 7.58 (t, J = 7.7 Hz, 
1H), 7.54-7.45 (m, 5H), 7.40-7.30 (m, 7H), 6.22 (d, J = 10.3 Hz, 1H), 5.97 (dt, J = 10.6, 4.7 Hz, 
1H), 5.78 (d, J = 8.8 Hz, 1H), 5.66 (d, J = 8.4 Hz, 1H), 5.32 (m, 1H), 5.21 (dd, d, J = 8.4, 1.8 Hz, 
1H), 4.93 (m, 1H), 4.75 (dt, J = 10.2, 4.4 Hz, 1H), 4.64 (d, J = 10.6 Hz, 1H), 4.55 (d, J = 11.7 
Hz, 1H), 4.50 (d, J = 11.7 Hz, 1H), 4.06-3.96 (m, 2H), 3.93-3.85 (m, 4H), 3.84-3.80 (m, 5H), 
3.71 (s, 3H), 3.67 (dd, J = 12.8, 4.7 Hz, 1H), 3.57 (dd, J = 11.3, 2.9 Hz, 1H), 2.91 (dd, J = 13.5, 
5.1 Hz, 1H), 2.46 (dd, J = 13.2, 4.7 Hz, 1H), 2.18 (t, J = 13.2 Hz, 1H), 2.07 (s, 3H), 1.98 (s, 3H), 
1.97 (s, 3H), 1.95 (s, 3H), 1.93 (s, 3H), 1.84 (t, J =12.8 Hz, 1H), 1.71 (s, 3H); 13C NMR (151 
MHz, CDCl3) : 170.6, 170.3, 170.3, 170.1, 169.7, 169.7, 169.1, 167.8, 166.6, 166.0, 165.4, 
163.5, 136.7, 133.8, 133.3, 130.1, 130.0, 129.7, 129.3, 129.3, 128.7, 128.6, 128.5, 128.4, 128.2, 
128.0, 98.3, 97.8, 73.4, 72.2, 70.9, 69.6, 69.1, 68.9, 68.5, 67.9, 67.8, 66.6, 62.4, 61.7, 60.0, 53.0, 
52.7, 50.8, 48.2, 37.5, 36.5, 23.5, 21.0, 20.7, 20.7, 20.4; ESIHRMS calcd for C62H68N2O26Na 
([M + Na]+) 1279.3928, found 1279.3939. 
 Methyl [methyl (4,7,8,9-tetra-O-acetyl-5-(N'-(2-phenylethyl)thioureido)-3,5-dideoxy-
D-glycero-α-D-galacto-2-nonulopyranosyl)onate]-(2→3)-[2,4,6-tri-O-benzyl-β-D-
galactopyranoside] (250): To a solution of isothiocyanate 226 (65.0 mg, 0.06 mmol) in 
anhydrous DCM (1.8 mL) under Ar was added 2-phenylethylamine (10.0 mg, 0.8 mmol) at room 
temperature. The resulting reaction mixture was stirred at room temperature for 1 h, then 
quenched with 1N HCl and washed with water (2.0 mL), and brine (2.0 mL). The solvent was 
evaporated under reduced pressure to give the title compound 250 (72.0 mg, 90%) as yellow 
foam. [α]D25= -9.4 (c = 0.4, CH2Cl2); 1H NMR (600 MHz, CDCl3) : 7.40 (d, J = 7.3 Hz, 3H), 
7.36-7.19 (m, 17H), 6.24 (br s, 1H), 5.40 (td, J = 7.7, 2.2 Hz, 1H), 5.27 (m, 1H), 4.95 (br s, 1H), 
4.89 (d, J = 11.3 Hz, 1H), 4.84 (d, J = 12.1 Hz, 1H), 4.72 (d, J = 11.7 Hz, 1H), 4.50 (t, J = 11.7 
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Hz, 2H), 4.43 (d, J = 11.7 Hz, 2H), 4.34 (d, J = 7.7 Hz, 1H), 4.12 (d, J = 8.8 Hz, 1H), 3.98 (dd, J 
= 12.4, 6.2 Hz 1H), 3.89 (m, 1H), 3.70 (d, J = 2.2 Hz, 1H), 3.68 (s, 3H), 3.67-3.59 (m, 4H), 3.54 
(s, 3H), 2.85 (m, 2H), 2.46 (dd, J = 13.2, 4.0 Hz, 1H), 2.14 (m, 1H), 2.09 (s, 3H), 1.96 (s, 9H); 
13C NMR (151 MHz, CDCl3) : 171.2, 170.4, 170.4, 170.1, 169.9, 168.2, 139.2, 138.1, 128.7, 
128.3, 127.9, 127.8, 127.7, 127.6, 127.6, 127.1, 127.1, 126.6, 104.6, 98.9, 77.5, 76.4, 76.2, 74.8, 
74.6, 73.4, 73.0, 72.5, 70.0, 69.6, 68.6, 67.5, 62.1, 60.0, 57.1, 54.5, 52.7, 36.0, 34.9, 21.3, 21.1, 
20.9, 20.7; ESIHRMS calcd for C55H66O17N2SNa ([M + Na]
+) 1081.3938, found 1081.3980.  
 Methyl [5-(N'-(2-phenylethyl)guanidino)-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulo-pyranosylonate]-(2→3)-[2,4,6-tri-O-benzyl-β-D-galactopyranoside] (252): To a 
solution of thiourea 250 (83.0 mg, 0.07 mmol) in anhydrous dichloromethane (2.0 mL) under Ar 
was added DMAP (1.0 mg, 0.008 mmol) followed by DIPEA (50.0 mg, 0.38 mmol) at room 
temperature. The resulting reaction mixture was treated with methyl iodide (33.0 mg, 0.23 
mmol) drop wise and stirred at room temperature for 30 h, then quenched with 0.1N HCl (2.0 
mL) and was washed with water (2.0 mL), and brine (2.0 mL). The solvent was evaporated under 
reduced pressure and the residue was purified by silica gel column chromatography eluting with 
30% EtOAc in hexanes to give the isothiourea 251212 (57.0 mg, 80%) as a colorless liquid, which 
was taken forward to the next step without further characterization. A stirred solution of 
compound 251 (33 mg, 0.03 mmol) in anhydrous dimethylformamide (1.5 mL) was transferred 
into a glass tube and cooled to -33 °C. Dry gaseous ammonia was then passed into the reaction 
for 5min ,after which the reaction mixture was stirred at 0 ºC for 5 min to enable evaporation of 
excess ammonia. The glass tube was sealed and the reaction was stirred at 130 ºC for 36 h. The 
solvent was evaporated under reduced pressure and the residue was purified by silica gel 
chromatography (eluent: gradient elution of 5-60% ammonical methanol in EtOAc) to give the 
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title compound 252 (11.0 mg, 49%) as a colorless oil. [α]D25= -10.1 (c=0.7, dichloromethane); 1H 
NMR (600 MHz, CDCl3) : 7.46 (d, J = 7.3 Hz, 3H), 7.36-7.16 (m, 17H), 5.00 (d, J = 11.3 Hz, 
1H), 4.84 (d, J = 11.3 Hz, 1H), 4.75 (d, J = 11.3 Hz, 1H), 4.60 (br s, 1H), 4.56 (d, J = 11.7 Hz, 
1H), 4.39 (d, J = 11.7 Hz, 1H), 4.35-4.29 (m, 2H), 4.25 (d, J = 7.7 Hz, 1H), 3.96 (d, J = 2.2 Hz, 
1H), 3.93 (m, 1H), 3.78 (dd, J = 11.3, 2.5 Hz, 2H), 3.65-3.60 (m, 2H), 3.60-3.54 (m, 2H), 3.54 (t, 
J = 7.7 Hz, 1H), 3.49 (m, 4H), 3.42 (m, 1H), 3.39-3.34 (m, 2H), 3.30 (m, 1H), 2.89 (dd, J = 12.4, 
4.7 Hz, 1H), 2.81 (m, 2H), 1.79 (t, J = 12.1 Hz, 1H); 13C NMR (151 MHz, CDCl3) : 173.3, 
157.4, 139.1, 138.6, 137.9, 137.8, 128.4, 128.2, 128.2, 128.0, 127.9, 127.8, 127.7, 127.5, 127.2, 
127.1, 127.0, 126.32, 104.5, 100.1, 78.1, 75.8, 75.1, 74.9, 74.7, 73.2, 72.8, 72.6, 71.8, 69.1, 68.9, 
62.8, 60.0, 55.9, 48.0, 42.8, 40.5, 34.5; ESIHRMS calcd for C46H58O13N3 ([M + H]
+) 860.3970, 
found 860.3945.  
 Methyl [Sodium (3,5-dideoxy-α-D-gluco-2-nonulopyranosyl)onate]-(2→3)-[β-D-
galactopyranoside] (253): Sodium methoxide (3.0 mg, 0.05 mmol) was added to a solution of 
compound 236 (26.0 mg, 0.03 mmol) in MeOH (1.0 mL). After stirring for 1 h at room 
temperature, the mixture was diluted with MeOH (1.0 mL) and 2N NaOH (0.2 mL) and refluxed 
at 70 ºC, for 2 h. The solution was neutralized with Amberlyst-15, filtered through small plug of 
Celite, and the filter plug washed with MeOH (2.0 mL). The combined filtrates were 
concentrated under reduced pressure to furnish a residue, which was taken up in phosphate 
buffer ( pH =7, 1.0 mL) treated with 5% Pd on carbon (30.0 mg), and stirred at room temperature 
for 15 h under 1 atm of H2. The reaction mixture was filtered through Celite, and the filtrate was 
concentrated in vacuo. The residue was purified by chromatography on a Sephadex G-10 column 
(eluent: water) and then by chromatography on Dowex 50 WX8-100 sodium ion exchanger 
eluting with water. The resulting solution was frozen in a dry-ice/acetone bath, and then 
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lyophilized to give compound 253 (11.5 mg, 91%) as a white foam. []20D = -12.3 (c = 0.7, 
H2O); 
1H NMR (600 MHz, D2O) δ: 4.17 (d, J = 8.1 Hz, 1H), 3.86 (dd, J = 9.5, 2.9 Hz, 1H), 3.72 
(d, J = 2.9 Hz, 1H), 3.69-3.63 (m, 3H), 3.61 (d, J = 12.1 Hz, 1H), 3.57-3.50 (m, 2H), 3.48-3.41 
(m, 2H), 3.37 (br s, 1H), 3.36 (s, 3H), 3.31 (t, J = 9.5 Hz, 1H), 2.46 (dd, J = 11.7, 3.6 Hz, 1H), 
1.62 (d, J = 9.9 Hz, 1H), 1.33 (t, J = 11.7 Hz, 1H), 1.30 (d, J = 12.1 Hz, 1H); 13C NMR (151 
MHz, CDCl3) : 174.3, 103.4, 100.0, 75.4, 74.8, 72.1, 71.2, 71.0, 69.0, 67.4, 65.3, 62.3, 60.8, 
56.8, 40.2, 33.9; ESIHRMS calcd for C16H27O13 ([M - H]
-) 427.1452, found 427.1461. 
 Methyl [sodium (3,5-dideoxy-5-C-propyp-D-glycero-α-D-galacto-2-
nonulopyranosyl)onate]-(2→3)-β-D-galactopyranoside (254): Sodium methoxide (1.7 mg, 
0.03 mmol) was added to a solution of compound 238 (14.0 mg, 0.02 mmol) in MeOH (0.5 mL). 
After 30 min of stirring at room temperature, the mixture was diluted with MeOH (1.0 mL) and 
2N NaOH (0.2 mL) and refluxed at 70 ºC, for 2 h. The solution was neutralized with amberlyst-
15 and filtered through small plug of celite and was washed with MeOH (2.0 mL). The solution 
was then concentrated under reduced pressure to furnish a crude residue. The solution of the 
deacetylated product in phosphate buffer ( pH =7, 0.5 mL) with suspended 5% Pd on carbon 
(17.0 mg) was stirred at room temperature for 8 h under H2 atmosphere. The whole mixture was 
filtered through celite, and the filtrate was concentrated in vacuo. The residue was purified 
through a Sephadex G-10 column and passed through Dowex 50 WX8-100 sodium ion 
exchanger both using water as eluent. The resulting solution was frozen in a dry-ice/acetone 
bath, and then lyophilized to get compound 254 (7.0 mg, 93%) as a white foam. []20D = -18.2 (c 
= 0.5, H2O); 
1H NMR (600 MHz, D2O) δ: 4.19 (d, J = 8.1 Hz, 1H), 3.89 (dd, J = 9.9, 3.3 Hz, 
1H), 3.73 (d, J = 2.9 Hz, 1H), 3.72-3.68 (m, 2H), 3.55 (m, 4H), 3.49 (dd, J = 8.4, 4.0 Hz, 2H), 
3.47-3.42 (m, 2H), 3.38 (s, 3H), 3.33 (t, J = 8.1 Hz, 1H), 2.47 (dd, J = 12.1, 4.4 Hz, 1H), 1.43 (t, 
178 
 
 
 
J = 11.7 Hz, 1H), 1.31 (m, 1H), 1.24 (m, 1H), 1.16 (m, 1H), 1.01 (m, 1H), 0.69 (t, J = 7.3 Hz, 
3H); 13C NMR (151 MHz, CDCl3) : 174.5, 103.4, 99.4, 75.3, 74.8, 73.7, 72.3, 69.0, 68.4, 67.8, 
67.3, 62.5, 60.8, 60.0, 56.8, 41.4 , 27.3 , 17.6 , 13.9; ESIHRMS calcd for C19H33O13 ([M - H]
-) 
469.1921, found 469.1907. 
 Methyl [sodium (3-dideoxy-5-(glyceramido)-D-glycero-α-D-galacto-2-
nonulopyranosyl)onate]-(2→3)-β-D-galactopyranoside (255): Sodium methoxide (1.6 mg, 
0.02 mmol) was added to a solution of compound 242 (16.0 mg, 0.015 mmol) in MeOH (0.5 
mL). After 30 min of stirring at room temperature, the mixture was diluted with  MeOH (1.0 mL) 
and 2N NaOH (0.2 mL) and refluxed at 70 ºC, for 2 h. The solution was neutralized with 
amberlyst-15 and filtered through small plug of celite and was washed with MeOH (2.0 mL). 
The solution was then concentrated under reduced pressure to furnish a crude residue. The 
solution of the deacetylated product in phosphate buffer ( pH =7, 0.5 mL) with suspended 5% Pd 
on carbon (30.0 mg) was stirred at room temperature for 20 h under H2 atmosphere. The whole 
mixture was filtered through celite, and the filtrate was concentrated in vacuo. The residue was 
purified through a Sephadex G-10 column and passed through a Dowex 50 WX8-100 sodium ion 
exchanger both using water as eluent. The resulting solution was frozen in a dry-ice/acetone 
bath, and then lyophilized to get compound 255 (7.0 mg, 91%) as a white foam. []25D = +0.4 (c 
= 0.5, H2O); 
1H NMR (600 MHz, D2O) δ: 4.18 (d, J = 8.1 Hz, 1H), 3.91 (s, 2H), 3.89 (dd, J = 
9.9, 3.3 Hz, 1H), 3.74 (d, J = 2.9 Hz, 1H), 3.72 (d, J = 10.2 Hz, 1H), 3.67 (m, 2H), 3.59 (dd, J = 
11.3, 4.4 Hz, 1H), 3.63-3.50 (m, 3H), 3.47 (m, 1H), 3.43 (dd, 1H), 3.38 (d, J = 9.2 Hz, 1H), 3.36 
(s, 3H), 3.33 (t, J = 8.1 Hz, 1H), 2.57 (dd, J = 12.1, 4.4 Hz, 1H), 1.60 (t, J = 12.1 Hz, 1H); 13C 
NMR (151 MHz, CDCl3) : 175.6, 173.7, 103.8, 99.6, 75.7, 74.8, 72.4, 71.7, 69.0, 67.9, 67.8, 
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67.3, 62.3, 60.8, 60.8, 56.8, 51.2, 39.5; ESIHRMS calcd for C18H30O15N ([M - H]
-) 500.1615, 
found 500.1633.  
 Methyl [sodium (3-dideoxy-5-(N’-(2-phenylethyl)guanidino)-D-glycero-α-D-galacto-
2-nonulopyranosylonate]-(2→3)-β-D-galactopyranoside (256): The solution of 252 (15.0 mg, 
0.02 mmol) in methanol (1.0 mL) was treated with 5% Pd on carbon (30.0 mg) was stirred at 
room temperature for 10 h under 1 atm of H2. The mixture was filtered through Celite, and the 
filtrate was concentrated in vacuo. The residue was purified through a Sephadex C-25 column 
and passed through a Dowex 50 WX8-100 sodium ion exchanger both using water as eluent. The 
resulting solution was frozen in a dry-ice/acetone bath, and then lyophilized to get compound 
256 (5.2 mg, 52%) as white foam. []20D = -10.7 (c = 0.1, H2O); 1H NMR (600 MHz, D2O) δ: 
7.21 (t, J = 7.3 Hz, 2H), 7.13 (m, 3H),  4.19 (d, J = 7.7 Hz, 1H), 3.89 (dd, J = 9.9, 2.9 Hz, 1H), 
3.76-3.70 (m, 2H), 3.68 (dd, J = 12.1, 2.5 Hz, 1H), 3.60-3.51 (m, 3H), 3.50-3.43 (m, 4H), 3.38 
(s, 3H), 3.37-3.30 (m, 3H), 3.21 (t, J = 9.2 Hz, 1H), 2.72 (dt, J = 6.6, 1.8 Hz, 2H), 2.57 (dd, J = 
12.4, 4.7 Hz, 1H), 1.55 (t, J = 12.1 Hz, 1H); 13C NMR (151 MHz, CDCl3) : 173.4, 156.4, 138.4, 
128.8, 128.7, 126.9, 103.4, 99.4, 75.6, 74.7, 72.5, 71.9, 69.0, 68.4, 68.1, 67.1, 62.3, 60.8, 56.9, 
54.3 , 42.6, 39.8, 34.2; ESIHRMS calcd for C25H40O13N3 ([M - H]
-) 588.2405, found 588.2422. 
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ABSTRACT 
SYNTHESIS OF APRAMYCIN AND PAROMOMYCIN DERIVATIVES AS 
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 AGAs are clinically important antibacterials for human therapy and have long been used 
as highly potent antibiotics for treating several bacterial infections. The fidelity of protein 
synthesis is affected by AGAs in the course of binding to specific sites of the bacterial rRNA. 
The clinical use of AGAs and their applications as therapeutics is restricted by toxicity 
(irreversible ototoxicity and reversible nephrotoxicity) and by the resistance of pathogens. The 
objective of this research was the development of proficient AGAs that are less toxic (i.e., more 
selective) and that evade resistance. The first three chapters of this thesis are aimed towards 
developing new aminoglycoside antibiotics with the emphasis on their chemical synthesis, and 
the biological evaluation of newly synthesized analogues, as well as the exploration of structure-
activity relationships to understand the mechanism of their antimicrobial activity. In particular, 
studies have focused on the modification of the aminoglycosides apramycin and paromomycin so 
as to develop the next generation of potent AGAs.  
 Chapter two reveals the importance of the 6' and N7' positions of the apramycin by 
investigation of the antibacterial activity and antiribosomal activity of the ten apramycin 
derivatives which were synthesized by modifying these locations. The effect of such 
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modifications on antiribosomal activity is discussed in terms of their influence on drug binding 
to specific residues in the decoding A site. This information is useful in the development of a 
structure activity relationship for the antibacterial activity of the apramycin class of 
aminoglycosides and will also assist in the future design and development of more active and 
less toxic aminoglycoside antibiotics. 
 Chapter three describes the structure-based design of an improved paromomycin 
derivative which carries an apramycin-like bicyclic ring I and a conformationally restricted 
hydroxyl or amine functionality. The influence of the bicyclic paromomycin 6'-hydroxy or amine 
groups on the binding pattern between AGA and bacterial RNA was investigated by using cell 
free translational assays. It was found that the bicyclic paromomycin derivative 155 with the 
equatorial 6’-hydroxy group has a better activity profile than parent paromomycin. 
 In chapter four, an efficient sialyl donor was developed for the challenging α-sialylation 
by means of a highly electron withdrawing isothiocyanato group incorporated at C-5 position 
sialic acid. The isothiocyanato sialyl donor 218 proved to be an excellent α-directing group in 
sialylation for a wide range of acceptors, and provided high yields. Further, the sialylation of 
corresponding sialyl phosphate donor 231 was also demonstrated to give excellent selectivity, 
but yields are lower due to competing elimination. In addition, the rich chemistry of 
isothiocyanate functionality is explored to introduce a variety of novel functionalities at the 5-
position of the sialosides including deamination, an alkyl chain, various amides, and guanidine 
derivatives. 
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